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Abstract 
Sphingosine kinase 1 (SK1) catalyses the synthesis of the important bioactive sphingolipid 
sphingosine-1-phosphate (S1P), that has an important role in vascular tone regulation and 
cardioprotection against ischaemia/reperfusion injury. The work presented in this thesis 
describes the influence of short periods of hypoxia on expression of SK1 in vascular 
endothelium and how this may regulate vascular function. The aims were achieved by 
using wire myography to study vascular function and confocal microscopy for the studies 
of expression and distribution of SK1 under normoxic and hypoxic conditions. 
In the first study, it was found that exposure of isolated rat coronary artery to a short period 
of hypoxia increases SK1 expression and ser225 phosphorylation. It was also demonstrated 
that the hypoxia-induced increase in SK1 expression was reduced by pre-treatment with 
cycloheximide, a protein synthesis inhibitor, SKi, a non-selective SK inhibitor and PF543, 
a selective SK1 inhibitor. However, pre-treatment with proteasomal and/or lysosomal 
inhibitors did not increase SK1 expression under normoxia or hypoxia. Similarity, SK1 
expression was also increased in aortic endothelium following exposure to short-term 
hypoxia and this effect was also inhibited by cycloheximide, SKi and PF543. Collectively, 
these data suggest that hypoxia increases SK1 synthesis in coronary and aortic 
endothelium. Moreover, the SKi-induced reduction in SK1 expression in coronary 
endothelium was reversed by proteasomal and/or lysosomal inhibitors, indicating that SKi 
stimulates both proteasomal and lysosomal degradation of SK1 under normoxia and 
hypoxia. In chapter two, it was demonstrated that S1P and CYM5541, an S1P3 agonist, 
induced dose-dependent relaxation in endothelium-intact aortic rings, whereas the S1P1 
agonist SEW2871 was without effect. The S1P stimulated relaxation was significantly 
enhanced in endothelium-intact aortic rings subjected to short-term hypoxia and this effect 
was entirely endothelium-dependent. Interestingly, the vasorelaxation response to S1P was 
inhibited by pre-treatment with SKi and PF543 but not ROMe, a selective SK2 inhibitor 
under both normoxia and hypoxia.  A nitric oxide synthase inhibitor also inhibited the S1P-
induced relaxation in aortic rings. Moreover, the enhanced relaxation response to S1P due 
to hypoxia was maintained in aortae obtained from spontaneously hypertensive Wistar 
Kyoto rats. These findings suggest that the vasorelaxation response to S1P under normoxia 
and the enhanced response under hypoxia are mediated by SK1 and NO. 
In chapter five, it was found that hypoxia did not change the SK1b expression in HUVECs 
and pre-treatment with SKi or cycloheximide exerted no effect under both normoxia and 
xvi 
 
hypoxia. However, proteasomal and/or lysosomal inhibitors increased SK1 expression 
under hypoxic conditions. In heart tissue, no significant difference was seen in expression 
of SK1 following exposure to hypoxia. However, SK1 expression was reduced by pre-
treatment with SK inhibitors and cycloheximide under normoxia but not hypoxia. SK1a 
was identified in heart tissue, which is more sensitive to the degradation-induced by SK 
inhibitors than SK1b. 
In summary, the results of this study imply that short-term hypoxia induces an increase in 
SK1 expression in coronary and aortic vascular endothelium. The increased SK1 induced 
by hypoxia appears to mediate the enhanced vasorelaxation response to S1P in 
endothelium-intact aortae. In HUVECs and heart tissue, it is likely that hypoxia induces 
resistance of SK1 to SK inhibitor-induced downregulation through a compensatory 
increase in SK1 expression. 
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Chapter one 
1 General introduction 
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1.1 Cardiovascular system 
1.1.1 Structural organisation 
The cardiovascular system (CVS) is responsible for transporting essential substances 
including gases, nutrients, and hormones to various cells and tissues in the body. It is also 
responsible for removing the waste products of metabolism and plays a significant role in 
the regulation of body temperature by transport of heat as well as monitoring the water 
content of the cells. This system is composed of the heart, blood and an intricate network 
of blood vessels including arteries, veins and capillaries. The heart is the key organ in the 
cardiovascular system. Its main function is to maintain adequate circulation of oxygenated 
blood around the vascular network of the body. The oxygen-rich blood is ejected from the 
left ventricle through the aorta at high pressure to be distributed to the peripheral tissues. 
The deoxygenated blood returns to right atrium via the inferior and superior vena cava and 
is then pumped into the lung from the right ventricle via the pulmonary artery where the 
gas exchange process takes place. 
1.1.2 Histology of the arterial wall 
The arterial wall consists of three concentric layers: the tunica intima, tunica media and 
tunica adventitia. The innermost layer, tunica intima, is a thin single sheet of endothelial 
cells attached to a thin layer of connective tissue; the basal lamina. Endothelial cells line all 
blood vessels from the heart to the capillaries and regulate the exchanges between the 
bloodstream and surrounding tissue. The tunica media is composed mainly of vascular 
smooth muscle cells (VSMCs) arranged roughly in spiral layers and located between the 
internal and external elastic laminae. The tunica media is responsible for regulating the 
total peripheral resistance (vascular tone) and the distribution of blood flow throughout the 
body. The outermost layer, the tunica adventitia, is made chiefly of longitudinally arranged 
collagen fibres and surrounds the tunica media. The adventitia serves to anchor the blood 
vessels to nearby organs, giving it stability. 
1.1.3 Vascular endothelium function 
The endothelium is a thin monolayer that lines the inner surface of the entire vascular 
system, separating the circulating blood from the tissues. This continuous layer constitutes 
approximately 1% of body mass (1 kg) (Galley and Webster, 2004). The shape of 
endothelial cells varies across the vascular tree, but generally they are thin and slightly 
3 
 
elongated, approximately 50-70 µm long, 10-30 µm wide, and 0.1-10 µm thick. In the 
blood vessel wall, endothelial cells are orientated along the axis of the vascular wall and 
this helps to minimize the shear stress forces induced by the blood flow. Up to the early 
1970s, the endothelium was thought of as a mere diffusion barrier preventing the access of 
the blood cells to the vascular matrix, but it has now become clear that this monolayer 
plays a predominant role in the control of blood fluidity, platelet activation, cellular 
adhesion, vascular tone and angiogenesis. 
1.1.3.1 Blood fluidity, thrombosis and thrombolysis 
In the heart, arteries and veins and under physiological conditions, the endothelium plays 
an important role in maintaining the proper haemostatic balance. Under normal conditions, 
endothelial cells help to maintain blood fluidity by means of different antiplatelet and 
anticoagulant mechanisms. These cells prevent adhesion, aggregation and activation of 
platelets and enhance platelet de-aggregation via expression of 13-hydroxyoctadecadienoic 
acid (13-HODE) on their surface cells, releasing nitric oxide (NO) and prostacyclin, 
hydrolysing ATP and ADP by membrane ectonucleotidases and inhibiting the action of 
thrombin, a potent aggregating enzyme (Michiels, 2003, Verhamme and Hoylaerts, 2006). 
They also inhibit the action of thrombin by expressing the thrombin receptor 
thrombomodulin on their surface, which promotes conversion of thrombin from a 
procoagulant to an anticoagulant enzyme. The thrombomodulin-bound thrombin activates 
protein C/protein S pathway leading to inactivation of coagulant factors Va and VIIIa and 
ultimately blocks the coagulation cascade (Rajendran et al., 2013). 
Moreover, endothelial cells play a pivotal role in all major haemostatic pathways upon 
vascular injury and restrict clot formation to the areas where haemostasis is required to 
restore vascular integrity. Disruption of endothelial continuity results in the exposure of 
blood to the subendothelial matrix and collagen fibres and this triggers platelet adhesion to 
these structures. Von Willebrand factor (vWF), a multimeric protein, is mainly generated 
by endothelial cells and plays a crucial role in initial platelet aggregation and clot 
formation. It acts as a bridge between the tissue and the platelet through GPIb/IX/V 
glycoprotein receptor, a platelet receptor for vWF and other molecules including thrombin, 
P-selectin, factor XI and factor XII. The rapid formation of a platelet plug provides an 
initial defence mechanism against vessel wall injury and bleeding. Furthermore, the 
activated platelets secrete different platelet agonists such as thromboxane A2, ADP and 
serotonin that mediate vascular smooth muscle cell contraction and therefore induce 
4 
 
vasoconstriction. Platelet-mediated primary haemostasis goes hand in hand with the 
activation of the coagulation system. Clot formation also occurs in response to exposure of 
blood to subendothelial tissue upon endothelial damage. Endothelial cells are involved in 
regulation of the haemostatic response, both in the initiation and amplification of thrombin 
formation and in the anticoagulant pathways that control the haemostatic response. The 
initiation of the coagulation cascade is primarily mediated by tissue factor (TF). In heathy 
blood vessels, TF is mainly located in the adventitial layer and the subcutaneous tissue. 
Direct contact of the blood with TF and the subsequent binding to factor VIIa initiates the 
coagulation cascade. The TF-VIIa complex converts circulating factor X and factor XI into 
active enzymes, namely factors Xa and XIa. Factor XIa promotes the activation of factor 
X. Factor X catalyses the generation of thrombin. Thrombin plays a pivotal role in 
amplification of the coagulation cascade via cleavage of fibrinogen to fibrin, activation of 
factors V, VIII, XI, XIII, and platelet activation (Figure 1-1). 
 
Figure  1-1 Schematic representation of the coagulation cascade.  
In injured blood vessels, the tissue factor binds factor VIIa to activate factors X and IX: activated 
factor IX enhances the activation of factor X and the later catalyses the generation of thrombin. The 
thrombin that is generated in the initiation phase promotes amplification of the coagulation cascade 
via cleavage of fibrinogen to fibrin, activation of factors V, VIII.    
 
When the blood clot is no longer needed for haemostasis, the fibrinolytic system degrades 
the clot and restores the patency of the blood vessel. The fibrinolytic system dissolves the 
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clot via action of plasmin which degrades the fibrin component of the blood clot into 
soluble degradation products. The plasmin is present as an inactive proenzyme, 
plasminogen, which is converted to active plasmin via two different activators, tissue-
plasminogen activator (t-PA) and urokinase-plasminogen activator (u-PA). Both t-PA and 
u-PA are synthesized and released by endothelial cells. 
1.1.3.2 Leukocyte trafficking 
The interaction between leukocytes and vascular endothelium contributes to several 
physiological and pathophysiological processes including the immune response, wound 
repair and thrombosis as well as to acute and chronic inflammation. Transmigration of 
leukocytes from the circulation to the surrounding tissue is a multi-step process involving 
the capture, rolling and arrest of the leukocytes, followed by their extravasation to the 
surrounding tissue (or diapedesis) (Ley and Reutershan, 2006). The recruitment of 
leukocytes at sites of vascular injury is a very rapid response and mostly depends on the 
expression of the selectin family of adhesion molecules, in both endothelial cells and 
leukocytes. The capture and rolling of leukocytes is mainly regulated by E-selectin and P-
selectin. Following rolling, endothelial chemokines stimulate conformational changes in 
integrins; adhesion receptors expressed by leukocytes. Integrins bind to their ligands on the 
endothelial cells such as vascular cell adhesion molecule (VECAM-1), platelet-endothelial 
cell adhesion molecule (PECAM-1), intracellular adhesion molecule (ICAM-1) or 
junctional adhesion molecule (JAM). Then, leukocytes migrate through the endothelium 
preferentially via inter-endothelial junctions and this process is regulated mainly by 
PECAM-1, ICAM-1 and VECAM-1 (Ley and Reutershan, 2006). 
1.1.3.3 Regulation of vascular tone 
The endothelium acts not only as a physical barrier between the circulation and the tissue, 
but it plays an important role in regulation of vascular tone by secreting a variety of 
regulatory substances. Endothelial cells control the vascular tone by releasing vasodilators 
such as nitric oxide (NO) and prostacyclin (PGI2), as well as vasoconstrictors including 
endothelin, thromboxane A2, angiotensin II, superoxide, and platelet-activating factor. 
These different compounds are not stored in intracellular granules. Rather, their major 
physiological effects are controlled by specific receptors on vascular cells, via their rapid 
metabolism, or at the level of gene transcription. Endothelial cells generate NO through 
oxidation of the amino acid L-arginine to NO and this process is catalysed by nitric oxide 
synthase (NOS) (Palmer et al., 1988). Three isoforms of NOS are identified: neuronal 
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isoform (nNOS) which forms NO to work as a neuronal messenger that modulates synaptic 
neuronal transmitter release (Prast and Philippu, 2001), Macrophage or Inducible isoform 
(iNOS) which is only induced in cells which have been exposed to particular inflammatory 
mediators that activate the macrophages (Michel and Feron, 1997), and endothelial NOS 
(eNOS) which synthesizes nitric oxide in vasculature (Lamas et al., 1992). These isoforms 
are not only expressed in the cells they were originally found in but they also exist in other 
cells. For example, all three NOS can be expressed in the vascular wall. nNOS is present 
not only in perivascular nerves but can also be expressed in endothelial and vascular 
smooth muscle (Gonzalez et al., 1997, Boulanger et al., 1998). iNOS expression has been 
reported in all nucleated cells in the cardiovascular system (Papapetropoulos et al., 1999) 
and eNOS can be detected in cardiomyocytes and platelets (Balligand et al., 1993, Sase 
and Michel, 1995). It is known that the dilation of the blood vessels is largely dependent on 
the activity of eNOS; therefore this introduction will now focus on this isoform. 
Inactive eNOS is attached to the protein caveolin and is located in caveolae; small 
invaginations in the cell membrane (Bucci et al., 2000). eNOS is detached from caveolin 
and activated when the intracellular level of Ca
2+
 is increased (Bucci et al., 2000). Several 
receptor-dependent agonists such as bradykinin, acetylcholine, thrombin, adenosine di-
phosphate (ADP), adenosine tri-phosphate (ATP) and substance P can stimulate the 
detachment of eNOS from caveolin by releasing Ca
2+
 from the endoplasmic reticulum (Bae 
et al., 2003, Sandoo et al., 2010). Depletion of intracellular Ca
2+ 
stores leads to opening of 
Ca
2+
channels allowing Ca
2+
 influx from the extracellular space (Schilling et al., 1992, 
Schilling and Elliott, 1992). Ca
2+
 binds to the protein calmodulin in the cytoplasm of the 
cells and this leads to structural changes which enables it to attach to eNOS (Fleming and 
Busse, 1999). Activated eNOS then converts L-arginine to NO and so this pathway of NO 
generation depends upon the intracellular levels of Ca
2+
 in the endoplasmic reticulum as 
well as Ca
2+
 influx into the cells from extracellular stores. A decrease in Ca
2+
 results in 
dissociation of the calcium-calmodulin complex from eNOS which in turn attaches to 
caveolin and becomes inactivated (Fleming and Busse, 1999). However, there are 
additional mechanisms which can activate eNOS including phosphorylation via protein 
kinases such as protein kinase A (Bae et al., 2003) and cyclic guanosine-3’, 5’-
monophosphate (cGMP) protein kinase dependent II (Butt et al., 2000). Shear stress can 
also activate eNOS via the action of protein kinase A and Akt (Boo et al., 2002). Shear 
stress is caused by increased blood flow in the vessel and can elevate NO generation by 
eNOS phosphorylation or an increase in intracellular Ca
2+
 levels through stimulation of 
Ca
2+
-activated K
+
 channels on the endothelial cell surface; allowing K
+
 efflux and Ca
2+
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influx into the cells (Tran et al., 2000). Once generated, NO diffuses to the underlying 
smooth muscle where it activates the enzyme soluble guanylyl cyclase (sGC) (Ignarro et 
al., 1986). This enzyme catalyses the conversion of guanosine triphosphate (GTP) to 
cGMP, which decreases Ca
2+
 release from the sarcoplasmic reticulum in the smooth 
muscle cells and also helps to restore Ca
2+
 to the sarcoplasmic reticulum (Cornwell et al., 
1991). Both actions induce relaxation of smooth muscle cells. Apart from its vasodilator 
effect, endothelium-derived NO also prevents leukocyte adhesion to endothelium and 
decreases inflammatory mediators in response to vascular injury (Peng et al., 1998). 
Furthermore, prostacyclin (PGI2) and thromboxane A2 (TXA2) are also involved in 
regulation of vascular function (Bunting et al., 1983). Their synthesis is catalysed by 
cyclooxygenase enzymes (COX), of which there are two isoforms: COX-1 and COX-2. 
COX-1 is generated continuously in endothelial cells; in contrast COX-2 is only produced 
when the endothelium is injured and exposed to inflammatory cytokines (FitzGerald, 1991, 
Needleman and Isakson, 1997). COX enzymes catalyse the conversion of arachidonic acid 
to prostaglandin H2 (PGH2) and the latter is converted to PGI2 by prostacyclin synthase 
(McAdam et al., 1999). Then PGI2 binds to the prostacyclin receptors (IP) on smooth 
muscle cells to activate adenylate cyclase which produces cyclic adenosine monophosphate 
(cAMP). The latter then activates protein kinase A, which allows relaxation of the smooth 
muscle by the same mechanism as for NO (Stitham et al., 2004). Prostacyclin receptors are 
also expressed on platelets and their activation by PGI2 leads to inhibition of platelet 
aggregation (Higgs et al., 1978). In contrast to PGI2, TxA2 induces vasoconstriction and 
platelet aggregation (Thomas et al., 1998). It is produced by converting arachidonic acid to 
PGH2 and then TxA2 is generated by thromboxane synthase (Bunting et al., 1983). TxA2 
induces its effects through thromboxane-prostanoid (TP) receptors which are expressed on 
platelets and whose stimulation enhances platelet aggregation (FitzGerald, 1991). The TP 
receptors are also located on smooth muscle cells and their activation by TxA2 results in an 
increase in intracellular Ca
2+
 levels, leading to vasoconstriction (Cogolludo et al., 2003). 
The balance in the activity between PGI2 and TxA2 is important in maintaining 
homeostasis in the healthy vessel. 
Endothelin-1 (ET-1) is another vasoconstrictor which is released by endothelial cells. ET-1 
is synthesized by converting big ET-1 to ET-1 via endothelin converting enzyme 
(Yanagisawa et al., 1988). ET-1 synthesis and release is stimulated by inflammatory 
mediators such as interleukins and TNF-α and reduced by NO and PGI2 (Alonso and 
Radomski, 2003). Shear stress causes a reduction in ET-1 expression, after initially 
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enhancing it. ET-1 receptors (ETA and ET-B2) have been identified on smooth muscle cells 
and (ET-B1) receptors on endothelial cells (Davenport et al., 1995). Activation of ETA and 
ET-B2 by ET-1 results in Ca
2+
 influx into smooth muscle cells, leading to vasoconstriction 
in a similar mechanism to TxA2. In contrast, stimulation of ET-B1 receptors on the 
endothelium causes vasodilatation by releasing NO and PGI2 (de Nucci et al., 1988). 
1.1.3.4 Angiogenesis 
Recovery of cardiac function and prevention of heart failure following myocardial 
infarction remains a challenge and there is no  satisfactory strategy to overcome such 
complications. In the last two decades, proangiogenic therapy to enhance reperfusion and 
function of ischaemic hearts appeared a promising therapeutic intervention in preclinical 
studies. However, in clinical trials, this strategy has shown disappointing results, 
increasing the need for better understanding of angiogenic mechanisms in ischaemic 
hearts. The endothelium plays an important role in blood vessel formation. When a 
primitive network has been formed via vasculogenesis, it expands and remodels into a 
functional vascular network. This process involves angiogenesis; the growing of 
microvessels from pre-existing vessels. In the adult, angiogenesis is involved in regulation 
of reproduction, in wound repair and in response to stimuli such as inflammation and 
hypoxia. Several diseases are caused by abnormal angiogenesis or conversely by 
insufficient angiogenesis or vessel regression (Fischer et al., 2006). Although endothelial 
cells are normally quiescent, during angiogenesis they can proliferate rapidly with a 
turnover time less than 5 days (Folkman and D'Amore, 1996). Angiogenesis is a 
sophisticated phenomenon remarkably regulated in a spatial and temporal manner. In 
response to angiogenic factors produced by surrounding hypoxic tissues, endothelial cells 
degrade the extracellular matrix, proliferate, migrate towards these angiogenic signals and 
create tubular structures, the basis of the new blood vessels (Egeblad and Werb, 2002). 
Vascular endothelial growth factor (VEGF) plays a pivotal role in this phenomenon with 
additional contribution of other factors including angiopoietin-1 and integrins. VEGF and 
angiopoietin might also be involved in tube formation whereas ephrins, Eph receptor 
ligands, guide the forming vessel toward its target. Moreover, VEGF also promotes 
survival of the endothelial cell-constituted new blood vessel. However, the angiogenic 
process can differ markedly depending upon the origin of the neovascularization 
(physiological or pathological) and the vascular bed involved (Fischer et al., 2006).  
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1.2 Cardiovascular disease 
Cardiovascular disease (CVD) is a general term that describes all diseases involving the 
heart and blood vessels including coronary heart disease (CHD), stroke, peripheral arterial 
disease and aortic disease. CVD is one of the leading causes of death in the United 
Kingdom. In 2014, CVD was the second most common cause of death in the UK, with a 
total of around 155,000 deaths (British Heart Foundation, 2015). Among them 41,000 were 
premature deaths (people below the age of 75). CVD is a multifactorial disease with 
interaction of both genetic and environmental risk factors such as smoking, diet and 
lifestyle. The most common causes of CVD deaths are CHD and stroke. In 2014, 44% of 
CVD deaths were caused by CHD and 25% were from stroke in the UK (British Heart 
Foundation, 2015). 
1.2.1 Coronary heart disease (CHD) 
Coronary artery disease (CAD) constitutes a major public health problem and is one of the 
leading causes of morbidity and mortality among adults worldwide. Each year more than 
29 million people suffer a myocardial infarction, leading to 17 million deaths around the 
world. Moreover, coronary artery disease is the most common aetiology of sudden cardiac 
death which is responsible for 300 000 to 400 000 deaths every year in the United States 
alone (Santini et al., 2007). In 2014, CHD was responsible for 69,000 deaths in UK and 
Scotland had the highest rate of premature CHD deaths for both men (83/100,000) and 
women (28/100,000)(British Heart Foundation, 2015). There are several risk factors that 
have been confirmed to increase the risk of coronary heart disease including: hypertension, 
high cholesterol levels, cigarette smoking, and diabetes (Gordon et al., 1977, Kannel and 
McGee, 1979, Gordon and Kannel, 1982, Khot et al., 2003). Other factors such as obesity, 
left ventricular hypertrophy, previous family history of CHD, and oral contraception have 
also been considered in defining CHD risk (Kannel, 1991, Wilson et al., 1998, Logue et al., 
2011). 
1.2.2 Pathophysiology of coronary heart disease 
Coronary atherosclerosis is by far the most common cause of ischaemic heart disease, and 
plaque disruption with superimposed thrombosis is the leading cause of acute coronary 
syndromes including unstable angina, myocardial infarction and sudden death (Arbab-
Zadeh et al., 2012). Coronary events can also be caused by coronary dissection, coronary 
spasm, arteritis and thromboembolism without obvious coronary artery disease (Davies, 
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2000). Coronary thrombosis is most commonly triggered by plaque disruption or 
endothelial erosion. In white males more than 85% of major coronary thrombi are 
associated with vulnerable plaque rupture. In contrast, endothelial erosion is responsible 
for ≥ 50% of coronary thrombi in women (Burke et al., 1997, Arbustini et al., 1998). 
Several studies have demonstrated that the atherosclerotic plaque type at the greatest risk 
of rupture is thin-cap fibroatheroma, characterized by a large necrotic core surrounded by a 
thin fibrous layer of cap (Virmani et al., 2006, Calvert et al., 2011, Stone  et al., 2011). 
During the atherosclerotic process, the necrotic core increases in volume as a result of 
macrophage infiltration, the demise of macrophages and intraplaque bleeding. This leads to 
separation of the necrotic core from the flowing blood by an ultra-thin layer of fibrous 
tissue that is depleted of smooth muscle cells and is infiltrated by inflammatory cells. Thus, 
plaque growth, the inflammatory process within the fibrous cap and external shear stress 
may disrupt the thinnest part of the fibroatheroma, causing tearing and exposure of the 
highly thrombogenic material to the blood (Virmani et al., 2006). This ultimately results in 
thrombus formation and, in severe cases, occlusion of the coronary artery. 
1.3 Endothelium and myocardial ischaemia 
Vascular endothelial cells play an essential role in regulation of vascular tone, 
angiogenesis, as well as of platelet and neutrophil function. Several experimental and 
clinical studies suggest that these important physiological functions of the endothelium 
deteriorate in numerous pathophysiological conditions, such as hypertension, 
hyperlipidaemia or diabetes. Such dysfunction can be manifested by a decrease in 
endothelial release of nitric oxide (NO) and an increased generation of oxygen-derived free 
radicals (Laude et al., 2001). A similar impairment in the endothelial production of NO has 
also been observed at the level of the coronary circulation after myocardial ischaemia and 
reperfusion (Yang et al., 2013). This may lead to marked deleterious consequences for the 
coronary arterial wall. 
Ischaemia is a process in which the demand for oxygen is greater than the available supply, 
most commonly caused by inadequate blood flow. In myocardial infarction, partial or total 
occlusion of a large epicardial coronary artery results in disruption of blood flow to the 
myocardium. In order to prevent irreversible myocardial tissue damage, it is essential to 
restore blood supply after severe ischaemia. However, reperfusion itself results in further 
tissue damage which might be more severe than the damage produced by ischaemia alone. 
Evidence that myocardial ischaemia causes coronary endothelial dysfunction was first 
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observed by Ku who showed that exposure to a defined period of ischaemia (90 min) 
followed by reperfusion for 1 to 2 hr led to a decrease in endothelium-dependent relaxation 
to thrombin in canine coronary arteries (Ku, 1982). Similar findings were also reported 
with other endothelium-dependent vasodilators such as acetylcholine (VanBenthuysen et 
al., 1987) whereas the response to nitroprusside, an endothelium-independent vasodilator, 
was intact. This impairment of endothelium-dependent relaxation to acetylcholine 
appeared to be a manifestation of reperfusion injury as ischaemia alone did not alter the 
relaxant response to acetylcholine (Tsao et al., 1990). It is likely that such prolonged 
endothelial impairment was a consequence of dysfunctional regenerated endothelium 
whereas the acute changes were a result of structural injury to endothelial cells (Pearson et 
al., 1990, Kaeffer et al., 1996). 
1.3.1 Mechanism of reperfusion-induced vascular endothelium 
dysfunction 
Although endothelial cells (EC) are less sensitive to ischaemia alone, they are quite 
sensitive to an IR insult in the heart (Brutsaert, 2003). It has been demonstrated that 
reperfusion causes a variety of cellular abnormalities that occur quickly such as increased 
reactive oxygen species (ROS) production, decreased NO bioavailability, induction of 
inflammatory processes and impaired Ca
2+
 homeostasis and these abnormalities enhance 
apoptosis of the endothelial cells. ROS are negatively charged short lived oxygen species 
that induce nonspecific and irreparable oxidative damage. It has been demonstrated that 
exposure of human umbilical vein ECs (HUVECs) to 2 hr hypoxia with glucose depletion 
followed by 1hr normoxia with glucose increased ROS production (Therade-Matharan et 
al., 2004, Therade-Matharan et al., 2005). The major source of endothelial ROS during an 
IR insult is the mitochondrial electron transport chain (Coudray et al., 1992, Quintero et 
al., 2006). ROS generation occurs rapidly during reperfusion and is a critical mediator for 
many downstream events. In cultured ECs, ROS production appears within minutes of 
reoxygenation based on electron paramagnetic resonance spectroscopy (Zweier et al., 
1994). Increased ROS production is associated with a decrease in vasoreactivity (Szocs, 
2004). In this regard, ROS release may overwhelm the endogenous antioxidant 
environment, reduce NO bioavailability, and consequently impair endothelium-dependent 
vasorelaxation (Szocs, 2004). Moreover, increased ROS release during IR insult might lead 
to expression of surface adhesion molecules (Patel et al., 1991, Gaboury et al., 1994) and 
complement activation (Lucchesi, 1994), which collectively enhance neutrophil adhesion 
to the EC surface. At the onset of ischaemia, NO release increases within 5-10 seconds and 
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this induces vasodilation but this effect decreases within 5-10 min (Vinten-Johansen et al., 
1999, Schulz et al., 2004, Davidson and Duchen, 2007). During reperfusion NO release 
again increases rapidly but reduces within the same time frame as for ischaemia (Wang and 
Zweier, 1996). Furthermore, several studies have demonstrated that delivery of an NO 
donor (e.g. sodium nitroprusside, nitroglycerin) or arginine, a substrate required for NO 
synthesis, protects the heart against IR injury via at least 2 mechanisms (Vinten-Johansen 
et al., 1999). First, NO activates the soluble guanylyl cyclase and this leads to activation of 
a host of cGMP kinases including protein kinase G, ion channels (e.g. Mito KATP channel) 
and phosphodiesterases (PDEs) (Grover and Garlid, 2000, Friebe and Koesling, 2003). 
Consequently this results in vasodilation and reduced platelet adhesion. NO has also direct 
effects on neutrophil adhesion independent of its influence on cGMP activity (Schulz et al., 
2004). There is also evidence that endogenous NO synthase inhibitors may have an 
important role in ischaemia/reperfusion injury. Impaired NO production may result from 
increased levels of asymmetrical dimethylarginine (ADMA), an endogenous competitive 
inhibitor of NOS (Cooke, 2000). It has been observed that ADMA is elevated in newly 
diagnosed patients with acute myocardial infarction compared to heathy subjects (Bae et 
al., 2005). Stühlinger et al observed that increased ADMA levels during early phase of 
reperfusion is due to inhibition of its metabolism by dimethylarginine 
dimethylaminohydrolase (DDAH) (Stühlinger et al., 2007). The end result is reduction of 
NO bioavailability and endothelial dysfunction and this effect can be reversed by 
administration of exogenous L-arginine or partial elimination of ADMA in a genetic 
mouse model (Stühlinger et al., 2007). Solid evidence exists that eNOS may contribute to 
protection against myocardial injury. It was observed that IR injury increased in eNOS 
knock out mice compared to wild type mice (Huang et al., 1995). 
Moreover, Ca
2+
 homeostasis may play a pivotal role in endothelial cell IR injury. Under 
normal conditions, Ca
2+
 levels in both cytosol and mitochondria are maintained in a narrow 
range (Davidson and Duchen, 2007, Peters and Piper, 2007). In contrast, during ischaemia 
intracellular Ca
2+
 increases slowly and increases further during reperfusion in both 
endothelial cells and cardiomyocytes (Symons and Schaefer, 2001, Peters and Piper, 
2007). Several studies assessed the contribution of Ca
2+
 overload to IR-induced myocardial 
injury and coronary vascular dysfunction in pigs and rats using cariporide, a Na
+
-H
+
 pump 
inhibitor (Symons et al., 1998, Symons and Schaefer, 2001, Scheule et al., 2003). 
Specifically, coronary relaxation in response to acetylcholine but not sodium nitroprusside 
was impaired after IR injury, suggesting an IR-induced endothelial dysfunction (Symons 
and Schaefer, 2001). Pre-treatment with cariporide preserved endothelial function in 
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coronary arteries after exposure to an IR insult and their relaxation in response to 
acetylcholine was depressed to a lesser degree (Symons and Schaefer, 2001). This suggests 
that pharmacological attenuation of calcium overload during ischaemia-reperfusion may be 
a promising strategy for cardioprotection.  
1.3.2 Mechanism of myocardial ischaemia/reperfusion injury 
Restoration of blood supply after the onset of acute myocardial ischaemia is crucial to 
preserve viable myocardium, limit myocardial infarct size, salvage left ventricular systolic 
function and prevent the onset of heart failure. However, the reperfusion itself can 
independently cause cardiomyocyte death (Braunwald and Kloner, 1985, Piper et al., 1998, 
Hausenloy and Yellon, 2007). IR induces four forms of myocardial injury: arrhythmia, 
myocardial stunning, microvascular obstruction and ultimately death of cardiomyocytes. 
First, sudden reperfusion of ischaemic myocardium might be associated with ventricular 
arrhythmia, which is usually reversible without treatment (Hearse and Tosaki, 1987). 
Myocardial stunning, reversible myocardial contractile dysfunction, occurs on reperfusion 
of acute ischaemic myocardium as a result of oxidative stress and intracellular Ca
2+
 
overload in myocardium (Kloner et al., 1998). Reopening of the occluded artery for 
reperfusion of ischaemic myocardium does not guarantee that the blood flow will return to 
pre-occlusion values. In severe cases, even in the presence of a completely patent artery, 
no-reflow phenomenon may occur secondary to disrupted coronary microcirculation 
(Menger et al., 1992, Reffelmann and Kloner, 2004, Ito, 2006). The major contributing 
factors to disrupted coronary microcirculation include capillary damage with impaired 
vasodilation, evoked mechanical capillary compression by endothelial cells and 
cardiomyocyte swelling, neutrophil trapping and /or platelet aggregation and micro-
embolization by friable material released from the atherosclerotic plaque. Ultimately, 
reperfusion causes death of cardiomyocytes (Piper et al., 1998). This could potentially 
result from oxidative stress, calcium overload, mitochondrial permeability transition pore 
(mPTP) opening and hypercontracture (Yellon  and Hausenloy 2007). Reperfusion-induced 
cardiomyocyte death has been observed in both experimental myocardial infarction models 
and in patients with STEMI, ST-segment elevation myocardial infarction, by the 
observation that therapeutic intervention applied only at the onset of reperfusion decreased 
MI size by 40%-50% (Yellon  and Hausenloy 2007). 
Therefore, it is important to understand the mechanism of IR injury at the level of the cell. 
During acute myocardial ischaemia, cessation of oxygen delivery switches cell metabolism 
14 
 
to anaerobic respiration and this leads to an increase in lactate production and a decrease in 
intracellular pH to less than 7.0. In contrast, normal pH is rapidly restored by the washout 
of lactate and stimulation of Na
+
-H
+
 exchanger at reperfusion (Lemasters et al., 1996). This 
contributes to reperfusion-induced cardiomyocyte death by permitting mPTP opening and 
cardiomyocyte rigor hypercontracture. Moreover, the electron transport chain is reactivated 
during reperfusion, generating ROS (Downey, 1990, Li and Jackson, 2002, Zweier and 
Talukder, 2006). But ROS can also be generated in endothelial cells (xanthine oxidase) and 
neutrophils (NADPH oxidase). ROS contribute to myocardial reperfusion injury via 
opening of mPTP, damage to the cell membrane by lipid peroxidation, enhancing 
neutrophil recruitment, and mediating dysfunction of the sarcoplasmic reticulum (SR)(Li 
and Jackson, 2002, Hausenloy and Yellon, 2013). As described above, Ca
2+
 overload in 
cardiomyocytes is one of the major contributing factors to IR injury. This begins during 
myocardial ischaemia and is exacerbated at reperfusion due to disruption of the plasma 
membrane, dysfunction of sarcoplasmic reticulum and mitochondrial re-energization 
(Miyamae et al., 1996). The mPTP opening is one of the most important contributors to IR-
induced myocardial and endothelial cell injury. It has been demonstrated that they remain 
closed during ischaemia and only open at the time of reperfusion in response to rapid 
restoration of physiological pH, mitochondrial Ca
2+ 
overload, oxidative stress and relative 
ATP depletion (Griffiths and Halestrap, 1995, Halestrap et al., 2004, Ruiz-Meana et al., 
2007). The opening of mPTP is associated with cell death, either necrotic or apoptotic 
(Mattson and Kroemer, 2003, Crow et al., 2004). The severity of damage induced by 
mPTP opening depends upon the duration of their opening and the number of mitochondria 
involved. Long lasting mPTP opening causes loss of mitochondrial membrane potential, 
ATP depletion and release of apoptotic factors such as cytochrome c, caspase 9 and 
caspase 3. Consequently, this leads to cell death and loss of oxidative phosphorylation 
capacity (Crompton, 1999, Mattson and Kroemer, 2003, Crow et al., 2004, Kroemer et al., 
2007) (Figure 1-2). 
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Figure  1-2 Flow chart shows the main mechanisms of ischaemia/reperfusion injury. 
Ischaemia causes a slight increase in ROS and Ca
2+
 overload and the opening of mPTP during 
ischaemia is limited due to low pH. During reperfusion, pH returns to its baseline levels and ROS 
generation increases, leading to prolonged mPTP opening which mediates irreversible cell damage 
during reperfusion.   
 
 
 
 
Ischaemia
Ca2+ ↑
ROS ↑
pH↓
Limited damage
Reperfusion
Ca2+ ↑
ROS ↑↑
pH ↑
NO ↓↓
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1.3.3 The relationship between endothelial cells and myocardial 
injury 
ECs modulate cardiomyocyte growth, metabolism, contractility, apoptosis and 
arrhythmogenicity by generating and releasing many signalling molecules (Brutsaert, 
2003). In addition to its vasodilatory effects, NO acts as a signalling molecule and because 
of the close proximity between ECs and cardiac cells, NO is able to diffuse to 
cardiomyocytes and plays a role in regulation of contractility, electrical activity and 
oxygen consumption of cardiomyocytes (Brutsaert, 2003). Other EC signalling molecules 
can also contribute to the interaction between ECs and cardiomyocytes and these include 
factors responsible for vasoregulation (e.g. prostacyclin, endothelin-1, and angiotensin II), 
inflammation (e.g. IL-1, TNF-α), and growth (PDGF, VEGF). Several studies have shown 
that a strong correlation exists between vascular and cardiac function in an isolated heart 
model immediately following an IR injury (Di Napoli et al., 1998, Fedalen et al., 2003, 
Mohara et al., 2005). In isolated rat hearts pre-treated with verapamil before subjecting the 
hearts to 30 min global ischaemia, preservation of coronary flow was significantly 
correlated with functional recovery (Mohara et al., 2005). It is still unclear how preserved 
endothelial function contributes to cardioprotection against IR injury, however, several 
mechanisms have been proposed including enhanced microcirculation and decreased 
capillary permeability and interstitial oedema (Di Napoli et al., 1998). 
1.3.4 Cardioprotection against ischaemia/reperfusion insult 
The term cardioprotection refers to protection against IR-induced myocardial injury. In this 
regard, several interventions have been studied to condition the heart in order to reduce the 
severity of myocardial injury and improve the prognosis of patients exposed to acute 
myocardial infarction. Indeed the most important determinant of myocardial damage 
during any ischaemia and reperfusion event is the myocardial infarct size (Geltman, 1984). 
It is therefore the most significant goal in management of acute myocardial infarction to 
reduce the infarct size as much as possible and avoid subsequent serious complications of 
AMI. Early reperfusion can help to prevent myocardial injury and reduce the infarct size 
(Maroko et al., 1972) and this can usually be achieved by the use of primary percutaneous 
coronary intervention (PCI) and thrombolytic therapy. However, as noted above, 
reperfusion itself paradoxically contributes to the myocardial injury and attenuates the 
benefits of restoration of the blood flow to the myocardium (Braunwald and Kloner, 1985, 
Garcia-Dorado and Piper, 2006). Therefore several studies have been carried out to 
develop new treatment protocols and/or surgical interventions to protect the heart against 
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ischaemia/reperfusion insult. In this regard, it has been shown that brief episodes of 
nonlethal ischaemia and reperfusion prior to sustained ischaemia can reduce myocardial 
infarct size and this has become known as ischaemic preconditioning (Murry et al., 1986). 
Moreover, brief episodes of nonlethal IR just at the onset of reperfusion have also reduced 
myocardial infarct size and this is termed ischaemic postconditioning (Zhao et al., 2003). 
1.3.4.1 Ischaemic preconditioning (IPC) and postconditioning (IPost) 
The phenomenon of myocardial ischaemic preconditioning has been confirmed in rats (Hu 
and Nattel, 1995), pigs (Schott et al., 1990, Vahlhaus et al., 1998), and rabbits (Liu et al., 
1991, Miura et al., 1992) as well as human isolated cardiomyocytes (Ikonomidis et al., 
1994). Furthermore, strong evidence exists that preconditioning may occur in vivo in 
human hearts (Deutsch et al., 1990, Cribier et al., 1992, Yellon et al., 1993). Ischaemic 
preconditioning confers several beneficial effects including infarct size limitation, 
reduction of IR-induced arrhythmia and contractile dysfunction and protects coronary 
endothelium (Minamino et al., 1998, Eisen et al., 2004, Garcia-Dorado et al., 2011). At the 
cellular level, the significant effects of ischaemic preconditioning are assumed to prevent 
cell death due to reperfusion injury. Many factors such as autacoids (eg, adenosine, 
bradykinin, and opioids), their receptors, kinase signalling pathways and mitochondria 
modulation are involved in the cardioprotective effects of ischaemic preconditioning. Short 
periods of ischaemia lead to production of endogenous autacoids and activation of their 
respective receptors. This results in activation of cardioprotective signalling pathways such 
as ERK1/2, PI3K/Akt, protein C and protein G, leading to inactivation of mitochondrial 
glycogen synthase kinase-3β (GSK-3β). This ultimately inhibits the opening of mPTP, 
which plays a pivotal role in cardiac cell apoptosis and necrosis (Miura and Tanno, 2012). 
Although the above studies show that IPC is effective in whole heart preparations, it has 
also been reported that preconditioning provides a protection at the level of the coronary 
endothelial cells and prevents the impaired endothelium-dependent relaxant responses to 
acetylcholine induced by prolonged ischaemia-reperfusion in rat models (Richard et al., 
1994, Laude et al., 2002) and in humans (Luca et al., 2013).   
In 2003, Zhoa et al reported that short periods of coronary occlusion and reperfusion at the 
onset of reperfusion following 60 min of ischaemia reduced myocardial infarction by 40% 
in canine hearts (Zhao et al., 2003). The cardioprotective effects of ischaemic 
postconditioning have been confirmed in many species including humans (Staat et al., 
2005, Skyschally et al., 2009). IPost protects the heart against IR through prevention of the 
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dramatic increase in intracellular pH during the early stages of reperfusion. Furthermore, 
during the early stages of reperfusion, there is robust generation of ROS in the vascular 
endothelium, cardiomyocytes, and mitochondria and this can be reduced by 
postconditioning (Sun et al., 2005, Serviddio et al., 2005). IPost also activates intracellular 
signal transduction in a way that is similar to preconditioning.    
1.3.4.2 Pharmacological treatment 
Several pharmacological agents are cardioprotective when administered before ischaemia 
or at the time of reperfusion. These drugs include adenosine (Whittaker et al., 1996), 
bradykinin (Brew et al., 1995), insulin (Sack and Yellon, 2003), Glucagon like peptide 1 
(Bose et al., 2005), cariporide (Zhang et al., 2006), atorvastatin (Birnbaum et al., 2003), 
sphingosine-1-phosphate (Knapp, 2011, Somers et al., 2012), cyclosporine (Piot  et al., 
2008) and sanglifehrin A (Clarke et al., 2002). All these drugs likely work upstream from 
mPTP except cyclosporine and sanglifehrin A which directly regulate mPTP. One of the 
important strategies for cardioprotection against IR insult is to prevent microvascular 
dysfunction as this will improve blood flow during reperfusion. Several studies 
demonstrated that preservation of vascular integrity during ischaemia/reperfusion may also 
protect the heart through limitation of no-flow phenomenon, decrease in post-infarct 
inflammatory response and limit the expansion of infarct size. In this regard, a number of 
drugs such as angiopoietin-like 4 (Galaup et al., 2012), sevoflurane (Annecke et al., 2010) 
and nitroglycerin (Lisi et al., 2012) protect vascular endothelium against an ischaemia 
reperfusion insult and confer secondary cardioprotection during acute myocardial 
infarction. 
1.4 Sphingosine-1-Phosphate (S1P) 
1.4.1 S1P overview 
The eukaryotic cell membrane consists of three main lipid types including cholesterol, 
glycerophospholipid, and sphingolipids. Sphingomylin metabolites are biologically active 
lipids synthesized from membrane phospholipids upon cell activation. Sphingosine-1-
phosphate (S1P) is one of the important phospholipid cellular metabolites that acts as an 
extracellular mediator and intracellular messenger. It is generated and released from many 
different cells by multistep enzymatic pathways in order to regulate diverse biological 
functions involving cell proliferation, migration, growth and survival. Although S1P has 
been extensively studied, much still remains to be investigated about this lysophospholipid. 
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1.4.2 Sphingosine-1-phosphate synthesis and degradation 
S1P biosynthesis starts with generation of ceramide from sphingomyelin via the action of 
the enzyme sphingomyelinase (Hannun et al., 2001) or de novo. This enzyme is stimulated 
by growth factors, arachidonic acid and oxidative stress to catalyse the generation of 
ceramide (Levade and Jaffrezou, 1999). The next step is deacylation of ceramide to 
produce sphingosine and non-esterified fatty acid and this step is catalysed by the enzyme 
ceramidase. Then sphingosine kinases (SK) catalyse the phosphorylation of sphingosine to 
produce S1P which in turn is dephosphorylated through the action of S1P phosphatase or 
degraded by S1P lyase (Figure 1-3). Interestingly the effect of ceramide and S1P on cell 
survival is completely different as ceramide promotes cell death (apoptosis) whereas S1P 
enhances cell survival. The intracellular levels of S1P are regulated by the balance between 
SK-mediated synthesis of S1P and its breakdown by S1P lyase or phosphatase. It has been 
reported that S1P can act as an intracellular messenger (Olivera and Spiegel, 1993, Spiegel, 
1999) or be released from cells in response to agonist stimulation to allow actions at S1P1-5 
receptors. De novo ceramide synthesis occurs in endoplasmic reticulum and is initiated by 
production of 3-Oxosphinganine from the serine palmitoyltransferase catalysed 
condensation of serine and palmitoyl-CoA. 3-Oxosphinganine is then reduced to 
dihydrosphingosine by an NAD(P)H-dependent reductase. Dihydroceramide is produced 
from N-acylation of dihydrosphingosine via dihydroceramide synthase. Dihydroceramide 
is later desaturated by dihydroceramide desaturase to produce ceramide (Pyne and Pyne, 
2000). 
1.4.3 S1P in circulation 
S1P is present in plasma at elevated concentrations ~ 0.1 to 1.1 μM (Murata et al., 2000) 
relative to the interstitial fluid of tissues. This S1P gradient is important in regulation of 
many physiological functions provided by extracellular S1P (Olivera et al., 2013). The 
high level of circulating S1P is maintained mainly by erythrocytes (Pappu et al., 2007, 
Xiong et al., 2014). The vascular endothelium is another important contributor to plasma 
S1P in adults (Venkataraman et al., 2008) and the lymphatic endothelium is the main 
source of lymphatic S1P (Pham et al., 2010). Furthermore, other blood cells such as 
activated platelets, neutrophils and monocytes may also contribute by releasing a small 
amount of S1P to the plasma (Yatomi et al., 1995). Within the plasma, S1P is bound to 
protein carriers such as HDL (50-60%) (Blaho et al., 2015), albumin (30–40%), LDL (~ 
8%) and VLDL (2-3%)(Okajima, 2002, Karuna et al., 2011). S1P is associated to HDL 
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specifically via apolipoprotein ApoM, which functions as an S1P chaperone that regulates 
the levels of S1P in blood (Christoffersen et al., 2011). Moreover, chaperones such as 
ApoM may also protect S1P from degradation and facilitate its delivery to S1P receptors.   
1.4.4 S1P receptors, Agonists and Antagonists 
The S1P receptors were originally known as endothelium differentiation gene (Edg) 
receptors because of the high expression of the gene encoding for this receptor in 
differentiating human umbilical vein endothelial cells. They are a G-protein coupled 
receptor family and each consists of approximately 400 amino acids (Hla and Maciag, 
1990, An et al., 1997, Okamoto et al., 1999, Im et al., 2000). The common features for S1P 
receptors include the seven transmembrane α-helices that extend through the lipid bilayer 
creating a polar internal tunnel, the C terminus and three intracellular loops exposed to the 
interior, and the N terminus and three extracellular loops exposed to the exterior. The S1P 
binds to these receptors with high affinity and therefore they are now named S1P receptors 
instead of Edg receptors. A set of five S1P receptors has been discovered, S1P1-5 but only 
S1P1-3 receptors are expressed in the cardiovascular system (Okazaki et al., 1993, 
MacLennan et al., 1994, Graler et al., 1998, Glickman et al., 1999, Yamazaki et al., 2000). 
The S1P receptors have 50% amino acid sequence homology and display overlapping as 
well as different expression patterns in tissue. S1P1 couples to particular pathways via Gi/o 
(Okamoto et al., 1998, Zondag et al., 1998). Stimulation of S1P1 receptor evokes certain 
responses including adenylyl cyclase inhibition, phospholipase C activation, Ca
2+
 
mobilisation (Okamoto et al., 1998) and activation of Ras-ERK and phosphatidylinositol 3-
kinase (PI3K)(O'Sullivan and Dev, 2013). S1P2 and S1P3 receptors couple via Gi/o, Gq and 
G12/13 and their stimulation leads to activation of phospholipase C (Kon et al., 1999), Ca
2+
 
mobilisation (Okamoto et al., 1998) and activation of Ras and extracellular signal related 
kinases (ERK)(An et al., 2000). S1P4 and S1P5 couple via Gi/o and G12/13 to activate Rho 
(O'Sullivan and Dev, 2013). 
S1P receptors appear to be specific as they have the ability to bind only S1P and dihydro-
S1P. In the past it was suggested that S1P receptors may be capable of binding 
lysophospholipids due to their structural similarity to S1P, however it is now widely 
believed that this is not the case (Contos et al., 2000). Sphingosine receptor agonists such 
as FTY720 have been used to study the activity of S1P receptors. The FTY720 is 
phosphorylated by sphingosine kinase 2 to generate its active form, phospho-FTY720, 
which is then able to bind to S1P receptors, with the exception of S1P2 (Paugh et al., 
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2003). FTY720 acts non-selectively and activates both S1P1/S1P3 receptors whereas 
SEW2871, AUY954 and AKP-11 can act as selective S1P1 agonists (Pan et al., 2006, 
Tsukada et al., 2007, Samuvel et al., 2015) and CYM5541 can selectively bind S1P3 
receptor (Jo et al., 2012). In terms of antagonists, the S1P3 receptor subtype can be blocked 
selectively by suramin (Ancellin and Hla, 1999) and BML-241 (also named CAY10444) 
but the receptor selectivity of the latter is still subject to debate (Salomone and Waeber, 
2011, Pyne and Pyne, 2011). VPC23019 is a dual S1P1/S1P3 antagonist, however its use 
has been limited because of its poor stability and in vivo efficacy (Davis et al., 2005, Awad 
et al., 2006, Salomone and Waeber, 2011). Conversely, W146 is widely utilized as a 
selective S1P1 receptor antagonist (Sanna et al., 2006). Although JTE-013 is capable of 
blocking S1P2 receptor activation, several studies showed that it also has antagonistic 
activity at S1P4 as well as non-S1PR-mediated effects (Salomone et al., 2008, Long et al., 
2010, Pyne and Pyne, 2011). Furthermore S1P has also been suggested to act as an 
intracellular messenger regulating intracellular Ca
2+
 mobilisation, cell proliferation and 
survival (Ghosh et al., 1990, Zhang et al., 1991). S1P has been demonstrated to bind and 
activate TRAF2, an E3 ligase that plays an important role in Lys 63-linked 
polyubiquitination of RIP1 and this process enhances cell survival by inhibiting switching 
of RIP1 from a prosurvival to proapoptotic adaptor protein (Alvarez et al., 2010). 
Prohibitin 2 (PHB2), a highly conserved protein that plays an important role in regulation 
of mitochondrial assembly and function, is another intracellular target for S1P. It was 
shown that interaction of S1P produced by SK2 in mitochondria with PHB2 is essential for 
cytochrome-c oxidase assembly and mitochondrial respiration (Strub et al., 2011). 
Moreover, Takasugi et al showed that S1P can bind to BACE1, the rate-limiting enzyme 
for amyloid-β peptide (Aβ) production, in vitro and enhances its proteolytic activity 
(Takasugi et al., 2011). A recent study found that S1P generated by SK2 in fibroblast 
nuclei interacts with hTERT, human telomerase reverse transcriptase, promoting its 
stability and consequently cell proliferation (Panneer Selvam et al., 2015). SK2 inhibition 
or deletion or mutating the S1P binding site reduced the stability of hTERT in cultured 
cells and enhanced senescence and loss of telomere integrity. It has also been reported that 
S1P acts as a ligand for PPARPeroxisome proliferator-activated receptor γ that regulates 
neoangiogenesis (Parham et al., 2015).Therefore, targeting S1P signalling pathway may 
help to understand the regulation of multiple systems including the cardiovascular system. 
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Figure  1-3 Summary of the steps involved in sphingosine-1-phosphate synthesis and 
breakdown. 
S1P synthesis is started by generation of ceramide from sphingomyelin via the action of the 
enzyme sphingomyelinase. Then sphingosine is formed from ceramide through the action of 
ceramidase enzyme. Thereafter, sphingosine kinases catalyse the phosphorylation of sphingosine 
to produce S1P which in turn is dephosphorylated through the action of S1P phosphatase or 
degraded by S1P lyase.    
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1.4.5 Physiological Role of S1P in the Cardiovascular System 
S1P and other sphingomyelin metabolites regulate a number of important functions in 
cardiac and vascular homeostasis. They may also play pivotal roles in the pathogenesis of 
several cardiovascular diseases including coronary artery disease, atherosclerosis, 
myocardial infarction, and heart failure. Therefore S1P has been extensively studied in 
recent years in order to elucidate its role in cardiovascular function. 
1.4.5.1 Effects of S1P on vascular development and tone 
Only S1P1, S1P2 and S1P3 are expressed in the cardiovascular system. Endothelial cells 
express mainly S1P1 receptors, less S1P3 and only very few S1P2 receptors under normal 
conditions (Ozaki et al., 2003, Saba and Hla, 2004, Alewijnse and Peters, 2008). On the 
other hand S1P2 receptors are predominately expressed in vascular smooth muscle cells 
(VSMC) where expression of S1P1 and S1P3 is much lower (Alewijnse and Peters, 2008). 
Moreover, there are relative differences in expression of S1P receptors in endothelial cells 
of different vascular beds (aortic, cerebral, coronary, renal, and mesenteric vessels) 
(Levkau, 2008, Igarashi and Michel, 2009). It has been reported that S1P may play an 
important role in angiogenesis as S1P1 knockout mice die during embryogenesis as a result 
of vascular haemorrhage due to a lack of support from vascular smooth muscle cell that 
fail to surround and support the developing vasculature (Liu et al., 2000b). This 
demonstrates that S1P1 receptors in endothelial cells but not VSMC play a decisive role in 
recruitment of VSMC and this is confirmed by the appearance of the same phenotype in 
endothelial-specific S1P1 knockout mice (Allende and Proia, 2002). SK1 and SK2 
knockout mice that completely lack S1P have identical defects (Mizugishi et al., 2005). 
These studies provide considerable evidence that S1P has an important role in vascular 
morphogenesis. 
S1P has been implicated in regulation of vascular tone and the first study to examine its 
effects on vascular tone used rat isolated mesenteric artery and intra-renal vessels. In both 
arteries, S1P induced vasoconstriction and this effect was mediated by a G-protein coupled 
receptor and associated with an increase in intracellular calcium (Bischoff et al., 2000). 
Since this initial demonstration of S1P’s role in regulation of vascular tone, further studies 
have been conducted in a variety of vessels which have shown that the degree and type of 
vascular response to S1P varies between species and vascular beds. For instance, 
exogenous application of S1P to isolated rat mesenteric and cerebral arteries has been 
reported to promote vasoconstriction in these vessels (Hemmings et al., 2004, Salomone et 
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al., 2008). Furthermore, Salomone et al (2008) demonstrated that the vasoconstrictor 
response of rat cerebral arteries to S1P was mediated through S1P3 receptor. It has also 
been reported that S1P may constrict rat coronary artery via a mechanism requiring S1P3 
receptor (Murakami et al., 2010). S1P-induced vasoconstriction has also been observed in 
porcine pulmonary (Hsiao et al., 2005), human placental (Hemmings et al., 2006), 
intrarenal (Czyborra et al., 2006) and hamster gracilis muscle resistance arteries (Keller et 
al., 2006). Rho-associated kinase activation (Hemmings et al., 2006) and increased reactive 
oxygen species production (Keller et al., 2006) are suggested mechanisms mediating 
contractions in these arteries (Figure 1-4). On the other hand, S1P can also induce 
vasorelaxation in particular vascular beds. It has been found that S1P induced relaxation of 
rat mesenteric artery and this response can be abolished by removal of endothelium or by 
addition of nitric oxide synthase inhibitor (Dantas et al., 2003), suggesting involvement of 
endothelial isoforms of nitric oxide synthase (eNOS) in the relaxant response (Figure1-4). 
The relaxant effect of S1P has also been demonstrated in rat aorta and this response was 
S1P3 receptor dependent and involved activation of the eNOS pathway (Nofer et al., 2004, 
Roviezzo et al., 2006). A reason behind the different effects of S1P on the same vessel 
preparation may be due to the differences in the receptor subtypes expressed within the 
vessels and the distribution of these receptors (Coussin et al., 2002). S1P is able to induce 
vasorelaxation via activation of eNOS and this effect is mediated by S1P1 receptor subtype, 
which is highly expressed in vascular endothelium (Igarashi and Michel, 2000, Igarashi et 
al., 2001). In contrast, S1P2, which is mainly expressed in vascular smooth muscle cells, 
can mediate vasoconstriction via increased intracellular calcium levels and activation of 
Rho kinase in VSMC (Hemmings et al., 2006, Peters and Alewijnse, 2007). Thus, the 
receptor subtype expression in the vascular bed and the balance between the vasodilator 
and vasoconstrictor signals stimulated by S1P play an important role in determination of 
the overall effect on vascular tone. Another important factor is the concentration range of 
agonist used in the studies. For instance, S1P-induced vasoconstriction of rat mesenteric 
artery only developed at high agonist concentration (˃3×10-5 M) (Hedemann et al., 2004) 
whereas S1P-induced vasodilation developed at much lower concentration range (1×10
-10
 
M - 1×10
-7
 M) (Dantas et al., 2003). Moreover, S1P had no effect on tone of rat aorta at 
high concentrations (˃3×10-5 M)(Coussin et al., 2002) but a lower concentration range 
(1×10
-8
 M - 3×10
-5
 M) induced relaxation (Roviezzo et al., 2006). Therefore, S1P may 
have a relaxant effect at low physiological levels and cause constriction at higher, non-
physiological levels. In the coronary artery, S1P may potentially have constrictor and 
dilator effects. S1P has been observed to induce contraction of cultured coronary smooth 
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muscle cells via S1P2 (Ohmori et al., 2003). It has also been demonstrated that S1P 
stimulates cAMP production in these cells, which would be expected to have a relaxant 
effect via cAMP-induced uncoupling of excitation-contraction. cAMP production in these 
cells was inhibited by indomethacin and the S1P2 receptor blocker, JTE-013 (Damirin et 
al., 2005). In mice hearts, S1P may reduce myocardial perfusion via its coronary 
vasoconstrictor effect (Levkau et al., 2004). In contrast, there is growing evidence that S1P 
can induce coronary artery vasorelaxation. It has been observed that sphingomyelinase, the 
enzyme responsible for synthesis of S1P precursors, induces dilatation of the bovine 
coronary artery via production of nitric oxide (Mogami et al., 2005). Furthermore, Mair et 
al demonstrated that S1P can induce vasorelaxation in rat coronary artery via a mechanism 
requiring CB2 and S1P3 receptors. Indeed this study has shown that there is an interaction 
between anandamide and S1P in mediating the relaxant effect on rat coronary artery (Mair 
et al., 2010). Moreover, transient receptor potential channels, of vanilloid subtype (TRPV), 
function as sensory mediators, being stimulated by endogenous ligands, mechanical, 
osmotic and heat stress (Baylie and Brayden, 2011). Within blood vessels, TRPV channels 
are expressed in endothelial cells, smooth muscle cells, as well as peri-vascular nerves. 
Activation of TRPV1 channels in endothelial cells can contribute to vasorelaxation via 
nitric oxide- and prostacyclin-dependent pathways (Baylie and Brayden, 2011). Several 
studies showed that S1P and its precursor sphingosine activate these channels and this may 
play a role in regulation of vascular tone (Numata et al., 2011, Langeslag et al., 2014). 
1.4.5.2 Role of S1P in regulation of blood pressure 
Several studies have demonstrated that S1P signalling may contribute to regulation of 
blood pressure. Administration of S1P and its analogue, FTY720 has been shown to induce 
a transient decrease in blood pressure initially and a mild increase in blood pressure 
following long-term use (Camm et al., 2014). It has been suggested that the initial 
hypotensive effect is likely due to S1P1/S1P3-dependent activation of eNOS, whereas 
downregulation of S1P1 in endothelial cells might be the cause of long-term hypertensive 
response. Cantalupo et al has recently shown that S1P/S1P1/eNOS pathway is critical for 
vascular function and blood pressure homeostasis (Cantalupo et al., 2015). In the same 
study, it has been found that deletion of Nogo B, a membrane protein of the endoplasmic 
reticulum that inhibits serine palmitoyltransferase, systemically or specifically in 
endothelial cells led to hypotension and resistance to angiotensin II-induced hypertension. 
Increase in eNOS activity and NO production were also reported in Nogo-B-null mice 
(Cantalupo et al., 2015). Moreover, inhibition of S1P1 but not S1P2 or S1P3 receptors 
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reversed the enhanced vasorelaxation in Nogo-B-null mice. In contrast, another study has 
reported that knocking out or inhibition of SK1 attenuates Angiotensin II-induced 
intracellular Ca
2+
 rise in vascular smooth muscle cells and consequently inhibits both the 
rapid increase in blood pressure in response to Angiotensin II and the chronic hypertensive 
response to continuous administration of S1P in mice, suggesting that S1P generated by 
SK1 may contribute to development of hypertension (Wilson et al., 2015). Obviously, 
more studies are required to interrogate the role of S1P signalling in control of blood 
pressure and whether vascular response to S1P can differ under certain circumstances.                  
1.4.5.3 Influence of S1P endothelial integrity 
The intimal-located ECs in the blood vessels are essential to maintain barrier integrity and 
thus regulate extravasation of blood cells and other molecules. The permeability of this 
barrier is regulated by extracellular cell-cell and cell-matrix forces as well as intracellular 
cytoskeleton configuration by actin-myosin interactions. S1P stimulates synthesis of actin 
lamellipodia and membrane ruffles and increases actin assembly leading to an enhanced 
barrier function (Garcia et al., 2001). Several studies have demonstrated that S1P promotes 
EC barrier integrity primarily through activation of S1P1 receptor (Garcia et al., 2001, 
Feistritzer and Riewald, 2005, Singleton et al., 2005), which strengthens EC junctions. 
Moreover, the role of S1P1 in maintaining EC barrier was confirmed by studies using S1P1 
knockout mice (Liu et al., 2000b, Allende and Proia, 2002) (Figure 1-4). In vivo studies 
have also shown that S1P1 antagonism causes loss of capillary integrity in mouse skin and 
lung (Sanna et al., 2006). Christoffersen et al showed that HDL-associated S1P is carried 
by ApoM which delivers S1P to S1P1 receptors in endothelial cells (Christoffersen et al., 
2011). S1P carried by ApoM in the HDL fraction was shown to play an important role in 
maintaining endothelial barrier integrity via promoting endothelial cell migration and 
formation of endothelial adherens junctions (Christoffersen et al., 2011). Recently it has 
been demonstrated that the increased pulmonary vascular permeability of ApoM-deficient 
mice was related to reduced plasma S1P levels and rapidly reversed by addition of 
ApoM/S1P-enriched plasma or SEW2871, an S1P1 agonist (Christensen et al., 2016). This 
study has also reported that deletion of endothelial S1P1 receptor was associated with 
increased susceptibility to inflammation-induced vascular leakage. Conversely, the effect 
of S1P2 and S1P3 activation on EC barrier is still an area of controversy. Several studies 
ruled out a protective function for these receptors on EC barrier (Garcia et al., 2001, Lucke 
and Levkau, 2010). However, other studies observed that these receptors are negative 
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regulators of barrier integrity (Gon et al., 2005, Singleton et al., 2006, Sanchez et al., 
2007). 
1.4.5.4 Influence of S1P on cell adhesion 
Several studies demonstrated that S1P has an inhibitory effect on leukocyte adhesion; an 
initial step for cell extravasation and inflammatory responses. For instance, Nofer et al 
showed that HDL-associated lysophospholipids decrease TNFα-induced expression of E-
selectin in a partially S1P3-dependent manner (Nofer et al., 2003). Other studies showed 
that the S1P1 signalling pathway is also involved in the prevention of leukocyte adhesion 
via a decrease in expression of adhesion molecules such as VE-cadherin and E-selectin 
(Krump-Konvalinkova et al., 2005) (Figure 1-4). In addition to the inhibitory effect on the 
expression of adhesion molecules, S1P also reduced the production of proinflammatory 
cytokines. Tolle et al provided evidence that S1P is able to reduce production of monocyte 
chemoattractant protein-1 (MCP-1), via an action at S1P3 receptors (Tolle et al., 2008) 
(Figure 1-4) and Bolick et al showed that S1P inhibits TNFα-mediated leukocyte adhesion 
by reduction of proinflammatory cytokine production in an S1P1-mediated manner (Bolick 
et al., 2005). Moreover, cross activation of TGF-β, a potent anti-inflammatory cytokine, 
via S1P3 decreases the expression of proinflammatory genes such as inducible NO 
synthase, secretory phospholipase A2 and matrix metalloproteinase-9 in mesangial cells 
(Xin et al., 2004). However, others have demonstrated that S1P may enhance adhesion 
molecule expression in ECs (Kimura et al., 2006) and stimulate the release of MCP-1 and 
interleukin-8 (IL-8) (Lin et al., 2006). It has also been reported that S1P increases E-
selectin expression and leukocyte adhesion via intracellular signalling pathways in vascular 
endothelial cells (Weis et al., 2010) and this is in agreement with others (Lee et al., 2004b, 
Lin et al., 2007). 
1.4.5.5 Effects of S1P on inflammation and atherosclerotic plaque instability 
It has been demonstrated that treatment with FTY720, an S1P analogue, significantly 
decreases atherosclerotic plaques in mouse models (Keul et al., 2007b, Nofer et al., 2007). 
A recent study showed that deletion of S1P1 receptors in endothelial cells enhanced the 
expression of proinflammatory adhesion molecules such as ICAM-1, whereas 
overexpression of S1P1 exhibited protective effects against vascular inflammation in mouse 
aortic endothelium (Galvani et al., 2015). This study also found that HDL-S1P enhanced 
the formation of a cell surface S1P1–β-arrestin 2 complex in HUVECs and reduced NF-kB 
activation by proinflammatory cytokine TNFα. Micaud et al provided evidence that S1P2 
28 
 
has an inhibitory effect on macrophage migration in vitro (Michaud et al., 2010). 
Moreover, S1P2 and apoE knockout result in inhibition of macrophage pro-inflammatory 
activities and atherosclerosis (Wang et al., 2010, Skoura et al., 2011). Selective attenuation 
of toll like receptor 2 may underlie the atheroprotective effects of S1P (Duenas et al., 
2008). Furthermore, the S1P receptors might be involved in rebalance alterations in the 
coagulation pathway (Ruf et al., 2009) and thus reduce the risk of thrombosis. 
1.4.5.6 Influence of S1P on proliferation and migration of ECS and VSMCS 
S1P plays an important role in regulation of proliferation and migration of many cells 
including ECs and VSMCs (Kimura et al., 2000, Kluk and Hla, 2001). Cell migration and 
proliferation is an important process not only for embryogenesis but also for inflammation, 
angiogenesis, wound healing and tumour growth. Kimura and co-workers demonstrated 
that S1P1/3 receptors are essential in EC proliferation (Kimura et al., 2000) (Figure 1-4). 
Overexpression of S1P1 in VSMCs results in activation of p70S6 kinase and cyclin D 
expression and therefore promotes VMSCs proliferation (Kluk and Hla, 2001, Kluk and 
Hla, 2002) (Figure 1-4). In addition to positive proliferation effects, anti-proliferative 
responses could be shown as well. Deletion of S1P2 in mouse embryonic fibroblasts 
(MEFs) enhances their proliferation compared with wild type MEFs (Goparaju et al., 
2005). Therefore, it seems to be that S1P has both stimulatory and inhibitory effects on 
proliferation and this may depend upon the cell and receptor subtype involved. Several 
studies identified an important role for S1P1/3 receptor subtypes in regulation of EC 
migration (Kimura et al., 2000, Panetti et al., 2000). It could also be shown that S1P 
migratory effect is essential for the formation of blood vessels (Argraves et al., 2004). 
Moreover, Anelli et al identified SK1 as an important mediator of S1P-induced migration 
and tube formation in ECs in vitro (Anelli et al., 2010). In contrast, other studies 
demonstrated an inhibitory potential of S1P on the migration of ECs and VSMCs. S1P 
reduces the PDGF-induced chemotaxis of human VSMCs (Bornfeldt et al., 1995). 
Moreover, Tamama et al showed that HDL-associated S1P inhibits VSMC migration 
(Tamama et al., 2005). It has also been demonstrated that S1P-induced inhibitory actions 
were decreased by S1P2-specific siRNA in human coronary artery smooth muscle cells 
(Damirin et al., 2007) and JTE-013, an S1P2 antagonist, could promote EC and VSMC 
migration (Osada et al., 2002). In vivo studies were consistent with these findings. 
Deletion of S1P2 induced large neointimal lesions after ligation of the carotid artery 
(Shimizu et al., 2007). Moreover, S1P enhanced VSMCs migration rate compared with 
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VSMCs in wild type mice (Shimizu et al., 2007). Others confirmed that inhibiting S1P2 
increases migration rate (Inoue et al., 2007).       
1.4.5.7 Apoptosis 
Pathological conditions affecting the blood vessels often induce endothelial dysfunction 
that results in an increased cell turnover rate and hence ECs undergo apoptosis. S1P is a 
potent factor protecting ECs against apoptosis by inhibition of caspases, cytochrome c 
release and DNA fragmentation (Cuvillier et al., 1996). Moreover, HDL-associated S1P 
can directly protect mouse cardiomyocytes and isolated hearts subjected to oxidative injury 
and this prosurvival signal stimulation is dependent on both S1P1 and S1P3 receptors (Tao 
et al., 2010). The protective role of S1P is not only mediated by its receptor activation and 
downstream G-protein-mediated signalling pathways (Radeff-Huang et al., 2004), but also 
through its function as an internal signalling molecule. NO is a known inhibitory factor of 
endothelial apoptosis and mediates protection via nitrosylation of cysteine residues in the 
catalytic centre of caspases and thus results in enzyme inactivation (Rössig et al., 1999, 
Sun et al., 2006a). Kwon provided evidence that S1P protective effects are mediated 
through S1P1/3 activation and this effect is reversed by inhibition of NO synthase (Kwon et 
al., 2001). Other studies showed cytoprotective effects of S1P through S1P1-3 (Donati et al., 
2007, Hofmann et al., 2009, Nieuwenhuis et al., 2009). In many cell types, apoptosis is 
enhanced by tumour necrosis factor α (TNF-α) which activates TNF-receptor 1. It has been 
reported that activation of SK by tumour necrosis factor α protects human umbilical vein 
endothelial cells from apoptosis (Xia et al., 1999). Other studies showed that an 
overexpression of SK inhibits apoptosis in a pertussis toxin (PTX)-independent way 
(Olivera et al., 1999). Another important factor inducing apoptosis in vascular diseases is 
the increased generation of ROS in the vasculature. It was demonstrated that S1P prevents 
EC apoptosis via a decrease in ROS production. Indeed, H2O2-induced apoptosis in ECs 
can be reversed by S1P pre-treatment (Moriue et al., 2008). 
1.4.5.8 Role of S1P in cardiac development, function and heart rate 
S1P1, S1P2 and S1P3 are expressed in adult rodent heart with S1P1 being more highly 
expressed than the other two (Alewijnse et al., 2004) whereas in human hearts, S1P1 and 
S1P3 are expressed in similar amounts. S1P1 is mainly expressed in ventricular, atrial and 
septal cardiomyocytes and in endothelial cells of coronary vessels (Mazurais et al., 2002). 
Moreover, the enzymes responsible for generation and breakdown of S1P also exist and are 
active in the heart. SK1 and SK2 are expressed in cardiac tissue as early as the linear heart 
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tube stage (E8.5) (Wendler and Rivkees, 2006). S1P phosphatase 1, the enzyme that 
catalyses S1P degradation is also expressed in the adult heart (Mandala et al., 2000, 
Johnson et al., 2003) and throughout the early stages of cardiac development (Wendler and 
Rivkees, 2006). Cardiomyocytes have been found to express more S1P lyase than cardiac 
fibroblasts (Bandhuvula et al., 2011). This indicates that S1P may play an important role in 
early cardiac morphogenesis where it regulates migration, differentiation, and survival of 
embryonic cardiac cells (Wendler and Rivkees, 2006). 
There was no significant change in blood pressure and cardiac function in S1P2-deficient 
(Lorenz et al., 2007) and S1P3-deficient mice (Levkau et al., 2004). Systemic 
administration of S1P was reported to decrease heart rate in rats (Benediktsdottir et al., 
2002) and mice (Sanna et al., 2004). This effect is thought to be mediated by S1P3 receptor 
as in S1P3 knockout mice, S1P had no effect on heart rate. In cardiomyocytes in vitro, S1P 
promotes protein synthesis and cellular hypertrophy mainly via S1P1 receptors (Robert et 
al., 2001). Moreover, it has been reported that S1P activates STAT3 in ventricular 
cardiomyocytes (Frias et al., 2009), which is involved in the physiological hypertrophic 
response (Kunisada et al., 1998). Involvement of S1P in cardiac remodelling was also 
observed in in vivo studies. A significant association between increased S1P in the plasma 
and left ventricular hypertrophy was reported in patients with Fabry disease, suggesting 
that S1P may play a pivotal role in cardiac remodelling in these patients (Brakch et al., 
2010). Zhang et al has recently shown that the SK1/S1P/S1P1 signalling pathway is 
promoted within 4 weeks post MI and this markedly contributes to cardiac inflammatory 
response, remodelling and dysfunction (Zhang et al., 2016a). In contrast, S1P levels have 
been found unchanged in the peripheral circulation of patients with chronic systolic heart 
failure (Knapp et al., 2012). Furthermore, S1P exerts many effects on ion currents in 
cardiomyocytes in vitro. It activates the inward rectifier potassium current (I(K.Ach)) 
leading to a reduction of spontaneous pacing rate (Guo et al., 1999) and prevents the 
isoproterenol-induced increase in L-type calcium channel (ICa,L) currents. It also 
attenuates the hyperpolarization-activated inward current (If), thereby limiting the positive 
chronotropic effects of β-adrenergic stimuli in sinoatrial node cells and ventricular 
cardiomyocytes (Guo et al., 1999, Landeen et al., 2008). 
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Figure  1-4 Diverse physiological processes are regulated by S1P.  
(A) vascular tone, (B) endothelial integrity, (C) apoptosis, (D) cellular adhesion, (E) proliferation and migration.
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1.5 Sphingosine kinase (s) 
Two SK isoforms exist in mammalian cells, identified as SK1 and SK2. In humans, they 
are generated from two distinct genes, SPHK1 and SPHK2, which are located on 
chromosomes 17 and 19, respectively. Human SK1 and SK2 vary markedly in size (384 
and 618 amino acid for SK1a and SK2a, respectively) (Liu et al., 2000a), but they share 
80% similarity and 45% overall sequence identity. The two isoforms exhibit partial 
redundancy since SK1 knockout or SK2 knockout mice are phenotypically normal whereas 
deletion of both genes causes embryonic lethality due to vascular and neurological defects 
(Mizugishi et al., 2005). SK1 and SK2 have five conserved domains (C1-C5), with the 
catalytic domain located within C1-C3 and the ATP binding domain formed in the C2 
region (Pitson et al., 2002). The activity of both SK isoforms is regulated in a spatial and 
temporal manner by post-translational modification and interaction with various proteins 
and lipids. Furthermore, both SK isoforms are ubiquitously expressed in all human tissues 
with highest expression of SK1 in lung, heart, spleen and leukocytes and SK2 in the liver 
and kidney (Melendez et al., 2000, Liu et al., 2000a). For SK1, three isoform variants 
(known as SK1a, SK1b, and SK1c) exist that differ only at their N termini. SK1a has a 
molecular mass of 42.5 kDa, while SK1b has an 86 amino acid N-terminal extension and is 
a 51 kDa protein (Pitson et al., 2000, Ota et al., 2004). Moreover subcellular localisation of 
SK1 varies between cell types. For instance, it exhibits cytoplasmic, plasma membrane, 
and vesicular distribution in HUVECs and it is also localised to the endoplasmic reticulum 
and Golgi apparatus and associated with the cytoskeleton in other cell lines such as the 
cultured smooth muscle cell line DDT1MF-2 (Taha et al., 2006b, Wattenberg et al., 2006). 
Two variants of SK2 have been described and characterized (Liu et al., 2000a, Okada et 
al., 2005), the shorter isoform is known as SK2a and the larger one is named SK2b which 
has an additional 36 amino acids at the N-terminus. Subcellular localisation of SK2 also 
depends on the cell type. In HeLa cells, for example, SK2 predominantly localises to the 
nucleus, whereas it is a cytoplasmic protein in HEK293 cells (Igarashi et al., 2003). 
Localisation of SK2 in endoplasmic reticulum has also been reported under stress 
conditions (Hait et al., 2005). 
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1.5.1 Role and regulation of SK1 
Of the two SKs, SK1 is by far the most well studied. Several studies have demonstrated 
that overexpression of SK1 increases cell survival and proliferation and induces neoplastic 
transformation (Xia et al., 2000). SK1 is a cytoplasmic protein and its phosphorylation by 
Extracellular signal regulated kinase1 and 2 (ERK1/2) enhances its catalytic activity and 
also facilitates translocation of SK1 from cytosol towards the plasma membrane through 
binding to calcium and integrin-binding protein 1 (CIB1) (Pitson et al., 2003, Jarman et al., 
2010). It has been demonstrated that CIB1 mediates agonist-dependent relocalisation of 
SK1 to the plasma membrane and a subsequent increase in S1P production in HeLa cells 
(Jarman et al., 2010). Moreover, knock down of CIB1 in HeLa cells led to a decrease in 
S1P generation, indicating that CIB1 is required for activation and translocation of SK1 to 
the plasma membrane.    
ERK1/2 directly phosphorylates SK1 at ser225 which leads to a 14-fold rise in SK1 
catalytic activity while not changing its affinity for sphingosine or ATP (Pitson et al., 
2003). In most cases, the enhanced SK1 activity caused by phosphorylation is transient due 
to dephosphorylation by an enzyme named phosphatase 2A (PP2A) (Barr et al., 2008). At 
this location, SK1 catalyses the generation of S1P from plasma membrane associated 
sphingosine and this facilitates the extracellular transport of S1P to act on cell surface S1P 
receptors and the interaction with intracellular targets to mediate downstream signalling 
and enhance cell survival, proliferation, migration, angiogenesis and inflammation 
(Maceyka et al., 2009, Neubauer and Pitson, 2013, Pyne et al., 2016). Interestingly, the 
activity of SK1 can also be regulated via phosphorylation-independent mechanisms (ter 
Braak et al., 2009, Gault et al., 2012). Ser225 phosphorylation is not required for all 
membrane translocation of SK1. For example, ter Braak et al (2009) demonstrated that 
translocation of SK1 in response to muscarinic receptor activation is mediated by the Gq G-
protein in HEK-293 cells. It has also been reported that translocation of SK1 in response to 
K-RasG12V in mouse embryonic fibroblasts does not require ser225 phosphorylation 
(Gault et al., 2012).  
1.5.1.1 Interacting proteins that activate and inhibit SK1   
Several studies have revealed that a variety of proteins can directly interact with and 
activate SK1. This interaction between SK1 and these proteins only leads to a modest rise 
in SK1 activity, but it is sufficient to initiate a number of distinct cellular responses. In 
mast cells, two Src family protein tyrosine kinases (PTKs), Lyn and Fyn have been 
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demonstrated to interact with and directly promote the catalytic activity of SK1 (Urtz et al., 
2004, Olivera et al., 2006). Other studies showed that δ-catenin and eukaryotic elongation 
factor 1A (eEF1A) could also enhance SK1 activity in vitro and in cells (Fujita et al., 2004, 
Leclercq et al., 2008). Moreover, adaptor protein associated with TNF-α receptor 1 
(TRAF2) may also associate with and activate SK1 when overexpressed (Xia et al., 2002, 
Alvarez et al., 2010). This SK1-TRAF2 interaction is essential for TNF-α-induced 
stimulation of pro-survival, pro-inflammatory transcription factor NF-κB. On the other 
hand, a number of studies have reported that some proteins can interact and inhibit the 
catalytic activity of SK1. For instance, FHL-2 (Sun et al., 2006b, Hayashi et al., 2009) and 
PECAM-1 (Fukuda et al., 2004) have been demonstrated to interact with SK1 and inhibit 
its activity in cardiomyocytes and vascular endothelial cells, respectively. However, SK1 
dissociates from these inhibitory complexes upon stimulation with extracellular signals and 
becomes more active. SK1 interacting protein (SKIP) (Lacana et al., 2002) and 
aminoacylase 1 (Maceyka et al., 2004) are other proteins that could interact and inhibit 
SK1, although the physiological roles of these interactions are not known. 
1.5.1.2 Interacting proteins that alter subcellular localisation of SK1 
Subcellular localisation plays an essential role in the regulation and signalling functions of 
many signalling proteins. A growing body of evidence has shown that the cellular 
localisation of sphingolipids and sphingolipid-metabolising enzymes is crucial for their 
functions (Wattenberg et al., 2006). Given that SK1 is one of the important regulators of 
the sphingolipid system and that the localisation of this enzyme seems to be essential for 
its function, a number of studies have investigated the control of the subcellular 
localisation of SK1. Under basal condition, SK1 appears to reside in the cytoplasm (Pitson 
et al., 2003). However, phosphorylation of SK1 at Ser225 by ERK1/2 results in 
translocation of SK1 from cytosol to the plasma membrane. Numerous studies have 
suggested that this process is mediated by calmodulin since either inhibition of calmodulin 
or mutation of the calmodulin-binding site of SK1 prevented the plasma membrane 
localisation of SK1 (Young et al., 2003, Sutherland et al., 2006). Recently, it has been 
demonstrated that SK1 translocation to the plasma membrane is mediated by the CaM-
related, calcium- and integrin-binding protein 1 (CIB1) (Jarman et al., 2010). Like other 
calcium-myrisoyl switch proteins, translocation of CIB1to the plasma membrane requires 
both its myristoylation and calcium binding, providing a mechanism for active 
relocalisation of SK1 to the plasma membrane following an increase in calcium levels that 
are known to be associated with SK1 activation (Spiegel and Milstien, 2003). The process 
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of SK1 translocation to the plasma membrane appears to be integral not only for cell 
survival and proliferation but also for cell motility. For instance, the plasma membrane 
translocation of SK1 to the migrating front of the cell has been revealed to be fundamental 
in the generation of lamellipodia and polarised cell movement in a process that is likely to 
be mediated by filamin A, an actin binding protein (Maceyka et al., 2008). Notably, 
filamin A acts as a scaffolding protein that attaches to both SK1 and p21-activated kinase 
and binds the complex to S1P1 at lamellipodia to regulate cell migration (Maceyka et al., 
2008). 
1.5.1.3 Regulation of SK1 by phospholipids 
While it is now known that relocalisation of SK1 to the plasma membrane following 
phosphorylation by ERK1/2 is mediated by CIB1 (Jarman et al., 2010), prevention of SK1 
being redistributed to the cytosol is thought to be achieved by its interaction with 
phosphatidic acid (PA) and phosphatidylserine (PS) that are normally found in the inner 
leaflet on the plasma membrane (Delon et al., 2004, Stahelin et al., 2005). Moreover, 
phosphorylation of SK1 at Ser225 appears necessary not only for translocation of this 
enzyme to the plasma membrane but it is also required for SK1 to interact with PS (Pitson 
et al., 2003, Stahelin et al., 2005). It was suggested that Ser225 phosphorylation of SK1 
may regulate the membrane binding through a conformational change in SK1 that leads to 
exposure of Thr54 and Asn89 on the surface of the enzyme and this allows these residues 
to interact with PS at the plasma membrane and endoplasmic reticulum (ER)/Golgi 
apparatus (Stahelin et al., 2005). Furthermore, the interaction of SK1 with these 
phospholipids also leads to enhanced SK1 activity (Olivera et al., 1996, Pitson et al., 
2000). Although the functional consequence of these interactions is not yet well 
understood, it is possible that the interactions with these phospholipids may help to localise 
SK1 in close proximity to its substrate, sphingosine, in the plasma membrane. 
1.5.2 Regulation of SK2 
Like SK1, the catalytic activity of SK2 can be increased rapidly following exposure to a 
variety of agonists such as TNF-α (Mastrandrea et al., 2005), EGF (Hait et al., 2005) and 
IL-1β (Mastrandrea et al., 2005). Since SK2 is closely related structurally to SK1, SK2 
activation can occur via phosphorylation by ERK1/2 (Hait et al., 2007). Notably, while 
SK1 phosphorylation occurs at Ser225, SK2 was shown to be phosphorylated by ERK1/2 
at two sites: Ser351 and Thr578 (Hait et al., 2007). Under normal conditions, SK2 resides 
predominantly in the nucleus and cytoplasm. Indeed, SK2 localisation appears to depend 
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upon cell type and cell density. For instance, SK2 mainly localises in the nucleus in HeLa 
cells whereas in HEK293 cells it is predominately cytoplasmic (Igarashi et al., 2003). 
Furthermore, it has been reported that the proportion of SK2 localised in the nucleus 
increased in COS-7 fibroblasts when they became more confluent in culture (Igarashi et 
al., 2003), suggesting that SK2 may play a role in contact inhibition responses which 
reduce cell proliferation. It has also been shown that SK2 localises to the endoplasmic 
reticulum (ER) under stress conditions (Maceyka et al., 2005). S1P generation at the ER 
can fuel the sphingosine salvage pathway driven by ER-localised S1P phosphatases and 
ceramide synthase, to ultimately produce pro-apoptotic ceramide (Maceyka et al., 2005). 
Moreover, mitochondrial localisation of SK2 has been demonstrated to enhance apoptosis 
via S1P and BAK-dependent membrane permeabilization and cytochrome c release (Strub 
et al., 2011, Chipuk et al., 2012). In contrast, several studies have shown that SK2 can have 
a physiological role in mediating survival and proliferation. Downregulation of SK2 by 
siRNA was associated with enhancement of apoptosis and reduction in chemotherapeutic 
resistance in several cancer cell lines (Sankala et al., 2007, Schnitzer et al., 2009, Dai et al., 
2014). Moreover, a recent study has demonstrated that hypoxic preconditioning protected 
cardiomyocytes against hypoxia/reoxygenation injury through upregulation of SK2 
expression and downstream activation of FAK/Akt signalling pathway (Zhang et al., 
2016b).  
1.5.3 Degradation of SKs 
Treatment of cells with DNA damaging agents such as etoposide, actinomycin D, 
doxorubicin and UV irradiation has been demonstrated to decrease SK1 protein levels 
while having no effects on levels of SK1 mRNA. Moreover, at least for UV irradiation, 
this appears to occur in a p53-dependant manner (Taha et al., 2004, Heffernan-Stroud et 
al., 2012). This suggests that a further level of SK1 regulation occurs through its 
breakdown. In this regard, recent studies have shown, using a number of cell lines, that 
SK1 might be degraded via ubiquitin-proteasomal pathway in response to different SK1 
inhibitors including 2-(p-hydroxyanilino)-4-(p-chloropenyl)thiazole (SKi), N,N-
dimethylsphingosine (DMS), FTY720 and PF543 (Loveridge et al., 2010, Tonelli et al., 
2010, McNaughton et al., 2016). Moreover, ABC294640, a selective SK2 inhibitor, was 
also demonstrated to induce proteasomal degradation of SK1a in prostate cancer cells 
(McNaughton et al., 2016). Furthermore, in most cells this effect was abolished when cells 
were treated with MG-132, a proteasomal inhibitor (Loveridge et al., 2010, Tonelli et al., 
2010, McNaughton et al., 2016). However, SK1b was reported to resist degradation 
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induced by SKi in particular cell lines such as androgen-independent prostate cancer cells 
and this might be due to a compensatory upregulation of SK1b and/or modification of 
SK1b that decreases its sensitivity to SKi-induced proteasomal degradation (Loveridge et 
al., 2010). The mechanism by which SKi-induces proteasomal degradation has been 
suggested to be due to inhibition of catalytic SK1 activity by SKi that results in an increase 
in ceramide levels and this leads to proteasomal degradation of SK1 (Loveridge et al., 
2010). Recently, Yu et al showed that SK1 could be acetylated on Lys27 and Lys29 which 
increases the stability of the enzyme by preventing ubiquitin-mediated protein degradation 
(Yu et al., 2012). Mutation of two lysine residues inhibited SK1 ubiquitination and 
proteasomal degradation, suggesting that the process of acetylation and ubiquitination may 
compete for the same lysine residues and play a role SK1 regulation. Interestingly, 
however, a number of studies have demonstrated that SK1 can also be degraded through 
the lysosomal pathway (Taha et al., 2006a, Ren et al., 2010). This notion is supported by 
the experimental evidence that SKi-induced SK1 degradation can be prevented by 
treatment with chloroquine, a general lysosomal inhibitor, and CA-074ME, a specific 
cathepsin B inhibitor (Ren et al., 2010). The SK1 degradation by the lysosomal pathway 
was further supported by the colocalisation of SK1 with the lysosome and cathepsin B (one 
of the most abundant lysosomal proteases) in MCF-7 cells (Taha et al., 2005). Moreover, it 
has been shown that SK1 can be cleaved by cathepsin B (Taha et al., 2006a), suggesting 
that SK1, under some circumstances, may be degraded via the lysosomal pathway. The 
SK2 degradation mechanism is still unknown, although Lim et al demonstrated that SK2 is 
degraded by a non-proteasomal and non-lysosomal route in response to ROMe, a selective 
SK2 inhibitor in HEK 293 cells (Lim et al., 2011). It has also been reported that SK2 can 
be cleaved by caspase-1 which appears to facilitate its release from apoptotic cells 
(Weigert et al., 2010). 
1.5.4 Sphingosine kinase inhibitors 
A number of SK inhibitors have been discovered which have potential for development as 
a treatment for several pathological conditions including cancer, inflammatory and 
cardiovascular diseases (Neubauer and Pitson, 2013). The majority of these inhibitors 
selectively inhibit SK1 or both SK isoforms. Recently, however, several SK2 inhibitors 
have been generated that show promising therapeutic properties. SKi is the most widely 
used SK inhibitor (French et al., 2003) and inhibits both SK1 and SK2. Among several 
findings, it has been shown that SKi reduces S1P production and induces apoptosis in 
tumour cells in vitro (French et al., 2003, French et al., 2006), abolishes tumour growth in 
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a mammary adenocarcinoma xenograft mouse model (French et al., 2006) and inhibits the 
S1P-induced relaxation in rat coronary artery (Mair et al., 2010). Indeed, this inhibitor has 
been commonly used as a direct SK1/2 inhibitor (Lee et al., 2004a, Maines et al., 2006, 
Nishiuma et al., 2008, Ricci et al., 2009), although many studies suggest that it works 
mainly to target SK1 via promoting degradation of this enzyme (Ren et al., 2010, 
Loveridge et al., 2010, McNaughton et al., 2016). While widely reported as an SK1-
specific inhibitor, SKi actually inhibits SK2 with slightly higher affinity than SK1 (Gao et 
al., 2012), however, it does not enhance degradation of SK2 (Watson et al., 2013). DMS 
has been demonstrated to inhibit SK activity in a variety of cell lines (Yatomi et al., 1996, 
Edsall et al., 1998). However, it has also been shown to inhibit PKC (Kim et al., 2005), 
basic fibroblast growth factor (Xu et al., 2002), and platelet-derived growth factor 
(Katsuma et al., 2002). Safingol, L-threo-dihydrosphingosine, FTY720 and (S)-FTY720 
vinylphosphonate have been found to inhibit SK1 activity in several cell types (Olivera et 
al., 1998, Tonelli et al., 2010). They can also inhibit protein kinase c and other kinases 
(Schwartz et al., 1993, Sensken and Graler, 2010) and therefore, they are not considered 
specific SK inhibitors. Recent studies have generated highly selective non lipid SK1 
inhibitors with nanomolar potency including PF543 and VPC96091 (Kennedy et al., 2011, 
Schnute et al., 2012). PF543 has also been reported to induce a decrease in SK1 expression 
in pulmonary artery smooth muscle cells (PASMC), which was reversed by pre-treatment 
with MG132 (Byun et al., 2013). VPC96091 was found to selectively inhibit SK1 in 
nanomolar concentrations, however both PF543 and VPC96091 were not effective in 
reducing DNA synthesis in PASMC (Byun et al., 2013). Furthermore, recent studies 
showed that PF543 decreased right ventricular hypertrophy but not vascular remodelling in 
mice subjected to chronic hypoxia for a period of 3 weeks and this was associated with 
protection against cardiomyocyte apoptosis (MacRitchie et al., 2016). (2S,3R)-1-
Deoxysphinganine (55-21) is another selective SK1 inhibitor that induces proteasomal 
degradation of SK1 and inhibits DNA synthesis, although it is a moderate potency inhibitor 
of SK1 (Byun et al., 2013). A number of SK2 selective inhibitors have been generated such 
as ABC294640, (R)-FTY720-OMe, SG-12 and trans-12a. ABC294640 is an orally 
bioavailable agent specifically inhibiting SK2 in a sphingosine competitive manner. No 
effect was reported with ABC294640 on SK1 at concentrations up to 100 µM (French et 
al., 2010, Gao et al., 2012). Different studies have examined the effect of this inhibitor on a 
variety of disease models. It has been demonstrated that ABC294640 significantly inhibits 
tumour growth in vivo in different tumour models in mice (French et al., 2010, Antoon et 
al., 2011, Beljanski et al., 2011, Antoon et al., 2012). Moreover, ABC294640 also appears 
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to have therapeutic potential for other diseases. For example, it attenuates disease 
progression in rodent models of osteoarthritis (Fitzpatrick et al., 2011b), Crohn’s disease 
(Maines et al., 2010), ulcerative colitis (Maines et al., 2008), rheumatoid arthritis 
(Fitzpatrick et al., 2011a), and diabetic retinopathy (Maines et al., 2006). Biochemically, 
ABC294640 has been shown to reduce S1P and increase ceramide levels in cells (French et 
al., 2010, Gao et al., 2012), reduce plasma S1P level in mice (Beljanski et al., 2011) and 
inhibit the activation of STAT3, Akt, and ERK2 (Gao et al., 2012). The mechanism by 
which ABC294640 induces cell death is still a conflicting subject, with a number of studies 
showing that apoptotic pathways are activated (French et al., 2010, Antoon et al., 2012) 
and others demonstrating the presence of autophagy markers (Beljanski et al., 2010, Gao et 
al., 2012). Moreover, McNaughton et al demonstrated that ABC294640 can indirectly 
induce proteasomal degradation of SK1a in prostate cancer cells (McNaughton et al., 
2016). (R)-FTY720-OMe (ROMe) is another selective SK2 inhibitor. It was found to 
competitively inhibit SK2 and show no effect on SK1 activity at 50µM (Lim et al., 2011). 
It was also found to reduce expression of SK2 and stimulate autophagy, but not apoptosis 
in LNCaP prostate cancer cells (Watson et al., 2013). Unlike ABC294640, (R)-FTY720-
OMe failed to reduce the expression of SK1a in prostate cancer cells (McNaughton et al., 
2016). SG-12 and trans-12a were also reported to inhibit SK2 in a number of cell types 
(Kim et al., 2005, Raje et al., 2012). SG-12 has been shown to induce cell death in CHO-
KI cells, which might be a result of SK inhibition, however, it also can inhibit PKC (Kim 
et al., 2005).  
1.6 Role of sphingosine kinase/S1P in cardioprotection 
In the last decade, it has become abundantly clear that SK and S1P play an essential role in 
cardioprotection against acute or chronic ischaemia or ischaemia/reperfusion injury. 
Therefore, these molecules and their synthetic analogues have been studied extensively to 
interrogate their therapeutic potential as modulators of cardiac responses to both acute and 
chronic myocardial injury. Much remains to be studied however, for example if the S1P in 
HDL is responsible for the beneficial and cardioprotective properties of HDL and also the 
role of S1P in the remodelling process after myocardial infarction. 
1.6.1 Studies of S1P in cardiomyocyte cell culture 
Several studies have demonstrated that S1P has protective effects against oxidative stress-
induced conditions such as acute or chronic ischaemia/hypoxia or ischaemia/reperfusion 
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injury. For example, exogenous S1P has been found to enhance neonatal rat cardiomyocyte 
survival during hypoxia (Karliner et al., 2001). Zhang et al provided evidence that S1P-
enhanced survival in adult mouse cardiomyocytes exposed to prolonged in vitro hypoxia is 
mediated by S1P1 receptor and Gi-dependent activation of Akt (Zhang et al., 2007). 
SEW2871, a selective S1P1 receptor agonist, and the sphingosine analogue FTY720 were 
also as effective as S1P in protecting cardiomyocyte viability during hypoxia (Zhang et al., 
2007). Indeed, another study demonstrated that deletion of both S1P2 and S1P3 receptors 
increased infarct size in mice exposed to ischaemia/reperfusion injury (Means et al., 2007). 
In these hearts, activation of Akt was significantly decreased compared with wild type 
mice, but deletion of either receptor alone had no effect on either infarct size or Akt 
activation after ischaemia/reperfusion injury (Means et al., 2007). S1P also enhanced Akt 
activity in murine cardiomyocytes, but was not effective in double knockout myocytes. 
Therefore, these findings suggest that S1P receptor subtypes (S1P2 and S1P3) might also be 
essential for cell survival during ischaemia/reperfusion injury (Figure 1-5). 
1.6.2 Role of sphingosine kinase in cardioprotection 
Deletion of SK1 gene in ventricular cardiomyocytes subjected to hypoxia resulted in 
increased cell death and cytochrome c release compared with wild type controls (Tao et al., 
2007). Moreover, exogenous S1P was found to prevent hypoxic cell death in SK1 null 
cardiomyocytes. It has also been shown that monoganglioside GM-1, which increases 
intracellular S1P by activating SK1 was cytoprotective in wild type cardiomyocytes but not 
in SK1 null myocytes (Tao et al., 2007). This suggests that GM-1 activates only SK1. 
Furthermore, the protective effects of GM-1 on wild type cardiomyocytes were decreased 
by preincubation with either S1P1 receptor antagonist or pertussis toxin, indicating that 
endogenous S1P was exported to the extracellular space for stimulation of its cognate G-
protein coupled receptors (Tao et al., 2007). GM-1 induced increases in S1P can also be 
inhibited by the SK inhibitor, DMS (Cavallini et al., 1999). In isolated adult mouse hearts, 
exogenous S1P and GM-1 separately decreased ischaemia/reperfusion myocardial injury in 
wild type mouse hearts as determined by haemodynamic and infarct size measurements 
(Jin et al., 2002, Lecour et al., 2002). Further experiments studied the hypothesis that SK 
may play a role in ischaemic preconditioning (ICP) in isolated mouse hearts. It was shown 
that IPC sufficient to decrease infarct size in wild type hearts enhanced SK activity and 
translocation from cytosol to membranes (Jin et al., 2004). Moreover, pre-treatment with 
10µM DMS prevented ICP-induced cardioprotection in wild type hearts (Jin et al., 2004). 
In contrast, low dose DMS (0.3 to 1µM) was reported to enhance cytosolic SK activity and 
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protect murine hearts against ischaemia/reperfusion (Jin and Karliner, 2006). DMS appears 
to stimulate SK in the cytosol via a PKCε-dependent mechanism (Jin and Karliner, 2006). 
Sphingosine, the immediate precursor of S1P, has also a biphasic effect on 
cardioprotection depending on the concentration used. At higher concentration (5µM), 
sphingosine was cardiotoxic, but at a physiological concentration (0.4µM) sphingosine as 
well as S1P was cardioprotective against ischaemia/reperfusion when both were added 
before ischaemia or at the time of reperfusion (Vessey et al., 2008b). 
In vivo experiments demonstrated that permanent left anterior descending coronary artery 
occlusion in mice led to a steady decrease in total SK activity over weeks (Yeh et al., 
2009). In these experiments, SEW2871, the selective S1P1 agonist, was given orally to 
mice and reduced apoptosis and improved echocardiographic ejection fraction over the 
first two weeks after infarction. These results suggest that oral S1P receptor agonist may 
have potential therapeutic benefits in the post-myocardial infarction heart. Furthermore, 
SK1 knockout mice were used for a series of studies to strengthen the evidence that the 
SK1 isoform can protect against ischaemia/reperfusion injury. Expression of SK2 increases 
in hearts after SK1 gene deletion, leading to total SK activity half that of wild type mice 
(Jin et al., 2007). SK1 knockout hearts exhibited normal hemodynamic performance under 
baseline conditions. However infarction and contractile dysfunction were more severe after 
ischaemia/reperfusion compared to that of wild type hearts. As predicted, knocking out 
SK1 prevented IPC-induced cardioprotection (Jin et al., 2007) but, exogenous S1P was 
able to induce cardioprotection in these SK1 knockout hearts. Although SK2 expression 
increased in the SK1 knockout hearts, treatment with DMS did not affect the infarct size, 
suggesting that the disruption of SK1 rather than increased expression of SK2 was crucial 
to the loss of cardioprotection in SK1 null hearts (Jin et al., 2007). Another study has 
shown that prior adenoviral gene transfer of SK1 prevented haemodynamic deterioration 
and deceased creatine kinase release and arrhythmias during acute ischaemia/reperfusion in 
isolated hearts (Duan et al., 2007). In addition, gene transfer at the time of acute left 
anterior descending coronary artery ligation resulted in improved left ventricular function 
in the treated mice, decreased infarct size, more neovascularisation, and reduced collagen 
content (Duan et al., 2007). Ischaemic postconditioning as well as ischaemic 
preconditioning is cardioprotective (Zhao et al., 2003). A number of studies examined 
whether the SK/S1P pathway is a determinant for successful postconditioning (Jin et al., 
2008). In this study, wild type hearts and SK1 knockout hearts were subjected to 
ischaemia/reperfusion and selected hearts were subjected at the time of reperfusion to three 
brief cycles of postconditioning (5 sec of ischaemia followed by 5 sec of reperfusion). In 
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treated hearts, haemodynamics were improved and infarct size was decreased compared to 
controls (Jin et al., 2008). Phosphorylated Akt and phosphorylated ERK levels were also 
increased. In post-conditioned hearts SK activity at the end of reperfusion was higher than 
control hearts. In SK1 null hearts, none of these findings were observed. Thus SK1 may 
play an important role in mediating successful postconditioning (Jin et al., 2008). It has 
also been reported that combined low dose sphingosine, S1P and ischaemic 
postconditioning can protect isolated hearts from as much as 90 min of ischaemia (Vessey 
et al., 2008a). 
Although, the significant role of S1P in cardioprotection against ischaemia/reperfusion 
insult has been demonstrated in many studies, S1P has also been implicated in cardiac 
remodelling. It was reported that S1P stimulated cellular hypertrophy in rat neonatal 
cardiomyocytes and this effect was inhibited by an S1P1 antagonist (Brinkmann et al., 
2002). Overexpression of SK1 in heart tissue was shown to contribute significantly to 
progressive myocardial degeneration and fibrosis in mice (Takuwa et al., 2010). Another 
study has also shown that TGF-β-stimulated increase in SK1 expression and/or activity 
was associated with an increase in collagen production in cardiac fibroblasts (Gellings 
Lowe et al., 2009). Recently, Zhang et al (2016) has demonstrated that increased S1P 
production and SK1 expression following myocardial infarction was associated with 
enhancement of cardiac remodelling and dysfunction in mice. Moreover, in the same 
study, inhibition of SK1 by PF543, a selective SK1 inhibitor, was protective against post-
MI remodelling. 
1.6.3 S1P Lyase 
S1P lyase (SPL) is responsible for the degradation of S1P. By decreasing available S1P 
pools, SPL enhances apoptosis under stress conditions, whereas downregulation of SPL 
enhances cell survival. It has been shown that SPL was stimulated by ischaemia in murine 
hearts and hearts of heterozygous SPL null mice exhibited decreased SPL activity, 
increased S1P levels, smaller infarct size, and improved functional recovery after 
ischaemia/reperfusion injury compared with littermate hearts (Bandhuvula et al., 2011). It 
has also been found that giving tetrahydroxybutylimidazole (THI), an SPL inhibitor, 
overnight in the drinking water resulted in a 30-40% increase in serum S1P and decreased 
SPL activity, decreased infarct size and promoted haemodynamic recovery after 
ischaemia/reperfusion in ex vivo hearts (Bandhuvula et al., 2011). Thus, increased S1P 
induced by inhibition of SPL is sufficient to induce cardioprotection and represents a new 
43 
 
target in the metabolism of S1P that can be used to protect the heart against an 
ischaemia/reperfusion insult. In contrast Zhang et al has demonstrated that SPL inhibition 
may exacerbate cardiac systolic dysfunction and aggravate post MI remodelling which is 
likely due to an increase in expression levels of remodelling genes (Zhang et al., 2016a). 
Moreover, it has been shown that SPL heterozygous mice are more sensitive to hypoxia-
mediated pulmonary hypertension (Chen et al., 2014) and so caution has to be exercised 
when considering SPL as a viable therapeutic target. 
1.6.4 Cardioprotective effects of High Density Lipoprotein (HDL) 
HDL is the major carrier of S1P in serum as described above (Murata et al., 2000, 
Okajima, 2002). It is well known that HDL plays an important role in prevention of 
atherogenesis. This protective effect might be due to the ability of S1P carried by HDL to 
preserve endothelium and reduce pro-inflammatory responses in endothelial and vascular 
smooth muscle (Nofer et al., 2001, Kimura et al., 2003, Tolle et al., 2007). Once FTY720, 
a synthetic sphingosine analogue, is phosphorylated by SK2, it acts as an agonist at S1P1 
and S1P3 receptor subtypes and has been demonstrated to decrease atherosclerosis in both 
low density lipoprotein receptor deficient mice (Nofer et al., 2007) and in apolipoprotein 
E-deficient mice (Keul et al., 2007b). A recent study has shown that knocking out S1P1 
receptors increased immunoexpression of proinflammatory adhesion proteins such as 
ICAM-1 and VCAM-1 in mouse aortic endothelium and overexpression of S1P1 receptors 
reduced the abundance of these proinflammatory molecules, suggesting that it has anti-
inflammatory effects (Galvani et al., 2015). In the same study, it was demonstrated that 
HDL-S1P reduced the TNFα-induced NF-kB activation and adhesion protein expression in 
HUVECs and this anti-inflammatory properties of HDL-S1P was mediated by S1P1 
receptors. Moreover, HDL-S1P stimulated the formation of an anti-inflammatory complex 
between S1P and β arrestin and the protective effects of HDL-S1P were antagonised by 
pre-treatment with P-FTY720, which enhances S1P1 degradation (Galvani et al., 2015). In 
acute myocardial ischaemia/reperfusion injury, it has been shown that HDL is a direct 
cardioprotective agent and that this cardioprotective effect occurs independently of its 
atheroprotective effect (Keul et al., 2007a). The biologically active HDL- S1P appears to 
be responsible for the protective effects of HDL on myocardium via inhibition of adhesion 
molecule expression and recruitment of leukocytes to the infarcted area (Argraves and 
Argraves, 2007). Toa et al demonstrated that HDL, via its cargo of S1P, can directly 
protect adult murine cardiomyocytes against oxidative injury induced by 
hypoxia/reoxygenation (Tao et al., 2010). This cytoprotective effect was inhibited by S1P1 
44 
 
and S1P3 receptor antagonist VPC23019, CAY10444, an S1P3 receptor antagonist, PD-
98059, a MEK inhibitor and by the PI-3 kinase inhibitor wortmannin (Tao et al., 2010). 
Both Akt and ERK1/2 pathways were activated via S1P-associated HDL and both S1P1 
and S1P3 receptors are involved in prosurvival signal activation. Moreover, HDL was 
found to protect neonatal rat ventricular cardiomyocytes against doxorubicin-induced 
apoptosis and this effect was mediated by the S1P2 receptor, ERK1/2 and STAT3 (Frias et 
al., 2010). Furthermore, both genetic disruption of S1P receptors and responses to HDL 
have provided additional evidence for the involvement of SK/S1P pathways in 
cardioprotection. For example, Nofer et al demonstrated that HDL stimulated NO release 
in human endothelial cells and induced NO-dependent vasorelaxation through S1P3 
receptor (Nofer et al., 2004). These effects could be inhibited in S1P3 knockout mice. 
Based on these results, HDL may improve myocardial perfusion and protect the heart 
against ischaemia/reperfusion insult in vivo through S1P3. 
1.6.5 FTY720 
FTY720, a structural homologue of sphingosine, is derived from myriocin. Once FTY720 
becomes phosphorylated by SK2, it acts as a potent agonist of S1P1 receptor and also binds 
(though less avidly) to S1P3 receptors (Mandala et al., 2002, Hla and Brinkmann, 2011). It 
is an FDA-approved drug as an oral treatment for patients with multiple sclerosis (Pelletier  
and Hafler 2012). Several studies have examined whether FTY720 is cardioprotective 
against ischaemia/reperfusion injury. For example, Zhang et al showed that FTY720 
promoted survival in isolated adult murine cardiomyocytes subjected to severe long 
periods of hypoxia (Zhang et al., 2007). It has also been demonstrated that FTY720 
prevented cardiac arrhythmia in an ex vivo rat heart model subjected to 
ischaemia/reperfusion (Egom et al., 2010). A subsequent study showed that FTY720 is 
able to protect neonatal rat ventricular cardiomyocytes against CoCl2-induced hypoxic 
injury and stimulated NO release via a pertussis toxin-sensitive PI3K/Akt/eNOS pathway 
(Egom et al., 2011). Another study reported that treatment with FTY720 at the time of 
reperfusion improved recovery of left ventricular developed pressure and decreased left 
ventricular end-diastolic pressure in isolated rat hearts subjected to ischaemia/reperfusion 
(Hofmann et al., 2009). A further study reported that long term treatment with FTY720 
improved survival in a mouse model of occlusive coronary atherosclerosis, MI and heart 
failure through enhancing cardiomyocyte resistance to ischaemic injury, oxidative stress 
and apoptosis and reducing inflammation in the heart (Wang et al., 2014). Recently a study 
showed that FTY720 exhibited cardioprotective effects against post MI cardiac 
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dysfunction and remodelling through interfering with SK1/S1P/S1P1 signalling pathway 
(Zhang et al., 2016a). In contrast to these beneficial effects in animals, it has been 
identified that oral administration of FTY720 causes an initial bradycardia. Therefore the 
FDA advises not to prescribe this drug for patients with heart problems or stroke within the 
previous 6 months or patients on anti-arrhythmic treatment. 
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S1P1 receptor activation enhances cardiomyocytes protection against ischaemia/reperfusion 
via signalling pathway involving activation of PI3K, Akt and inactivation of GSK-3β. S1P2 and 
S1P3 receptors also enhances cardioprotection via activation of Akt which increases 
endothelial NO synthase.  
 
Figure  1-5 Flow chart shows the mechanism of S1P-induced cardioprotection in 
cardiomyocytes. 
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Hypothesis and aims 
Myocardial hypoxia/ischaemia increases SK1 expression and generation of endogenous 
S1P in coronary endothelial cells and cardiomyocytes, which may have an effect on 
regulation of coronary reactivity and exert a cardioprotective effect against 
ischaemia/reperfusion injury. Thus the principal research aim of this thesis was to 
investigate the influence of hypoxia on SK1 expression in rat coronary artery and how this 
may regulate vascular function through generation of S1P. This was achieved through the 
following experimental study aims: 
 Examine the expression of S1P receptors within normoxic rat coronary artery. 
 Examine the expression of SK1enzyme within normoxic and hypoxic rat coronary 
artery in the presence and absence of SK1 inhibitors. 
 Compare the SK1 expression in coronary artery endothelium in the presence and 
absence of proteasomal and/or lysosomal inhibitors under normoxia and hypoxia.  
 Investigate the effect of hypoxia on SK1 expression in rat aorta and how this may 
regulate vascular reactivity. 
 Evaluate the influence of hypoxia on SK1 expression in HUVECS and rat cardiac 
tissue in the presence and absence of SK1 inhibitors. 
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Chapter two 
2 Materials and methods 
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2.1 Animal source 
All animal experiments were performed in accordance with the United Kingdom Home 
Office Legislation under the Animals (Scientific Procedure) Act 1986 (project licence 
70/8572). Sprague-Dawley rats were purchased from ENVIGO (UK) and spontaneously 
hypertensive Wistar Kyoto rats were a generous gift from Dr Lorraine Work (ICAMS, 
Glasgow University). Rats were housed in the Central Research Facility at University of 
Glasgow and maintained on 12 hour cycles of light and dark and the room temperature was 
held at 21°C. Rats had free access to both food and water. 
2.2 Chemicals and reagents  
S1P, CYM5541, SEW2871 and AMG9810 were purchased from Tocris Bioscience 
(Bristol, UK). Cycloheximide, CA-074 Me, SKi (2-(p-hydroxyanilino)-4-(p-chlorophenyl) 
thiazole) and PF543 were from Merck Biosciences Ltd (Nottingham, UK). MG132 was 
from Stratech Scientific Ltd (Suffolk, UK). Lactacystin was from Enzo Life Sciences 
(Exeter, UK) and CAY10444 was from Cayman Chemical (Cambridge, UK). The 
following chemicals were purchased from Sigma-Aldrich (Poole, UK): U46619, 
acetylcholine, and Nitric Oxide Synthase inhibitor (L-NNA, Nω-Nitro-L-arginine). ROMe, 
(R)-FTY720 methyl ether, was a kind gift from Prof Susan Pyne (Strathclyde University) 
(Table 2-1, page 54). Culture supplies were obtained from PromoCell Bioscience 
(Heidelberg, Germany) unless otherwise stated. All Western blot materials were obtained 
from Life Technologies (Paisley, UK) unless otherwise stated. 
2.3 Confocal microscopy 
The confocal microscope was invented by Minsky in 1955 from the conventional light 
microscope. The aim was to produce sharp images of thin cross sections, which had not 
been possible with conventional microscopy. The basic confocal microscope system has 
been improved upon over the last decade and confocal laser scanning microscopy (CLSM) 
is now a commonly used technique. Many confocal studies have been carried out on cells 
but recently this technique has also been used on whole blood vessels (Arribas et al., 2007, 
Daly et al., 2010). 
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2.3.1 The confocal microscope 
The confocal microscope is composed of a photomultiplier tube (PMT), a detector pinhole, 
a source pinhole, a dichroic mirror and an objective lens. It is based upon the principle that 
an excitation light from a laser is focused into the source pinhole and reflected by the 
dichroic mirror in order to pass it through the objective to the sample. The excitation light 
fills a converging cone as it is focused through the specimen to the object plane, and all the 
excitation light passes out through a similar diverging cone. The fluorophore in the 
specimen emits the fluorescent light in all directions. Light from the specimen returns 
through the objective and dichroic mirror respectively and is focused into the detector 
pinhole, then measured by the PMT. The detector pinhole is designed to ensure that only 
light from the in-focus planes reach the PMT, and prevents the light scattered from out-of-
focus planes reaching the PMT. An image is produced from individual pixels using a 
computer with imaging software to visualise a complete image. 
2.3.2 Principle of fluorescence 
When molecules with luminescence properties absorb light energy of a particular 
wavelength, they give off light of a different wavelength. This occurs because of their 
atomic structure. Electrons are arranged around the atom’s nucleus in different energy 
levels. When an electron absorbs light energy, it reaches a higher energy or excited state. 
The higher energy state is unstable and does not last long. The electron loses some of the 
absorbed energy as heat and the remaining extra energy is emitted as a photon of light 
(Figure 2-1). This emitted light is always of a lower energy than the excited light, so the 
wavelength of the emitted fluorescence is longer than that of the absorbed light. 
 
 
h 
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Figure  2-1 Fluorescence generation 
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2.3.3 Tissue preparation for immunofluorescence studies 
Male Sprague-Dawley rats (200-250 g body weight) were killed by cervical dislocation. 
The chest cavity was opened and the heart and thoracic aorta were rapidly removed and 
placed into cold Krebs-Henseleit solution (NaCl 118 mM, NaHCO3 25 mM, KCl 4.7 mM, 
KH2PO4 1.2 mM, MgSO4 1 mM, glucose 11 mM, and CaCl2 2.5 mM) previously gassed 
with 95% O2, 5% CO2 at room temperature. Under a binocular microscope, the right and 
left coronary arteries were carefully dissected free of connecting heart tissue with fine 
dissecting scissors and the thoracic aorta was also cleaned of adherent connective tissue. 1-
2 mm segments of freshly isolated coronary and 2-3 mm segments of thoracic artery were 
carefully opened longitudinally, treated with specific inhibitory agents for half an hour 
(Table 2-1, page 54), then subjected to normoxia/hypoxia (see hypoxia protocol in section 
2.3.5) for 30 min and fixed by 3% paraformaldehyde overnight at 4 °C. To determine the 
most appropriate method of preparing the coronary and aortic arteries for imaging, a series 
of experiments was carried out using whole vessels (without opening them longitudinally). 
In the whole vessels, it was not possible to focus into the endothelium and the smooth 
muscle layers because of the thick elastic wall of the arteries. Therefore, both coronary 
arteries and aorta were turned ‘inside out’ by cutting the vessel ring longitudinally, 
exposing the endothelium. By using this preparation, it was possible to image the vessels 
from the endothelium through to the media. Thus, the open preparation was applied in all 
experiments as it enabled imaging of the endothelium and smooth muscle cells with 
minimum damage. 
2.3.4 Label protocol 
2.3.4.1 Single label protocol 
After fixation with paraformaldehyde, the samples were washed 3 times with phosphate 
buffered saline (PBS) and incubated in blocking solution (10% normal goat serum) for 2 
hours. Thereafter, samples were incubated in a primary antibody against the protein of 
interest overnight at 4°C. Primary antibodies were diluted in PBS supplemented with 1% 
BSA (1:50 & 1:100 dilution used) (Table 2-2, page 55). Samples were then washed 3 times 
with PBS before incubation with an AlexaFlour 594 conjugated goat anti-rabbit secondary 
antibody for 1 hour at room temperature (Figure 2-2). Secondary antibody was also diluted 
in PBS supplemented with 1% BSA (1:250 dilution) (Table 2-3, page 55). Nuclear stain 
Syto 61 (1µM) was also added to the secondary antibody solution to stain the endothelial 
51 
 
and smooth muscle cell nuclei. Nuclear shape and position were used to distinguish 
endothelial from smooth muscle cells. 
2.3.4.2 Double label protocol for SK1 enzyme and S1P3 receptor 
Following fixation and washing as previously described, samples were incubated in 
blocking solution (5% normal donkey serum) for 2 hours and then incubated with anti-
S1P3 antibody (1:50) overnight at 4 °C. Samples were then washed 3 times with PBS 
before incubation with AffiniPure fab fragment goat anti-rabbit antibody (1:300) for 1-2 
hrs. Thereafter, samples were again washed by PBS (3 times) before incubation with 
AlexaFluor 488 conjugated donkey anti-goat secondary antibody (green) (1:250) for 1 hr. 
Samples were then washed 3 times with PBS and incubated with rabbit polyclonal anti-
SK1 primary antibody (1:50) overnight at 4 °C. Following washing with PBS, samples 
were incubated for 1 hr at room temperature in AlexaFluor 594 conjugated donkey anti-
rabbit secondary antibody (red) (1:250). Nuclear stain Syto 61 (1 µM) was also added to 
the secondary antibody solution to stain the endothelial and smooth muscle cell nuclei. 
Each staining step was performed sequentially in the dark. Primary and secondary 
antibodies were diluted in PBS supplemented with 1% BSA. A list of primary and 
secondary antibodies is presented in table 2-2 (Page 55) and table 2-3 (Page 55) 
respectively. 
 
 
Figure  2-2 Indirect immunofluorescence 
  
2.3.5 Hypoxia protocol 
Normoxia (~ 20% O2, pO2 ~160 mmHg) was induced by placing the artery in 1 ml Krebs’ 
solution which had been previously gassed with 95% O2, 5% CO2 (Solution was not gassed 
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during procedures) to keep oxygen tension at ~ 20% O2 saturation). Hypoxia was induced 
by placing the artery in 1 ml Krebs’ solution which had been constantly bubbled with 95% 
N2/5% CO2 for approximately 30 min to reduce oxygen tension to 1-1.5% O2 saturation 
(pO2 ~ 8-10 mmHg). An Optical Oxygen Meter-Fire Sting O2 (Pyro Science, Germany) 
was used to measure oxygen tensions before and after the experiment. Since the oxygen 
meter repeatedly yielded the same oxygen saturation values on several occasions, it was 
deemed unnecessary to measure oxygen tension in all experiments. Hypoxia was 
maintained for 30 min and temperature was held at 37°C. Arteries were then fixed in 3% 
paraformaldehyde and immunostained as outlined above. 
2.3.6 Slide mounting 
Once the incubation period was finished, each artery segment was laid flat on a microscope 
slide with the endothelial side uppermost. A small well was created on the microscope 
slide using grease and filled with the Krebs solution (NaCl 118 mM, NaHCO3 25 mM, KCl 
4.7 mM, KH2PO4 1.2 mM, MgSO4 1 mM, glucose 11 mM, and CaCl2 2.5 mM)  that the 
vessel was incubated in (Miquel et al., 2005) (Figure 2-3). A coverslip (thickness 1.5 µm) 
was placed on the top creating a chamber. 
 
Figure  2-3 Slide preparation 
 
2.3.7 Imaging 
Initially, the objective was cleaned in order to remove any dust particles and a glass rod 
was used to apply oil onto the objective to prevent air bubbles forming in the immersion 
oil. Then, the specimen was visualised through the microscope eyepiece and the 
microscope (Nikon Eclipse TE300) applied conventionally to focus on the specimen. 
When focussed, the visualisation was changed from the microscope eyepiece to the 
computer. Prior to starting an exploratory scan, the scan setting for the confocal 
microscope was selected. A series of preliminary experiments was carried out to establish 
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the best scan setting for the confocal microscope that allow to visualise the protein of 
interest with less noise in the image background. All vessels were visualised by the Bio-
Rad 2100 Confocal Laser Scanning microscope equipped with argon, HeNe and red diode 
lasers. x40 oil immersion and x20 oil/water immersion lenses were used for all 
experiments. For the rat coronary artery, the images were recorded mainly at zoom 3 and 6, 
HeNe laser intensity 100; a gain 30; offset 0.0 and pinhole setting of 3.0 were chosen. In 
the case of thoracic aorta, the gain was 40 with other settings remaining the same. The 
standard scan speed of 500 lines per second was used in all experiments. An image size of 
512 x 512 pixels produced a field size of 289 µm x 289 µm.  
Each vessel was imaged from endothelium to the media. At least three images were 
collected from random areas of the vessels. Each experiment was repeated at least three 
times in separate rats. Vessels were scanned using lambda strobing to minimize bleed-
through on individual channels. Kalman frame averaging varied between 3 and 5 was used 
to improve the quality of the image. Each fluorescent probe was imaged as close as 
possible to its excitation and emission maxima: AlexaFlour 594 secondary antibody (ex. 
591 nm, em. 614 nm); Syto 61 (ex. 637 nm, em. 660 nm). 
2.3.8 Image analysis  
2D images were produced (8 bit) and displayed spatially as pixels, where each pixel 
represents an intensity value between 0 (black) and 255 (white) from the Gray scale. 
Following image capture, Image J software (1.47 version) was used to analyse 2D images 
collected at zoom 3 and 6. Integrated density (the total amount of fluorescence) was 
measured from 3 images (zoom 3) taken from 3 different areas in each artery by Image J 
software (the three areas combined to give a single average value for each animal) and the 
mean data plotted in bar charts. Statistical comparisons between integrated densities 
generated in the presence and absence of hypoxia and specific inhibitory agents (Table 2-
1) were determined using an unpaired t test and one way analysis of variance (ANOVA) 
with Dunnett's post-test or Bonferroni multiple comparison post-test. P-values were 
considered statistically significant when p<0.05 
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Table  2-1 List of drugs and concentrations used  
Drugs Description Concentration Diluent 
Cathepsin B 
inhibitor (CA-
074ME) 
Lysosomal inhibitor 10 µM DMSO 
CAY10444 Selective S1P3 antagonist 10 µM DMSO 
Cycloheximide Protein synthesis inhibitor 10 µM Ethanol 
CYM5541 Selective S1P3 agonist 1 nM–30 µM DMSO 
Lactacystin Proteasomal inhibitor 10 µM Distilled water 
MG132 Proteasomal inhibitor 10 µM DMSO 
Nω-Nitro-L-
arginine (L-
NNA) 
Nitric Oxide Synthase 
Inhibitor 
100 µM DMSO 
PF543 Selective SK1 inhibitor 100 nM DMSO 
(R)-FTY720 
methyl ether 
(ROMe) 
Selective SK2 inhibitor 10 µM DMSO 
S1P Sphingosine-1-Phosphate 1 nM–30 µM PBS/BSA 
SEW2871 Selective S1P1 receptor 
agonist 
1 nM–30 µM Ethanol 
Sphingosine 
kinase inhibitor 
(SKi) 
Non-selective SK inhibitor 10 µM DMSO 
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Table  2-2 Primary antibodies used for immunofluorescence 
Epitope Clonality Host 
species 
Blocking 
serum 
Dilution Source 
Phospho SK1 Polyclonal Rabbit 10% NGS 1:50 ECM 
biosciences 
SP1641 
SK1 Polyclonal Rabbit 10% NGS 1:50 Abcam 
ab71700 
S1P1 Polyclonal Rabbit 10% NGS 1:50 Abcam 
ab23695 
S1P3 Polyclonal Rabbit 10% NGS 1:50 Santa Cruz 
Biotechnology 
sc-30024 
NGS: normal goat serum. Primary antibodies were diluted in PBS supplemented with 1% 
BSA and incubated at 4 °C overnight. Phospho SK1 antibodies were raised against 
phospho-SK1 (Ser-225) synthetic peptide corresponding to amino acids surrounding serine 
225 in human SK1. SK1 antibodies were raised against a synthetic peptide corresponding 
to human SPHK1 aa 286-315. S1P1 and S1P3 antibodies were raised against a synthetic 
peptide corresponding to human S1P1 aa 241-253 and human S1P3 aa 309-378 
respectively.  
Table  2-3 Secondary detection agents for immunofluorescence 
Linked 
molecule 
Epitope Clonality Host species Dilution Source 
Alexa 
Fluor® 594 
(Red) 
Rabbit IgG Polyclonal Goat 1:250 Stratech 
Scientific 
Alexa 
Fluor® 488 
(Green) 
Goat IgG Polyclonal Donkey 1:250 Stratech 
Scientific 
Alexa 
Fluor® 594 
(Red) 
Rabbit IgG Polyclonal Donkey 1:250 Stratech 
Scientific 
AffiniPure 
fab fragment 
Rabbit IgG Polyclonal Goat 1:300 Stratech 
Scientific 
Secondary antibodies were diluted in PBS supplemented with 1% BSA and incubated at 
room temperature for 1 hour. 
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2.4 Functional studies (wire myography) 
2.4.1 Vessel preparation and mounting 
Male Sprague-Dawley rats (200-250 g body weight) and spontaneously hypertensive 
Wistar Kyoto rats (350-400 g body weight) were killed by cervical dislocation. The chest 
cavity was opened and the thoracic aorta was rapidly removed and placed into cold Krebs-
Henseleit solution (NaCl 118 mM, NaHCO3 25 mM, KCl 4.7 mM, KH2PO4 1.2 mM, 
MgSO4 1 mM, glucose 11 mM, and CaCl2 2.5 mM) previously gassed with 95% O2, 5% 
CO2 at room temperature. Then the thoracic aorta was carefully dissected free from 
adherent connective tissue and cut into 2-3 mm rings. Vessel rings were mounted on two 
stainless steel pins in a four-channel small vessel wire myograph (Danish Myo 
Technology, Aarhus, Denmark). One of the pins was connected to a micrometer, to adjust 
the tension on the ring, and the other one was attached to a force transducer, which 
measures the force generated by the vessel ring in milliNewtons (Figure 2-4). Vessels were 
incubated at 37 °C in Krebs-Henseleit buffer with constant supply of 95% O2, 5% CO2 gas. 
The vessels were then allowed to equilibrate for 15-30 min at resting tension. Thereafter, 
vessels were stretched until an optimum resting tension of 1 gm (9.8 mN) was reached and 
allowed to equilibrate for 30 min. Chart™ 5 Pro software (ADInstruments, Chalgrove, 
U.K.) was used to record and measure vessel responses to different reagents. 
 
Figure  2-4 Representative picture of a rat aortic ring mounted in the small artery wire 
myograph.  
A 3 mm segment of artery was mounted on two pins with one attached to a force transducer and a 
computer to measure the changes in the tone of the vessel ring. The other pin was connected to a 
micrometer to adjust the tension on the ring. 
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2.4.2 Experimental protocols 
2.4.2.1 Wake up procedure 
In order to assess the viability of the vessels after dissection and mounting, the vessels 
were exposed to two additions of 40 mM KCl (Mair et al., 2010). Once the response had 
reached a plateau the vessels were rinsed two to three times with Krebs-Henseleit solution 
and rested for 10 min between additions. Contraction to KCl of ˃ 0.5 gram was indicative 
of vessel viability.  
2.4.2.2 U46619 protocol 
To investigate the effect of hypoxia on contraction to the thromboxane A2 mimetic 
U46619, (9,11-dideoxy-11α,9α-epoxymethanoprostaglandin F2α), aortic rings were 
subjected to 30 min hypoxia, then re-oxygenated and maintained under normoxic 
conditions. Then concentration response curves were generated by cumulative addition of 
U46619 (1×10
-9
-1×10
-6
M) with 10 min between each addition. In experiments where the 
effects of SKi, a non-selective SK inhibitor (10 µM), on U46619-induced contraction were 
to be investigated under hypoxia and normoxia, the SKi was added 15 min before exposure 
to hypoxia and was present during generation of the concentration-response curve. 
Hypoxia was induced by altering the bubbling of the myograph chamber from 95% O2-5% 
CO2 to 95%N2-5%CO2 (< 5% O2 saturation) for 30 min and thereafter the gas mixture was 
returned to control conditions. 
2.4.2.3 Agonist comparison 
After 30 min equilibration and challenge with KCl, aortic rings were submaximally 
contracted with U46619 (3×10
-8
M) (Mair et al., 2010). Once a plateau was achieved, 
concentration-response curves were performed by cumulative addition of agonists. S1P, 
CYM5541, a selective S1P3 receptor agonist, and SEW2871, a selective S1P1 receptor 
agonist, (1×10
-9
-3×10
-6
M) were added in half-log molar concentration in a cumulative 
manner with 5 min between each addition. Maximal response was measured five minutes 
after addition of each concentration of drug. 
2.4.2.4 Antagonists and inhibitors protocol 
In experiments where the effects of antagonists or inhibitors on agonist-induced relaxation 
were to be assessed, the antagonist of interest was added 30 min prior to contraction with 
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U46619, and was present during generation of the concentration-response curve. A list of 
antagonists and inhibitors and their final bath concentrations used are provided in table 2-1 
(Page 54). 
2.4.2.5 Hypoxia protocol 
In order to investigate the effect of hypoxia on the S1P-induced relaxation in thoracic 
aorta, thoracic aortic rings were subjected to hypoxia for 30 min just after testing the vessel 
viability with KCl, then reoxygenated and submaximally contracted with U46619 (5×10
-
9
M). Once a plateau was achieved, concentration response curves were performed by 
cumulative addition of S1P as described above. In experiments where the effects of 
antagonists or inhibitors on agonist-induced relaxation under hypoxic conditions were to 
be assessed, the antagonist or inhibitor of interest was added 30 min before exposure to 
hypoxia and was present during generation of the concentration-response curve. Hypoxia 
was induced as described above. 
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2.4.2.6 Endothelial denudation protocol 
Vascular endothelial function was assessed at the end of the experiment by adding 1 µM 
ACh. Relaxation to ACh of ˃ 50% was indicative of a vessel with an intact endothelium. 
Where indicated, endothelium was removed by gentle rubbing of the intimal surface with 
forceps. Relaxation to ACh < 10% denoted an endothelium denuded vessel (Figure 2-5).    
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2-5 Representative experimental recordings showing isometric tension (g) 
plotted against time in rat thoracic aorta.  
(A) Represents a recording generated by an endothelium-intact aortic ring with more than 50% 
relaxation to acetylcholine. (B) Represents a recording from an endothelium-denuded vessel 
with less than 10% relaxation to acetylcholine. 
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2.4.3 Statistical analysis 
Graph Pad Prism (version 5) software was used to analyse all the data. Contractile 
responses to U46619 were expressed as mean ± standard error of the mean (S.E.M) in 
grams. All relaxation responses were reported as a percentage loss of the tone induced by 
U46619. Results were expressed as mean ± SEM of n, where n is the number of arterial 
segments from different animals. Differences between concentration-response curves were 
tested by two ways analysis of variance (ANOVA) with a Bonferroni’s post-test. To 
compare the effect of enzyme inhibitors and antagonists on U44619-induced contraction in 
rat aorta, one-way ANOVA with Dunnett's post-test was used. In all cases, statistical 
significance was accepted when p < 0.05. 
  
2.5 Cell culture and tissue preparation 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) and 
immunoblotting were carried out using a Novex® NuPAGE® gel electrophoresis system 
(Life Technologies, Paisley, U.K.), in order to work out the relative expression of the 
proteins of interest. 
2.5.1 Human Umbilical Vein Endothelial Cells (HUVEC) culture 
HUVECs were a kind gift from Dr. Ian Salt (Institute of Cardiovascular & Medical 
Sciences, University of Glasgow). HUVECs were grown in 75 cm
3
 culture flasks and 
maintained in Endothelial Cell Growth Media MV / MV2 (PromoCell, Germany). The 
cells were kept incubated at 37 °C in a humidified atmosphere of 5% CO2 and 95% air. 
The media was replaced every 2 days. Cells were routinely sub-cultured when 
approximately 80-90% confluency was reached and used for experiments at passage 4 to 6. 
For HUVECs sub-culture, the cells were washed with sterile Dulbecco’s PBS (Sigma-
Aldrich, Poole, U.K.) prior to incubation with 3 ml of trypsin-ethylenediamine tetra-acetic 
acid (trypsin-EDTA) at 37 °C for at least 1 min. The complete medium was then added to 
stop the action of the trypsin-EDTA solution and allow sub-culturing of the cell 
suspension. 
2.5.2 Treatment of Human Umbilical Vein Endothelial Cells 
HUVECs were seeded in 6 well plates and grown to approximately 90% confluence. The 
cells were then incubated for 24 hr with serum free medium. Then the cells were treated 
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with specific inhibitory agents and subjected to normoxia/hypoxia (as outlined in the 
relevant results chapter) for a particular period of time. Thereafter, the 6 well plate was 
placed on ice and the media was removed by aspiration. Subsequently, ice-cold lysis buffer 
(Cell extraction buffer (Invitrogen, CA), supplemented with 1mM of protease inhibitor 
cocktail (Sigma Aldrich, UK), 1mM Phenylmethylsulfonyl fluoride (PMSF) and 1mM 
Dithiothreitol (DTT) (Sigma Aldrich, UK) was added to each well for 5 minutes. The cell 
extract was collected by scraping and transferred into ice-cold centrifuge tubes. The cell 
lysates were then centrifuged (13300 x g, 10 min) on a bench top centrifuge. The 
supernatants were stored at -80 °C for Western blotting. 
2.5.3 Preparation of heart tissue 
Heart tissue was removed and dissected immediately after death from Male Sprague-
Dawley rats (200-250 g body weight). The right ventricular wall was cut into 8 pieces and 
each piece of tissue was pre-incubated with a specific inhibitory compound before 
exposure to hypoxia or normoxia for a particular length of time (as described in results 
chapter). The samples were immediately snap frozen and stored at -80 °C until use. Heart 
tissue was pulverised in liquid nitrogen into a fine powder by using a mortar and pestle and 
resuspended in ice-cold lysis buffer. The extract was transferred into ice-cold centrifuge 
tubes and centrifuged (8000 x g, 10 min) on a bench top centrifuge. The supernatants were 
stored at -80 °C for Western blotting. 
2.5.4 Quantification of protein concentration 
Standard dilutions of bovine serum albumin (BSA) ranging from 0.1 mg/ml to 1mg/ml 
were used to generate a standard protein curve with distilled water as a blank. Lysates, 
analysed in triplicate, were diluted in distilled water at a ratio of 5:1. 10 µl of each sample 
and standards were added in triplicate to a 96 well plate followed by 100 μl DC™ Protein 
Assay Reagent (Bio-Rad Laboratories Ltd, Herts, UK). A FLUOstar OPTIMA microplate 
reader (BMG Labtech, Germany) was used to read absorbance at 595 nm. The mean 
absorbance from each sample was generated in triplicate and the protein concentration was 
determined by comparison with the BSA standard curve. 
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2.5.5 Western blotting 
2.5.5.1 SDS PAGE 
The lysates were mixed with 7.5 μl of DTT and 12.5 μl of NuPAGE® LDS sample buffer 
as a load dye, to a total volume of 50 μl and heated at 70°C for 20 mins prior to separation 
by SDS-PAGE. Samples were then loaded on NuPAGE® Novex® 4-12 % Bis-Tris mini 
gels (1.0 mm thick, 15 wells) at 10 µg of protein per well. 10 μl Novex® sharp pre-stained 
protein markers were used as a standard. Gels were run at a constant voltage of 200 V for 
approximately 45-60 minutes in NuPAGE® MOPS SDS running buffer until the tracking 
dye had reached the bottom of the gel. To transfer proteins from the gel to the 
nitrocellulose membrane, the gel was removed from the plate and an equal-sized sheet of 
nitrocellulose (0.45 μm pore size) was placed on it. They were then placed between two 
layers of 3 mm filter paper, prewashed with transfer buffer. After that the sandwich was 
inserted between the plates of the gel holder cassette and transfer was carried out at 30 V 
for 90 min in NuPAGE® transfer buffer containing 10 % (v/v) methanol. After removal of 
the nitrocellulose membrane from the transfer cassette, the efficiency of transfer was 
checked by the presence and intensity of pre-stained molecular weight standards using 
Ponceau S stain.  
2.5.5.2 Immunoblotting 
Non-specific sites on nitrocellulose membranes were blocked by incubation with 5 % (w/v) 
milk powder (Marvel) prepared in Tris-buffered saline (20mM Tris; 137mM NaCl  PH 7.4) 
containing 0.1% (v/v) Tween-20 (TBST) at room temperature with continuous shaking for 
60 minutes. After rinsing (3 x 5 min) the membranes in TBST, the membranes were 
incubated overnight at 4 °C in primary antibody diluted in 50% (v/v) TBST, 50% (v/v), 
OBB, Odyssey® blocking buffer (LI-COR, USA). The membranes were then rinsed (3 x 5 
min) with TBST before incubation, with shaking, for 60 min at room temperature with 
IRDye® 800CW Donkey anti-Rabbit IgG antibodies (Li-COR, USA) diluted in the same 
way as the primary antibody. Following this, the membranes were washed with TBST (3 x 
5 min) and TBS (1 x 5 min) before visualisation of immunolabelled bands using an 
Odyssey Sa Infrared Imaging System (LI-COR, USA) linked with Odyssey Sa Infrared 
Imaging System software (LI-COR, USA). Primary and secondary antibodies used in 
Western blotting are presented in table 2-5. 
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2.5.5.3 Stripping of nitrocellulose membranes 
Nitrocellulose membranes were incubated in Restore Plus Western Blot Stripping Buffer 
(Thermoscientific, UK) for 15 min at room temperature. Membranes were then rinsed with 
TSBT (3 x 5 min) and TBS (1 x 5 min). 
2.5.5.4 Quantification of protein bands 
The intensity of the immune-detected protein bands was quantified using ImageJ software 
(version 1.47). The housekeeping protein, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was employed as a protein loading control. Thus, data were expressed as a ratio 
of protein of interest to the loading control.  
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Table  2-4 Primary antibodies used for western blotting 
Epitope Clonality Host 
species 
Dilution Diluent Source 
GAPDH Polyclonal Rabbit 1:2000 50%TBST 
50% OBB 
Thermoscientific   
PA1-988 
Phospho 
SK1 
Polyclonal Rabbit 1:1000 50%TBST 
50% OBB 
ECM biosciences 
SP1641 
SK1 Polyclonal Rabbit 1:1000 50%TBST 
50% OBB 
Abcam ab71700 
OBB: Odyssey® blocking buffer. All blots were incubated 4 °C overnight. 
Table  2-5 Secondary detection agent for western blotting 
Linked 
molecule 
Epitope 
Host 
species 
Dilution Diluent Source 
IRDye® 
800CW 
Rabbit IgG Donkey 1:5000 50%TBST 
50% OBB 
LI-COR 
Biosciences 
926-32213 
All blots were incubated with secondary antibody for 1 h at room temperature. 
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Chapter three 
3 Effect of hypoxia on Sphingosine Kinase 1 
expression in rat coronary artery 
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3.1 Introduction 
Sphingosine-1-phosphate (S1P) is a potent signalling lipid and exhibits a wide range of 
cellular activities including cell proliferation, migration and survival. Once S1P is 
generated by phosphorylation of sphingosine it can either be exported from cells (via 
transporter proteins e.g. Spns2 and particular ABC transporters) or retained within the cell. 
Extracellular S1P is an agonist of five GPCRs named S1P1-5 (Blaho and Hla, 2014), but it 
can also function intracellularly as a second messenger. The level of S1P in plasma and 
tissue is regulated by the balance between its production and degradation (Thuy et al., 
2014). S1P is degraded via reversible dephosphorylation by S1P phosphatases or 
irreversible hydrolysis by S1P lyase (Pyne and Pyne, 2010). 
Synthesis of S1P is catalysed by two distinct isoforms of sphingosine kinase (SK1 and 
SK2), which are encoded by different genes and differ in their subcellular localisations; 
with SK1 being a mostly cytosolic protein and SK2 predominately nuclear (Siow and 
Wattenberg, 2011). Several stimuli can either activate or increase SK1 expression 
including agonists of GPCRs, tyrosine kinase receptors and immunoglobulin receptors, 
proinflammatory cytokines, calcium and protein kinase activators (Taha et al., 2006b, 
Alemany et al., 2007, Pyne et al., 2009). Hypoxia has also been demonstrated to increase 
SK1 expression in human pulmonary smooth muscle cells and the human endothelial cell 
line EA.hy926 (Ahmad et al., 2006, Schwalm et al., 2008). SK1 is activated by 
phosphorylation at ser225 and then the phosphorylated SK1 is translocated from the 
cytosol to the plasma membrane where it interacts with its substrate, sphingosine (Jarman 
et al., 2010). SK1 is deactivated by dephosphorylation at ser225 via the action of 
phosphatase 2A (Barr et al., 2008) and it can also be degraded via the ubiquitin proteasome 
mediated pathway and/or a cathepsin B mediated process (Taha et al., 2006a, Loveridge et 
al., 2010). 
There is a growing body of evidence suggesting that SK and S1P may play an important 
role in cardioprotection against acute or chronic ischaemia or ischaemia/reperfusion injury 
(Karliner, 2013). Therefore, the role of these molecules or their synthetic analogues in 
cardioprotection against ischaemia/reperfusion has been extensively studied over the last 
decades. For example, exposure of SK1 knockout mouse ventricular cardiomyocytes to 
ischaemia/reperfusion resulted in increased cell death and cytochrome c release compared 
with wild type controls (Tao et al., 2007). Moreover, pretreatment of SK1 null 
cardiomyocytes with exogenous S1P prevented hypoxia-induced cell death while 
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exogenous S1P decreased infarct size in isolated adult mouse hearts subjected to 
ischaemia/reperfusion (Jin et al., 2002, Lecour et al., 2002). Also, it has been shown that 
ischaemic preconditioning (ICP) sufficient to decrease infarct size in wild type hearts 
promoted SK activity and relocalisation from the cytosol to the membrane (Jin et al., 
2004). 
In addition to damaging cardiomyocytes, ischaemia/reperfusion may cause early and 
severe injury within the vasculature that could prevent a return to normal coronary 
perfusion, leading to inadequate myocardial perfusion (the “no-reflow” phenomenon). This 
phenomenon was observed in 30% of patients with myocardial infarction and was 
associated with a higher incidence of death (Ito, 2006, Niccoli et al., 2009). Therefore, 
prevention of coronary microvascular dysfunction and enhancing coronary perfusion 
represents a promising strategy to improve ongoing therapies that may reduce infarct size 
and prolong survival. 
Since control of vascular diameter is crucial in maintaining myocardial perfusion during 
hypoxia, there is a great deal of interest in the effect of endogenous vasoactive substances 
such as S1P and whether their activity is changed under hypoxic conditions. Several 
studies have reported that hypoxia induces vasodilation in human (Lynch et al., 2006) and 
rat coronary arteries (Kerkhof et al., 2002). It has been demonstrated that S1P induced 
vascular relaxation in intact rat coronary artery via a mechanism requiring S1P3 and CB2 
receptors under normoxic conditions and this effect was inhibited by pre-treatment with 
SKi (Mair et al., 2010). Another study showed that SK1 is upregulated in human 
endothelial cell lines (Schwalm et al., 2008) and human pulmonary artery smooth muscle 
cells subjected to acute and chronic hypoxia (Ahmad et al., 2006). Although the effect of 
hypoxia/ischaemia on SK activity in cardiomyocytes has been extensively studied, little is 
known about the effect of hypoxia/ischaemia on SK levels in coronary arteries. 
3.1.1 Aims 
 Study the distribution of sphingosine kinase 1 and S1P receptors in rat coronary 
artery endothelium. 
 Investigate the effect of hypoxia on SK1 expression in the presence and absence of 
different SK inhibitors. 
68 
 
 Examine the effect of hypoxia on SK1 expression in the presence and absence of 
proteasomal and lysosomal degradation inhibitors. 
3.2 Methods 
3.2.1 Tissue preparation 
Rat coronary artery sections were prepared, fixed and immunostained as detailed in section 
2.3.3. Briefly, vessels from male Sprague-Dawley rats were dissected immediately after 
death and placed into 1ml Krebs-Henseleit solution previously gassed with 95% O2, 5% 
CO2 at 37 °C. The segments were then treated with specific inhibitory agents for half an 
hour (detailed below), then subjected to normoxia/hypoxia for 30 min and fixed by 3% 
paraformaldehyde overnight at 4 °C. The vessels were then labelled with specific primary 
and secondary antibodies, placed on a glass slide and the protein of interest visualized by 
confocal microscopy. 
3.2.2 Hypoxia protocol 
Hypoxia was induced by placing the artery in 1 ml Krebs’ solution which had been 
constantly bubbled with 95% N2/5% CO2 for approximately 30 min to reduce oxygen 
tension to 1-1.5% O2 saturation. An optical oxygen meter (Fire StingO2 Pyro Science, 
Germany) was used to measure oxygen tension before and after the experiment. Since the 
oxygen meter repeatedly yielded the same oxygen saturation values in several experiments, 
it was deemed unnecessary to measure oxygen tension on all occasions. Hypoxia was 
maintained for 30 min and temperature was held at 37°C. Arteries were then fixed in 3% 
paraformaldehyde and immunostained as outlined in section 2.3.4. 
3.2.3 Experimental protocol 
3.2.3.1 SK inhibitors 
A series of experiments was carried out where the vessels were preincubated with 10 µM 
SKi, a non-selective SK inhibitor (Loveridge et al., 2010), 100 nM PF543, a selective SK1 
inhibitor (Schnute et al., 2012), or 10 µM ROMe, a selective SK2 inhibitor (McNaughton 
et al., 2016) followed by exposure to normoxia/hypoxia for 30 min. 
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3.2.3.2 Protein synthesis inhibitor 
A number of experiments were performed where the vessel was pre-treated with 10 µM 
cycloheximide, a protein synthesis inhibitor, for 30 min prior to exposure to 
normoxia/hypoxia for 30 min. 
3.2.3.3 Proteasomal and lysosomal inhibitors 
To study the effect of proteasomal and lysosomal degradation on SK1 expression under 
normoxic and hypoxic conditions, a series of experiments was carried out where the 
vessels were preincubated with 10 µM MG132, a proteasomal inhibitor (Loveridge et al., 
2010), 10 µM lactacystin, a proteasomal inhibitor (Loveridge et al., 2010), 10 µM CA-
074ME, a cathepsin B inhibitor (Ren et al., 2010) or a combination of MG132 and CA-
074ME for 30 min before exposure to normoxia/hypoxia for 30 min. Other experiments 
were performed where the arterial segments were pre-treated with MG132, lactacystin, 
CA-074ME or a combination of MG132 and CA-074ME for 30 min followed by treatment 
with 10 µM SKi for 30 min and then the segments were subjected to normoxia/hypoxia for 
30 min. 
3.2.4 Image analysis 
A Bio-Rad Radiance 2100 confocal microscope was used to visualise the protein of 
interest as described in detail in section 2.3.7. Following the image capture, Image J 
software (1.47 version) was used to analyse 2D images collected at zoom 3 and 6. 
Integrated density was measured from 3 images (zoom 3) taken from 3 different areas in 
each artery by Image J software. Statistical comparisons between integrated densities (the 
arithmetic sum of all the pixel values in an area) generated in the presence and absence of 
hypoxia and specific inhibitory agents were determined using an unpaired Student’s t-test 
and one way analysis of variance (ANOVA) with Bonferroni multiple comparison post-
test. P-values were considered statistically significant when p<0.05. 
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3.3 Results 
3.3.1 Expression of SK1 enzyme, S1P1 and S1P3 receptor 
subtypes in rat coronary artery endothelium. 
Using syto 61 stain (nuclear stain) allowed discrimination of endothelial cells from 
vascular smooth muscle cells. Endothelial cells were oval in shape and ran on the surface 
of the internal elastic lamina or in the grooves of the internal elastic lamina whereas 
vascular smooth muscle cells were spindle shaped cells and ran underneath the internal 
elastic lamina and in the opposite direction (Figure 3-1). The SK1 enzyme expression was 
examined in rat coronary artery endothelium obtained from three different animals. SK1 
enzyme was found to be expressed strongly in the endothelial cells of rat coronary artery. 
In figure 3-2, immunofluorescent staining of SK1 (red) appears as punctate staining in the 
cytosol of the cells. Specificity of SK1-labelling was examined by comparison of SK1-
labelled sections which had been incubated with SK1 antibody pre-absorbed with SK1 
peptide antigen (Abcam, ab187382). In those vessels pre-incubated with SK1 peptide 
antigen, SK1 immunostaining (red) was greatly diminished compared with controls (Figure 
3-3). Moreover, S1P1 and S1P3 receptors are prominently expressed in endothelial cells of 
rat coronary artery with S1P1 apparently located in the cytoplasm and S1P3 on the plasma 
membrane (Figure 3-4). Segments of rat CA were also used to examine the co-localisation 
of SK1 enzyme and S1P3 receptor subtypes in the endothelial cells. The confocal scan 
shows that both SK1 enzyme and S1P3 receptor subtype are abundantly expressed in the 
same endothelial cells but they were not co-localised (Figure 3-5).  
The SK1 immunostaining in rat coronary artery smooth muscle cells was very weak and 
this might be a result of poor penetration of the antibodies deep to the smooth muscle cells. 
To test this, I used anti-α smooth muscle actin antibody to test the antibody penetration 
ability. The signal with the α-actin antibody was very weak, meaning that it is likely the 
antibodies cannot penetrate the internal and external lamina to immunostain the medial 
layer (Figure 3-6). 
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Figure  3-1 Representative images showing the difference between endothelial and smooth 
muscle cell nuclei of rat coronary artery.  
(A) shows oval shaped endothelial cell nuclei (blue) running on the surface of internal elastic 
lamina (green) and between the grooves of the internal elastic lamina (B). Smooth muscle cells 
with spindle shaped nuclei run underneath the internal elastic lamina (C). Scale bar is 30 µm in all 
images. Images are representative of at least 3 experiments. 
 
 
Figure  3-2 Expression of SK1 in endothelial cells of rat coronary artery.  
Rat coronary artery sections were immunostained for SK1 (red) with anti-SK1 antibody. Syto 61 
nuclear stain was used to stain the endothelial and smooth muscle cell nuclei (blue). The green 
colour in the merged image represents the autofluorescence of internal elastic lamina. Scale bar is 
30 µm in all images. Images are representative of at least 3 separate experiments. 
 
A B C
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Figure  3-3 Anti-SK1 antibody specificity.  
Representative immunofluorescent images for SK1 (red) expression (panel A) in control sections. 
Panel B demonstrates that addition of blocking peptide greatly decreases the detection of SK1 by 
immunofluorescence. Results are representative of 3 separate experiments. Scale bar is 20 µm for 
all images. 
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Figure  3-4 S1P1 and S1P3 receptor expression in rat coronary artery endothelium. 
Representative immunofluorescent images (of 2 experiments) for S1P1 receptors (red) (A) and 
S1P3 receptors (red) (B). Scale bar is 30 µm for all images. 
 
 
Figure  3-5 Expression of SK1 enzyme and S1P3 receptors in rat CA endothelium. 
Representative immunofluorescent images demonstrate the expression of SK1 (red) and S1P3 
receptor subtype (green) in rat CA endothlial cells. S1P3 receptors (green) are differentiated from 
internal elastic lamina autofluorescence (green) by their punctate appearance. Results are 
representative of 3 separate experiments. Scale bar is 30 µm for all images. 
A B
Green Red Merge
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Figure  3-6 Anti-α smooth muscle actin antibody. 
Immunofluorescent images showing a very weak immunostaining‎of‎α‎smooth‎muscle‎actin‎in‎rat‎
CA smooth muscle cells (red). Internal (green) and external elastic lamina may reduce the antibody 
penetration to the smooth muscle cells. Green colour is the autofluorescence of internal elastic 
lamina collagen. Scale bar is 10 µm for all images. 
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3.3.2 Effect of hypoxia on SK1 enzyme expression in vascular 
endothelium. 
Exposure of rat coronary arteries to hypoxia for 30 min resulted in a significant increase 
(41%) in integrated density (total amount of fluorescence) 1.7 x 10
6
 ± 2.4 x 10
5
 AU, n=5 
compared with the corresponding levels in arteries maintained under normoxic conditions 
(1.0 x 10
6
 ± 5.2 x 10
5
 AU, n=4; Figure 3-7). There was also a significant increase in 
phosphorylated-SK1 (pSK1) integrated density in arteries subjected to hypoxia (2.8 x 10
6
 ± 
2.7 x 10
5
 AU, n=3) compared with the corresponding levels in controls (1.5 x 10
6
 ± 1.9 x 
10
5
 AU, n=3; Figure 3-8). 
3.3.3 Effect of cycloheximide on hypoxia-induced increase in SK1 
expression. 
Pre-treatment of coronary arteries with cycloheximide for 30 min under normoxic 
conditions led to a small reduction in SK1 integrated density (0.79 x 10
6
 ± 2.1 x 10
5
 AU, 
n=3) compared with controls (1.0 x 10
6
 ± 5.2 x 10
5
 AU, n=4; Figure 3-9). In those arteries 
pre-treated with cycloheximide prior to exposure to hypoxia, there was a significant 
reduction (60%) in integrated density of SK1 (0.68 x 10
6
 ± 2.8 x 10
5
 AU, n=3) compared 
with controls (1.7 x 10
6
 ± 2.4 x 10
5
 AU, n=5; Figure 3-9). 
3.3.4 Effect of sphingosine kinase inhibitors on hypoxia-induced 
increase in SK1 expression. 
Under normoxic conditions, pre-treatment with SKi significantly decreased the integrated 
density of SK1 (67%) in rat CA endothelium (0.33 x 10
6
 ± 0.21 x 10
5
 AU, n=3) compared 
with controls (1.0 x 10
6
 ± 5.2 x 10
5
 AU, n=4). Treatment with the selective nM potent SK1 
inhibitor PF543 visually appeared to reduce SK1 immunostaining (red punctate staining in 
the images) but image J software yielded no significant differences in the integrated 
density of SK1 and this is likely because image J is also quantifying the background noise 
in these images (0.93 x 10
6
 ± 1.7 x 10
5
 AU, n=4). The selective SK2 inhibitor ROMe had 
no effect on SK1 expression under normoxic conditions (1.2 x 10
6
 ± 2.6 x 10
5
 AU, n=4; 
Figure 3-10). However, both SKi and PF543 markedly reduced the increase in SK1 
expression caused by hypoxia when added 30 min prior to exposure to hypoxia (0.41 x 10
6
 
± 1.9 x 10
5
 AU, n=3 (76%)) and (0.45 x 10
6
 x 1.4 x 10
5
 AU, n=4 (73%)) respectively 
compared with controls (1.7 x 10
6
 ± 2.4 x 10
5
 AU, n=5). ROMe had no effect on the 
hypoxia-induced increase in SK1 expression (1.7 x 10
6
 ± 1.9 x 10
5
 AU, n=5; Figure 3-11).               
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Figure  3-7 Effect of hypoxia on SK1 expression levels.   
Immunofluorescent images show expression of SK1 (red) in rat coronary artery endothelium under 
normoxic conditions (A) and hypoxic conditions (B). (C) Quantitative fluorescence measurement of 
SK1 under normoxia and hypoxia. Scale bar is 30 µm for both images. *p<0.05 vs normoxia as 
determined by unpaired t test. Results are representative of 4-5 separate experiments. 
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Figure  3-8 Effect of hypoxia on pSK1 levels.  
Immunofluorescent images showing effect of hypoxia on pSK1 (red) level in rat coronary artery 
endothelium (B) compared with control (A). (C) Quantitative fluorescence measurement of pSK1 
under normoxia and hypoxia. Scale bar is 30 µm for both images. *p<0.05 vs normoxia as 
determined by unpaired t test. Results are representative of 3 separate experiments.     
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Figure  3-9 Effect of cycloheximide on hypoxia-induced increase in SK1 expression.  
Immunofluorescent images show expression of SK1 (red) in rat coronary artery endothelium (A) 
and following pre-treatment with cycloheximide (10 µM, 30 min) under normoxic conditions (B). 
Expression of SK1 in rat coronary artery subjected to 30 min hypoxia (C). Preincubation of rat 
coronary artery with cycloheximide reduced the hypoxia-induced increase in SK1 expression (D). 
(E) Quantitative fluorescence measurement of SK1 in the presence and absence of cycloheximide. 
*p<0.05 vs hypoxia alone as determined by one way ANOVA with Bonferroni multiple comparison 
post-tests. Results are representative of 3-5 separate experiments. Scale bar is 30 µm for all 
images.   
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Figure  3-10 Effect of Sphingosine Kinase inhibitors on SK1 expression in rat coronary artery 
endothelium under normoxia.  
Immunofluorescent images showing expression of SK1 (red) in rat coronary artery endothelium (A) 
and following pre-treatment with SKi (10 µM, 30 min) (B), PF543 (100 nM, 30 min) (C) and ROMe 
(10 µM, 30 min) (D). (E) Quantitative fluorescence measurement of SK1 in the presence and 
absence of Sphingosine Kinase inhibitors. *p<0.05 vs control as determined by one way ANOVA 
with Bonferroni multiple comparison post-tests. Results are representative of 3-4 separate 
experiments. Scale bar is 30 µm for all images.   
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Figure  3-11 Effect of Sphingosine Kinase inhibitors on SK1 expression in rat coronary artery 
endothelium under hypoxia.  
Immunofluorescent images showing an increase in SK1 (red) expression caused by hypoxia 
compared to normoxia (not shown) (A) and following pre-treatment with SKi (10 µM, 30 min) (B), 
PF543 (100 nM, 30 min) (C) and ROMe (10 µM, 30 min) (D). (E) Quantitative fluorescence 
measurement of SK1 in the presence and absence of Sphingosine Kinase inhibitors. **p<0.01 vs 
control as determined by one way ANOVA with Bonferroni multiple comparison post-tests. Results 
are representative of 3-5 separate experiments. Scale bar is 30 µm for all images. 
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3.3.5 Expression of SK1 in presence of degradation inhibitors in 
vascular endothelium. 
Preincubation of rat coronary arteries with MG132, lactacystin, CA-074ME, and a 
combination of MG132 and CA-074ME had no effect on integrated density of SK1 
compared with controls under normoxia (Figure 3-12 and Table 3-1) whereas under 
hypoxic conditions, only MG132 significantly inhibited the hypoxic-induced increase in 
SK1 integrated density (Figure 3-13 and Table 3-2). 
Table  3-1 Integrated density for SK1 in presence of degradation inhibitors under normoxia 
Agent (All agents used at 10 
µM concentration) 
Integrated density (± S.E.) in 
AU 
Number of separate 
experiments (n) 
Control 1.0 x 10
6
 ± 0.52 x 10
5 
4 
MG132  1.2 x 10
6 
± 3.6 x 10
5
 4 
Lactacystin  1.2 x 10
6
 ± 1.5 x 10
5
 4 
CA-074ME  0.79 x 10
6
 ± 0.65 x 10
5
 3 
MG132+CA-074ME  1.5 x 10
6
 ± 0.69 x 10
5 
3 
 
Table  3-2  Integrated density for SK1 in presence of degradation inhibitors under hypoxia 
Agent (All agents used at 10 
µM concentration) 
Integrated density (± S.E.) in 
AU 
Number of separate 
experiments (n) 
Control 1.7 x10
6
  ± 2.4 x 10
5 
5 
MG132  1.05 x 10
6
 ± 1.2 x 10
5
 *
 
6 
Lactacystin  2.0 x 10
6
 ± 4.1 x 10
5 
4 
CA-074ME  1.4 x 10
6 
± 1.4 x 10
5 
3 
MG132+CA-074ME   1.4 x 10
6 
± 2.7 x 10
5 
3 
* p<0.05 vs control (one way ANOVA with Bonferroni’s post test). 
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3.3.6 Effect of SKi on degradation of SK1. 
So far, it was shown that SK1 expression increased during hypoxia, an effect which 
involves protein synthesis and can be blocked by SK1 inhibitors but not SK2 inhibitors. A 
number of studies have demonstrated that SKi induces proteasomal degradation of SK1 in 
several cell lines such as human pulmonary artery smooth muscle cells, androgen-sensitive 
LNCaP prostate cancer cells, MCF-7 and MCF-7 HER2 breast cancer cells (Loveridge et 
al., 2010) and lysosomal degradation in human endothelial cell line EA.hy 926, glomerular 
podocytes and mesangial cells (Ren et al., 2010). Therefore I investigated the mechanism 
by which SKi decreases SK1 in rat CA endothelium. In this regard, pre-treatment of rat 
coronary arteries with MG132, CA-074ME or a combination of MG132 and CA-074ME 
significantly reversed the SKi-induced reduction in integrated density of SK1 under 
normoxic conditions, but pre-treatment with lactacystin had no effect (Figure 3-14)(Table 
3-3). Under hypoxia, the SKi-induced reduction in SK1 integrated density was also 
reversed when the arteries were pre-treated with MG132, CA-074ME or a combination of 
both MG132 and CA-074ME, but preincubation with lactacystin did not inhibit the SKi-
induced reduction in SK1 integrated density (Figure 3-15)(Table 3-4). 
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Table  3-3 Effect of SKi on degradation of SK1 under normoxic conditions 
Agent (All agents used in 10 
µM concentration) 
Integrated density (± S.E.) in 
AU 
Number of separate 
experiments (n) 
Control 1.0 x 10
6
 ± 0.52 x 10
5
 * 4 
SKi 0.33 x 10
6
 ± 0.21 x 10
5 
3 
MG132+SKi 1.4 x 10
6
 ± 2.9 x 10
5
 ** 3 
Lactacystin+SKi 0.65 x 10
6
 ± 1.0 x 10
5
 4 
CA-074ME+SKi 0.96 x 10
6
 ± 1.9 x 10
5
 * 5 
MG132+CA-074ME+SKi 1.7 x 10
6
 ± 3.0 x 10
5
  *** 4 
*p<0.05; **p<0.01; ***p<0.001 vs SKi (one way ANOVA with Bonferroni’s post test). 
Table  3-4 Effect of SKi on degradation of SK1 under hypoxic conditions 
Agent (All agents used in 10 
µM concentration) 
Integrated density (± S.E.) in 
AU 
Number of separate 
experiments (n) 
Control 1.7 x10
6
  ± 2.4 x 10
5
 ** 5 
SKi 0.41 x 10
6
 ± 1.9 x 10
5
 3 
MG132+SKi 1.3 x 10
6
 ± 0.32 x 10
5
 * 5 
Lactacystin+SKi 0.98 x 10
6
 ± 1.4 x 10
5
 5 
CA-074ME+SKi 1.9 x 10
6
 ± 4.8 x 10
5
 ** 3 
MG132+CA-074ME+SKi 2.3 x 10
6
 ± 2.9 x 10
5
 *** 4 
*p<0.05; **p<0.01; ***p<0.001 vs SKi (one way ANOVA with Bonferroni’s post test
84 
 
 
 
Figure  3-12 Effect of MG132, Lactacystin, CA-074ME and a combination of MG132 and CA-074ME on SK1 in rat coronary artery endothelium under 
normoxia.   
Immunofluorescent images showing expression of SK1 in rat CA endothelium (A) and the effect of pre-treatment with (B) MG132 (10 µM, 30 min), (C) Lactacystin (10 
µM, 30 min), (D) CA-074ME (10 µM, 30 min) and a combination of MG132 and CA-074ME (10 µM, 30 min)(E) on SK1 in rat CA endothelial cells under normoxic 
conditions. (F) Quantitative fluorescence measurement of SK1 in the presence and absence of degradation inhibitors. Results are representative of 3-4 separate 
experiments. Scale bar is 30 µm for all images. 
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Figure  3-13 Effect of MG132, Lactacystin, CA-074ME and a combination of MG132 and CA-074ME on SK1 in rat coronary artery endothelium under hypoxia.  
Immunofluorescent images showing expression of SK1 in rat CA endothelium (A) and the effect of pre-treatment with (B) MG132 (10 µM, 30 min), (C) Lactacystin (10 
µM, 30 min), (D) CA-074ME (10 µM, 30 min) and a combination of MG132 and CA-074ME (10 µM, 30 min)(E) on SK1 in rat CA endothelial cells under hypoxic 
conditions. (F) Quantitative fluorescence measurement of SK1 in the presence and absence of degradation inhibitors. *p<0.05 vs control as determined by one way 
ANOVA with Bonferroni’s‎post‎test. Results are representative of 3-6 separate experiments. Scale bar is 30 µm for all images. 
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Figure  3-14 Effect of degradation inhibitors on SKi-induced downregulation of SK1 in rat CA endothelium under normoxia.   
Immunofluorescent images showing expression of SK1 (red) in rat CA endothelium (A) and effect of SKi (10 µM, 30 min) on SK1 expression in rat CA endothelium (B); 
Significant reversal effect of pre-treatment with (C) MG132 (10 µM, 30 min); (D) Lack of reversal effect with Lactacystin pre-treatment (10 µM, 30 min); (E) Reversal by 
CA-074ME pre-treatment (10 µM, 30 min) of SKi (10 µM, 30 min)-induced reduction of SK1 in rat CA endothelium; (F) reversal by a combination of MG132 and CA-
074ME (both 10 µM, 30 min pre-treatment) of SKi (10 µM, 30 min)-induced downregulation of SK1 in rat CA endothelium. (G) Quantitative fluorescence measurement 
of SK1 in the presence and absence of degradation inhibitors and SKi. *p<0.05 vs SKi as determined by one way ANOVA with Bonferroni’s‎post‎ test. Results are 
representative of at least 3-5 separate experiments. Scale bar is 30 µm for all images. 
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Figure  3-15 Effect of degradation inhibitors on SKi-induced downregulation of SK1 in rat CA endothelium under hypoxia.  
Immunofluorescent images showing expression of SK1(red) in rat CA endothelium (A) and effect of SKi (10 µM, 30 min) on SK1 expression in rat CA endothelium (B); 
Significant reversal effect of pre-treatment with (C) MG132 (10 µM, 30 min); (D) Lack of reversal by Lactacystin pre-treatment (10 µM, 30 min); (E) reversal by CA-
074ME (10 µM, 30 min pre-treatment) on SKi (10 µM, 30 min)-induced reduction of SK1 in rat CA endothelium; (F) reversal by a combination of MG132 and CA-074ME 
(all 10 µM, 30 min pre-treatment) of SKi (10 µM, 30 min)-induced downregulation of SK1 in rat CA endothelium. (G) Quantitative fluorescence measurement of SK1 in 
the presence and absence of degradation inhibitors and SKi under hypoxic conditions. **p<0.01, ***p<0.001 vs SKi as determined by one way ANOVA with 
Bonferroni’s‎post‎test. Results are representative of 3-5 separate experiments. Scale bar is 30 µm for all images.    
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3.4  Discussion 
At the onset of this study, a series of preliminary experiments was conducted to establish 
the most appropriate vessel preparation and incubation conditions for the experimental 
protocol. It was important to use open vessel preparations to overcome the problem 
associated with poor penetration of lasers through the arterial wall to visualize the 
endothelial and smooth muscle cells. However even with open vessel preparations, it was 
not possible to visualize the proteins of interest present in smooth muscle cells due to poor 
antibody penetration to this depth. Several antibody dilutions were tested (1:250, 1:100, 
1:50) to determine the most appropriate dilution to immunostain the protein of interest. 
Syto 61 nuclear stain was used to stain the endothelial and smooth muscle cell nuclei and 
allow differentiation between them by virtue of their shape and positions. 
The lipid mediator S1P is produced by phosphorylation of membrane associated 
sphingosine by sphingosine kinase. Once generated, S1P is either transported out of the 
cell to exert its function via a family of five GPCRs named S1P1-5 or if retained within the 
cell, it functions as an intracellular second messenger. In blood vessels, S1P plays an 
important role in enhancing endothelial cell spreading, vascular maturation/stabilization, 
barrier function and regulation of vascular reactivity. The role of the SK/S1P pathway in 
protection against ischaemic injury has been studied extensively in cardiomyocytes, 
however little is known about the effect of hypoxia/ischaemia on SK levels in coronary 
arteries. One of the aims of this part of the study was to examine the distribution of SK1 
enzyme and S1P receptors in rat CA endothelial cells. Previous immunohistochemical 
studies using a rabbit polyclonal antibody directed against the C terminus of mouse SK1 
and human SK1, found a strong positive immunostaining in different tissues such as the 
cerebrum, cerebellum, kidney, platelets, endothelial cells of blood vessels and lung tissue 
(Murate et al., 2001, Johnson et al., 2005). In the present study, a polyclonal rabbit 
antibody to SK1 was used to examine the immunofluorescence localisation of SK1 in rat 
CA endothelial cells. The specificity of the detection of SK1 by the polyclonal rabbit 
antibody was tested using a blocking peptide. In those arteries probed with the antibody 
that was immunoabsorbed with the blocking peptide, there was a great reduction in 
detection of SK1 (Figure 3-3). Prominent SK1 immunostaining was detected primarily in 
the cytosol of the endothelial cells and it had a punctate appearance in the control vessels 
(Figure 2-3 & Figure 3-3). Several studies have shown that S1P promotes endothelial cell 
survival and migration via S1P1 and S1P3 receptors (Kimura et al., 2001, Kimura et al., 
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2003) and induces vasorelaxation of rat aorta and coronary arteries via S1P3 receptors 
(Nofer et al., 2004, Mair et al., 2010). Since SK is likely to generate S1P, it was important 
to study if there is co-localisation of S1P receptors with the SK1 enzyme. Polyclonal 
antibodies to S1P1 and S1P3 receptors were used to examine immunoexpression of S1P1 
and S1P3 receptor subtypes in rat CA endothelial cells. Previously, these antibodies were 
demonstrated to be quite immunospecific for detection of S1P1 receptors by Western blot 
analysis of total cell lysate from human umbilical vein endothelial cells (Igarashi et al., 
2014) and S1P3 receptors by immunofluorescent staining method in bone marrow-derived 
cells (Li et al., 2009). We also found that rat CA endothelial cells exhibit an intense 
immunostaining for S1P1 and S1P3. S1P1 receptors appear to be localised in the cytoplasm, 
suggesting that they have been already activated at the cell membrane and internalised, 
whereas S1P3 are on the plasma membrane (Figure 3-4). However, only two independent 
experiments were performed and more experiments are required to examine the expression 
and distribution of S1P1 and S1P3 receptors in rat coronary endothelium.  Using a double 
label protocol, this allowed detection of SK1 and S1P3 receptors in the same rat CA 
endothelial cells but no colocalisation was observed (Figure 3-5).   
Several studies have shown that hypoxia may upregulate SK1 in a variety of cell lines. For 
instance, exposure of human endothelial cells to hypoxia led to increased SK1 expression 
and enhanced activity (Schwalm et al., 2008). The same study showed that a hypoxic-
induced increase in endothelial cell migration was an SK1-dependent effect. Moreover, 
Ahmed et al demonstrated that short-term hypoxia resulted in an expressional upregulation 
of SK1 and SK2 whereas chronic exposure to hypoxia increased SK1 mRNA transcript 
levels but not SK2 in human pulmonary smooth muscle cells (Ahmad et al., 2006). Rapid 
increase in SK1 immunofluorescence was also shown in rat amoeboid microglial cells after 
exposure to short period of hypoxia and the SK1 increase commenced 15 min after 
exposure to hypoxia and reached the maximum level after 1 hr (Lin et al., 2011). SK1 
mRNA but not SK2 was also found to increase rapidly after hypoxia exposure from 1 hr 
and reached the peak level after 4 hr hypoxia in human glioma cells (Anelli et al., 2008). In 
the current study, it was found that exposure of rat coronary artery to short periods (30 
min) of hypoxia led to a marked increase in SK1 immunostaining in rat CA endothelial 
cells compared with controls (Figure 3-7). Using human anti-phospho-specific sphingosine 
kinase 1 (Ser-225) antibody also revealed a significant increase in pSK1 immunostaining 
under hypoxic conditions (Figure 3-8). Moreover, pre-treatment with cycloheximide 30 
min before exposure to hypoxia resulted in a significant reduction in the hypoxia-induced 
increase in SK1 immunostaining, suggesting that hypoxia may increase SK1 synthesis in 
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rat CA endothelium and this may consequently enhance S1P production (Figure 3-9). 
Under normoxia, a small reduction was also seen in SK1 immunostaining following 
treatment with cycloheximide. SKi pre-treatment led to a significant reduction in SK1 
immunostaining under normoxic conditions (Figure 3-10). In four vessels obtained from 
four different animals which were pre-treated with PF543, it was visually very clear that 
PF543 had decreased SK1 immunostaining (approximately 30-40%) in two vessels but in 
the other vessels the background noise was high and image J software yielded no 
significant differences overall in the integrated density of SK1. This requires further 
investigation to confirm the effect of PF543 on SK1 expression under normoxic 
conditions. ROMe did not decrease expression of SK1 in normoxic arteries. Under hypoxic 
conditions, preincubation with SKi and PF543 prior to exposure to hypoxia resulted in a 
reversal of the hypoxia-induced increase in SK1 immunostaining whereas additions of 
ROMe did not reduce SK1 immunostaining, suggesting that hypoxia increases SK1 
expression in rat CA endothelium (Figure 3-11). 
A number of studies have demonstrated that SKi can not only inhibit the catalytic activity 
of SK1 but also it induces lysosomal and/or proteasomal degradation of SK1 depending on 
the cell type. For example, it was reported that SKi induced lysosomal degradation in 
human endothelial cells EA.hy 926, human podocytes and mesangial cells (Ren et al., 
2010). Ren et al showed that the SKi triggered SK1 degradation was reversed by pre-
treatment with chloroquine, a general lysosomal inhibitor, and CA-074ME, a specific 
inhibitor of the lysosomal protease cathepsin B, whereas pre-treatment with lactacystin, a 
specific proteasomal degradation inhibitor, failed to reverse the SKi-induced SK1 
downregulation. Other studies, in contrast, have shown that SKi induces proteasomal 
degradation of SK1 in human pulmonary artery smooth muscle cells, prostate and breast 
cancer cells (Loveridge et al., 2010, Tonelli et al., 2013). It was shown that pre-treatment 
with proteasomal degradation inhibitors MG132 and lactacystin were able to reverse the 
effect of SKi whereas CA-074ME had no effect (Loveridge et al., 2010, Pitman et al., 
2015). This effect might be due to an increase in the amount of ceramide (which may 
activate proteasomal degradation) as a consequence of catalytic inhibition of SK1 by SKi. 
In the same study and in line with this possibility, the ceramide synthase inhibitor, 
fumonisin B1 was able to partially reverse the effect of SKi. Other SK1 inhibitors such as 
FTY720, (S)-FTY720 vinylphosphonate and PF543 have also been shown to induce 
proteasomal degradation of SK1 in human pulmonary smooth muscle cells, prostate cancer 
and breast cancer cells and this effect was reversed by pre-treatment with MG132 (Tonelli 
et al., 2010, Byun et al., 2013, McNaughton et al., 2016). In the present study, pre-
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treatment of rat coronary artery with MG132, lactacystin, CA-074ME or a combination of 
MG132 and CA-074ME had no effect on SK1 immunostaining compared with controls 
under normoxic conditions (Figure 3-12). Pre-treatment with MG132 but not lactacystin or 
CA-074ME prior to exposure to a short period of hypoxia significantly inhibited the 
hypoxia-induced increase in SK1 immunostaining whereas addition of MG132 and CA-
074ME as a combination had no effect on the SK1 increase caused by hypoxia, suggesting 
that MG132 may direct some SK1 for lysosomal degradation (Figure 3-13). It was also 
found that pre-treatment with MG132, CA-074ME or a combination of MG132 and CA-
074ME before addition of SKi significantly reversed the SKi triggered downregulation of 
SK1 under normoxic conditions, whereas lactacystin failed to reverse the SKi-induced 
reduction in SK1(Figure 3-14). Moreover, the SKi-induced reduction of the hypoxia-
induced increase of SK1 was significantly reversed by pre-treatment with MG132, CA-
074ME or a combination of MG132 and CA-074ME but lactacystin pre-treatment did not 
reverse the SKi-induced reduction in SK1(Figure 3-15). These findings suggest that SKi 
may induce both lysosomal and proteasomal degradation of SK1 in rat CA endothelial 
cells under normoxic and hypoxic conditions. 
To improve the short and long term outcomes of patients with acute myocardial infarction 
(AMI), it is important to restore adequate myocardial perfusion as quickly as possible. 
Rapid restoration of blood supply in ischaemic myocardium provides oxygen and nutrients 
to the starved cardiac tissue, thus reducing the extent of damage. However, reperfusion 
also causes microvascular dysfunction, inflammation, and oxidative damage. One of the 
important contributors to myocardial damage after ischaemic events is increased vascular 
permeability (Murakami and Simons, 2009). Therefore prevention of vascular leak and 
oedema may help in improving microcirculation flow during reperfusion post-AMI and 
prevents no flow phenomenon. In this regard, several studies showed that S1P may play an 
important role in maintenance of vascular barrier integrity (Lee et al., 1999, Garcia et al., 
2001, Sanchez et al., 2003, Jung et al., 2012). Cardiopulmonary bypass is a commonly 
used technique in thoracic surgery; however it may cause a number of side effects 
including ischaemia/reperfusion injury and systemic inflammatory response syndrome 
leading to vascular dysfunction. A recent study showed that pre-treatment with FTY720 or 
SEW2871, an S1P1 agonist, relieved vascular dysfunction associated with 
cardiopulmonary bypass in the coronary and mesenteric arteries (Samarska et al., 2014). 
Moreover, it has been demonstrated that anandamide-stimulated relaxation was inhibited 
by SKi pre-treatment under normoxic conditions in rat coronary artery, suggesting that SK 
or SK-derived S1P may mediate the relaxation response to particular vasoactive agents 
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(Mair et al., 2010). Thus, increased SK1 levels and activities during myocardial ischaemia 
could play an important part in coronary protection through generation of more S1P which 
enhances vascular endothelial integrity and dilates coronary arteries to increase myocardial 
blood supply. Hypoxia-induced increase in SK1 may also be exploited in hypoxic 
preconditioning and postconditioning strategies to protect vascular endothelial cells from 
hypoxia/reoxygenation injury. Furthermore, vascular endothelium has been reported to 
contribute to circulating S1P concentration in mice (Hisano et al., 2012) and humans 
(Baranowski et al., 2015). Thus, increases in plasma S1P levels during an ischaemic attack 
may help induce cardioprotection in part by stimulating coronary vasodilatation and 
decreasing heart rate.             
3.5 Conclusion 
In summary, we found very distinct immunostaining for SK1, S1P1 receptors and S1P3 
receptors in rat CA endothelial cells. Hypoxia increases the SK1 expression in rat coronary 
artery endothelial cells. This effect can be reduced by cycloheximide, suggesting that 
hypoxia may enhance SK1 protein synthesis. The increased SK1 level induced by hypoxia 
may enhance generation of the cardioprotective lipid mediator S1P, which can play a role 
in protection against microvascular dysfunction, inflammation, and oxidative damage 
caused by ischaemia/reperfusion injury. Hypoxia-stimulated increase in SK1 was also 
inhibited by pre-treatment with SKi and PF543 but not ROMe. Furthermore, the data 
obtained using SKi, CA-074ME, and MG132 suggests that SKi might reduce SK1 
expression by promoting the proteasomal and lysosomal degradation of SK1.                
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Chapter four 
4 The effect of hypoxia-induced increase in SK1 
on vascular function 
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4.1 Introduction 
S1P plays an important role in regulating vascular tone through binding to and activating 
S1P receptors in endothelial and vascular smooth muscle cells.  ECs express mainly S1P1 
and S1P3 receptors, whereas S1P2 receptors are predominately expressed in VSMCs (Ozaki 
et al., 2003, Saba and Hla, 2004, Alewijnse and Peters, 2008). Generally, S1P is capable of 
stimulating both vasodilation and vasoconstriction but the net effect of S1P on vascular 
tone is dependent on the specific vascular bed, species, S1P concentration and the S1P 
receptors expressed and stimulated. For instance, exogenous application of S1P to isolated 
rat mesenteric, cerebral and coronary arteries has been reported to promote 
vasoconstriction via a mechanism requiring S1P3 receptors (Hemmings et al., 2004, 
Salomone et al., 2008, Murakami et al., 2010). On the other hand, it has been demonstrated 
that S1P induces a NO-mediated vasorelaxation in rat aorta and mesenteric arteries (Dantas 
et al., 2003, Nofer et al., 2004). Moreover, Mair et al showed that S1P stimulates 
vasorelaxation in rat coronary artery through a mechanism requiring CB2 and S1P3 
receptors (Mair et al., 2010). Furthermore, there is evidence that TRPV channel activation 
within the blood vessels may contribute to vasorelaxation via nitric oxide, prostacyclin, 
and intermediate/small conductance potassium channel-dependent pathways (Baylie and 
Brayden, 2011). A number of studies have demonstrated that S1P and its precursor 
sphingosine activate these channels and this may play a role in the regulation of vascular 
tone (Numata et al., 2011, Langeslag et al., 2014). 
In chapter 3, I showed that exposure of rat coronary arteries to short-term hypoxia induced 
an increase in SK1 expression in endothelial cells of rat coronary artery. This increase in 
SK1 expression was significantly reduced by pre-treatment with the protein synthesis 
inhibitor cycloheximide and both the non-selective SK inhibitor, SKi and the selective SK1 
inhibitor, PF543. Functionally, exposure of the blood vessels to hypoxia can lead to either 
vasodilation or vasoconstriction depending on the vascular bed, the animal species being 
studied and the experimental methodology. For example, several studies have shown that 
hypoxia causes dilation of the coronary arteries in isolated whole heart preparations (Daut 
et al., 1990, Gasser et al., 1998). However, results obtained from studies using isolated 
coronary arteries to examine the effect of hypoxia were not consistent, with some showing 
dilation (Kerkhof et al., 2002, Lynch et al., 2006) and others constriction (Graser and 
Vanhoutte, 1991, Muramatsu et al., 1992). Herrera and Walker provided evidence that 
hypoxia elicits vasorelaxation in endothelium-denuded rat aortic rings in part via inhibition 
of L-type Ca
2+
 channels (Herrera and Walker, 1998). A role for reduced Ca
2+
 efflux 
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through voltage gated calcium channels (VGCC) has also been shown in smooth muscle 
from porcine coronary, rabbit cerebral, femoral and coeliac arteries (Franco-Obregon and 
Lopez-Barneo, 1996, Smani et al., 2002). Moreover, several studies showed that hypoxia 
stimulates the release of relaxing factors by the endothelium such as prostacyclin in rat tail 
artery, rat skeletal muscle arterioles and canine femoral artery (Busse et al., 1983, Messina 
et al., 1992). Thus, the mechanisms for hypoxia-induced effects on the vasculature remain 
controversial. 
Considering the aforementioned background, I hypothesized that hypoxia may increase 
SK1 in rat aortic endothelium. Once SK1 is activated, it is re-located from the cytosol to 
the plasma membrane where it is in close proximity to its substrate, sphingosine. Thus S1P 
is synthesised and exported through transporter proteins into the extracellular milieu where 
it acts as an agonist for S1P receptors or is retained within the cell to function as an 
intracellular messenger.    
Moreover, it has been reported that the SK/S1P pathway may contribute to the regulation 
of blood pressure. Indeed, it has been demonstrated that administration of S1P or FTY720, 
S1P receptor agonist, to anaesthetised rats was associated with a transient decline of blood 
pressure followed by an equally rapid restoration of pressure (Forrest et al., 2004). The 
initial reduction in blood pressure is likely to be due to decreased heart rate. In contrast, 
continuous infusion of FTY720 was associated with an increase in blood pressure to 
conscious rats (Forrest et al., 2004). S1P has also been shown to regulate blood pressure, 
enhance histamine clearance and facilitate recovery from anaphylactic shock via S1P2 
receptors (Olivera et al., 2010). Recently, it has been shown that Nogo-B deficient mice 
were significantly hypotensive compared with wild type controls (Cantalupo et al., 2015). 
Nogo-B is a membrane protein of the endoplasmic reticulum that negatively regulates 
endothelial S1P formation by inhibiting serine palmitoyltransferase, a rate-limiting enzyme 
of de novo sphingolipid biosynthesis. In the same study, it was demonstrated that Nogo-B 
null mice are resistant to angiotensin II-induced hypertension through S1P/S1P1 eNOS-
dependent pathway. In contrast, genetic deletion of SK1 significantly inhibits both the 
acute hypertensive response to angiotensin II in anaesthetized mice and the sustained 
hypertensive response to continuous administration of angiotensin II in conscious mice, 
suggesting that S1P generated by SK1 may have a pro-hypertensive role (Wilson et al., 
2015). The significant role of the SK/S1P signalling pathway has been shown not only in 
systemic hypertension but also in pulmonary arterial hypertension. Chen et al has reported 
that SK1 is upregulated in lung and PASMCs of patients with pulmonary arterial 
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hypertension (Chen et al., 2014). Deletion of SK1 or inhibition of SK1 by SK inhibitor or 
antagonising S1P2 receptor using JTE013 in mice was protective against development of 
hypoxia-induced pulmonary hypertension and pulmonary vascular remodelling, suggesting 
a critical role for SK1/S1P/S1P2 pathway in pathogenesis of pulmonary arterial 
hypertension (Chen et al., 2014). A recent study has also demonstrated that inhibiting SK1 
activity using PF543, a selective SK1 inhibitor decreased right ventricular hypertrophy in a 
mouse hypoxic model of pulmonary arterial hypertension (MacRitchie et al., 2016). Thus, 
a full understanding of S1P-mediated regulation of blood pressure may offer novel 
therapeutic options in the treatment of hypertension and related cardiovascular diseases.   
4.1.1 Aims 
 Examine the effect of hypoxia on the contractile response to U44619 in 
endothelium-intact and denuded rat aortic rings. 
 Study the distribution of SK1 and S1P receptors in rat aortic endothelium. 
 Investigate the effect of hypoxia on SK1 expression in the presence and 
absence of SK inhibitors in rat aorta. 
 Examine S1P-induced relaxation under normoxic and hypoxic conditions and 
elucidate the potential mechanisms of action underlying these effects. 
 Investigate the S1P-induced relaxation in the presence and absence of 
hypoxia in rat aortic rings obtained from spontaneously hypertensive Wistar 
Kyoto rats.  
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4.2 Methods 
4.2.1 Tissue preparation for immunofluorescent studies 
Rat aortic sections were prepared, fixed and immunostained as detailed in Section 2.3.3. 
Briefly vessels from male Sprague-Dawley rats were dissected immediately after death and 
placed into 1ml Krebs-Henseleit solution previously gassed with 95% O2, 5% CO2 at 37 
°C. The segments were then treated with specific inhibitory agents for 30 min (detailed 
below), then subjected to normoxia/hypoxia for 30 min and fixed by 3% paraformaldehyde 
overnight at 4 °C. The vessels were then labelled with specific primary and secondary 
antibodies, placed on a glass slide and the protein of interest visualized by confocal 
microscopy. 
Hypoxia was induced by placing the artery in 1 ml Krebs’ solution which had been 
constantly gassed with 95% N2, 5% CO2 for approximately 30 mins to reduce oxygen 
tension to 1-1.5% O2 saturation (Kerkhof et al., 2002). 
4.2.2 Experimental protocols 
4.2.2.1 Protein synthesis inhibitor 
A number of experiments were performed where the vessel was pre-treated with 10 µM 
cycloheximide, a protein synthesis inhibitor (Schneider-Poetsch et al., 2010), for 30 min 
prior to exposure to normoxia/hypoxia for 30 min. 
4.2.2.2 SK inhibitors 
A series of experiments was carried out where the vessels were preincubated with 10 µM 
SKi, a non-selective SK inhibitor (Mair et al., 2010) or 100 nM PF543, a selective SK1 
inhibitor (Schnute et al., 2012) followed by exposure to normoxia/hypoxia for 30 min. 
4.2.3 Image analysis 
A Bio-Rad Radiance 2100 confocal microscope (x20 oil/water immersion lenses) was used 
to visualise the protein of interest as described in detail in Section 2.3.7. 
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4.2.4 Tissue preparation for myography 
Rat aortic sections were prepared for functional studies as detailed in Section 2.4.1. 
Briefly, vessels from male Sprague-Dawley rats or spontaneously hypertensive Wistar 
Kyoto rats were dissected immediately after death and placed into Krebs-Henseleit 
solution previously gassed with 95% O2, 5% CO2 at room temperature. Then the thoracic 
aorta was carefully dissected free from adherent connective tissue and cut into 2-3 mm 
rings. Vessel rings were mounted in a wire myograph and maintained at 37 °C in 
oxygenated Krebs-Henseleit buffer (95% O2, 5% CO2). The vessels were allowed to 
equilibrate for 15-30 min. Thereafter, vessels were stretched until an optimum resting 
tension of 1gm was reached and allowed to equilibrate for 30 min prior to challenge with 
KCl (80 mM) to assess viability. Vascular endothelial function was assessed at the end of 
the experiment by adding 1 µM ACh. Relaxation to ACh ˃ 50% was indicative of a vessel 
with an intact endothelium. Where indicated, endothelium was removed by gentle rubbing 
of the intimal surface with forceps. Relaxation to ACh < 10% denoted an endothelium-
denuded vessel. 
4.2.5 Experimental protocols for myography 
The experimental and hypoxia protocol for myography were described in detail in Section 
2.4.2 (see also Figure 4-1, page 100 and Figure 4-14, page 117). 
4.2.5.1 U46619 protocol 
To investigate the effect of hypoxia on contraction to the thromboxane A2 mimetic 
U46619, endothelium-intact and denuded aortic rings were subjected to 30 min hypoxia 
then re-oxygenated and maintained under normoxic conditions. Then concentration 
response curves were generated by cumulative addition of U46619 (1×10
-9
-1×10
-6
M) with 
10 min between each addition. In experiments where the effects of SKi, a non-selective 
sphingosine kinase inhibitor (10 µM), on U46619-induced contraction were to be 
investigated under hypoxia and normoxia, the SKi was added 15 min before exposure to 
hypoxia and was present during generation of the concentration-response curve. 
4.2.5.2 Agonist comparison 
After 30 min equilibration and challenge with KCl, aortic rings under normoxic conditions 
were submaximally contracted with U46619 (3×10
-8
M). When a stable level of contraction 
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was achieved, concentration-response curves were performed by cumulative addition of 
agonists. S1P, CYM5541, a selective S1P3 receptor agonist, and SEW2871, a selective 
S1P1 receptor agonist, (1×10
-9
-3×10
-6
M) were added in half-log molar concentration in a 
cumulative manner with 5 min between each addition. 
4.2.5.3 Antagonists and inhibitors protocol 
In experiments where the effects of antagonists or inhibitors on agonist-induced relaxation 
were to be assessed, the antagonist of interest was added 30 min prior to contraction with 
U46619, and was present during generation of the concentration-response curve. A list of 
antagonists and inhibitors and their final bath concentrations used was provided in Chapter 
Two (Table 2-1).  
4.2.5.4 Statistical analysis 
Graph Pad Prism (version 5) software was used to analyse all the data. Contractile 
responses to U46619 were expressed as mean ± standard error of the mean (S.E.M) in 
grams. All relaxation responses are reported as a percentage loss of the tone induced by 
U46619. Results are expressed as mean ± SEM of n, where n is the number of arterial 
segments from different animals. Differences between concentration-response curves were 
tested by two way analysis of variance (ANOVA) with a Bonferroni’s post-test. To 
compare the effect of enzyme inhibitors and antagonists on U44619-induced contraction in 
rat aorta, one-way ANOVA with a Dunnett’s post was used. In all cases, statistical 
significance was accepted when p < 0.05. 
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Figure  4-1 Diagram showing the experimental protocols used for the myography experiments. 
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101 
 
 
4.3 Results 
4.3.1 Effect of hypoxia on contractile responses to U46619 in rat 
aorta. 
In order to determine whether hypoxia alters the contractile response to U46619, a series of 
experiments was carried out to examine the response of endothelium-intact and denuded 
rat thoracic aorta under control and hypoxic conditions. Addition of the thromboxane A2 
receptor agonist U46619 (1x10
-9
-1x10
-6
 M) to intact thoracic aorta in the presence or 
absence of hypoxia resulted in a concentration-dependent contraction. Previous exposure 
to 30 mins of hypoxia significantly enhanced the contractile response to U46619 (maximal 
contraction 1.7 ± 0.2 g, n=8; Figure 4-2A) compared with vessels under normoxic 
conditions (maximal contraction 1.2 ± 0.2 g, n=9; Figure 4-2A). The contractile response 
to U46619 was also significantly enhanced in denuded rat thoracic aorta subjected to 30 
min hypoxia (maximal contraction 2.0 ± 0.3 g, n=9; Figure 4-2B) compared with denuded 
vessels under normoxic conditions (maximal contraction 1.4 ± 0.2 g, n=9; Figure 4-2B).  
Pre-treatment of the vessels with the non-selective SK inhibitor SKi (10 µM) did not 
significantly alter the contraction induced by U46619 in intact rat aorta (maximal 
contraction 1.4 ± 0.8 g, n=9; Figure 4-3A) or denuded rat aorta (maximal contraction 1.7 ± 
0.3 g, n=10; Figure 4-3B) under control conditions. However, pre-treatment of the intact 
aorta with SKi prior to exposure to hypoxia significantly reduced the enhanced contraction 
ordinarily induced by hypoxia (maximal contraction 1.0 ± 0.2 g, n=8; Figure 4-4A). In 
contrast, SKi had no effect on hypoxia-enhanced contractile response to U46619 in 
denuded rat aorta (maximal contraction 1.8 ± 0.2 g, n=9; Figure 4-4B). 
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Figure  4-2 Contractile responses to U46619 in rat aorta under control and hypoxic 
conditions.  
Concentration response curves for the contractile effect of U46619 (1×10
-9
-1×10
-6 
M) in (A) 
endothelium-intact rat aorta in presence (n=8) and absence (n=9) of hypoxia and (B) endothelium-
denuded rat aorta in presence (n=9) and absence (n=9) of hypoxia.  Data are expressed as 
U46619-induced tone (in grams) and shown as mean ± SEM for n arteries from different animals. 
***p<0.001 vs control as determined by two-way ANOVA.  
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Figure  4-3  Contractile responses to U46619 in rat aorta in presence and absence of SKi 
under control conditions.  
Concentration response curves for the contractile effect of U46619 (1×10
-9
-1×10
-6 
M) in (A) 
endothelium-intact rat aorta in presence (n=9) and absence (n=9) of SKi (10 µM) and (B) 
endothelium-denuded rat aorta in presence (n=10) and absence (n=10) of SKi.  Data are 
expressed as U46619-induced tone (in grams) and shown as mean ± SEM for n arteries from 
different animals. 
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Figure  4-4 Contractile responses to U46619 in rat aorta in presence and absence of SKi and 
under hypoxic conditions. 
Concentration response curves for the contractile effect of U46619 (1×10
-9
-1×10
-6 
M) in (A) 
endothelium-intact rat aorta in presence (n=8) and absence (n=8) of SKi (10 µM) and (B) 
endothelium-denuded rat aorta in presence (n=9) and absence (n=9) of SKi.  Data are expressed 
as U46619-induced tone (in grams) and shown as mean ± SEM for n arteries from different 
animals. **p<0.01 vs control determined by two-way ANOVA.  
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4.3.2 S1P-induces vascular relaxation in an endothelium 
dependent manner. 
To confirm that S1P has a relaxant effect on rat aorta, its effect on aortic tone was directly 
assessed. Addition of S1P (1 nM-30 µM) to endothelium-intact thoracic aorta pre-
contracted with U46619 resulted in a concentration-dependent, slowly developing 
relaxation, which reached a maximum of 22.5 ± 3.3%, n=6; Figure 4-5A. A significant 
difference was observed between maximal relaxation induced by S1P and loss of 
contractile force in time control vessels (maximal relaxation 7.9 ± 0.9%, n=6; Figure 4-
5A). In aortic rings where the endothelial layer was removed, relaxation in response to S1P 
was abolished (maximal relaxation 7.8 ± 1.7%, n=6; Figure 4-5B). 
Furthermore, the expression of S1P1 and S1P3 receptors was examined in endothelium of 
rat aorta by immunofluorescent studies. It was found that both receptor subtypes are 
expressed widely in the endothelium (Figure 4-6 and 4-7 respectively). To determine 
whether S1P-stimulated vascular relaxation is mediated through S1P1 and/or S1P3 
receptors, dose response curves for a selective S1P1 agonist, SEW2871, and a selective 
S1P3 agonist, CYM5541, were constructed in endothelium-intact U46619 pre-contracted 
arteries. SEW2871 did not induce significant vasorelaxation in rat aorta (maximal 
relaxation 5.9 ± 2.0%, n=5; Figure 4-8A), whereas addition of CYM5541 (1 nM-30 µM) 
induced a concentration-dependent relaxation of a similar magnitude to S1P itself 
(maximal relaxation 20.2 ± 4.0%, n=6; Figure 4-8B). In aortic rings where the endothelial 
layer was removed, relaxation in response to CYM5541 was markedly attenuated 
(maximal response 11.1 ± 2.9%, n=7; Figure 4-8C). 
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Figure  4-5 S1P stimulated aortic relaxation in an endothelium dependent manner.  
(A) Concentration–response curves showing the vasorelaxant effect of S1P alone (1 nM–30 µM) 
on U46619-pre-contracted endothelium-intact aortic rings (n=6) compared to time control (n=6). (B) 
Vasorelaxant effect of S1P alone (1 nM-30 µM) on U46619-pre-contracted endothelium-intact (n=6) 
and endothelium-denuded (n=6) rat aorta. ***p<0.001 vs S1P alone as determined by two-way 
ANOVA.  
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Figure  4-6 S1P1 receptor expression in rat aortic endothelium.  
Representative immunofluorescent images for S1P1 receptors (red). Syto 61 nuclear stain was 
used to stain the endothelial and smooth muscle cell nuclei (blue). The green colour in the merged 
image represents the autofluorescence of the internal elastic lamina. Results are representative of 
3 separate experiments. Scale bar is 30 µm for all images. 
 
Syto 61 S1P1 Merge
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Figure  4-7 S1P3 receptor expression in rat aortic endothelium.  
Representative immunofluorescent images for S1P3 receptors (red). Syto 61 nuclear stain was 
used to stain the endothelial and smooth muscle cell nuclei (blue). The green colour in the merged 
image represents the autofluorescence of the internal elastic lamina. Results are representative of 
3 separate experiments. Scale bar is 30 µm for all images. 
Syto 61 S1P3 Merge
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Figure  4-8 S1P and CYM 5541 induce aortic relaxation in an endothelium-dependent manner.  
(A) Concentration–response curves showing the effect of SEW2871, a selective S1P1 receptor 
agonist, (1 nM–30 µM) on U46619-pre-contracted endothelium-intact (n=5) rat aorta compared to 
time control (n=6).(B) Vasorelaxant effect of S1P and CYM 5541, a selective S1P3 receptor 
agonist, (1 nM-30 µM, n=6) on endothelium-intact U46619 pre-contracted, rat aorta. (C) 
Vasorelaxant effect of CYM 5541, a selective S1P3 receptor agonist, (1 nM-30 µM) on endothlium-
intact (n=6) and endothelium denuded (n=7) U46619 pre-contracted, rat aorta. ***p<0.001 vs CYM 
5541 (C) as determined by two-way ANOVA.  
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4.3.3 TRPV1 channels are involved in S1P-stimulated relaxation. 
To assess whether TRPV1 channels contribute to S1P-induced relaxation, aortic rings were 
pre-treated with AMG 9810, a TRPV1 antagonist 30 min before addition of S1P. This led 
to a significant attenuation of S1P-mediated relaxation (maximal relaxation 9.7 ± 0.8%, 
n=6, Figure 4-9). 
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Figure  4-9 Role of TRPV1 channels in S1P-mediated relaxation.  
Concentration–response curves showing the vasorelaxant effect of S1P (1 nM–30 µM) on U46619-
pre-contracted endothelium-intact rat aorta in the presence and absence of AMG 9810, a TRPV1 
antagonist (10 µM, n=6). ***p<0.001 vs S1P alone as determined by two-way ANOVA. 
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4.3.4 Effect of hypoxia on SK1 enzyme expression in rat aortic 
endothelium. 
It was found that SK1 is prominently expressed in endothelial cells of rat aorta. Similar to 
rat CA, immunofluorescence staining for SK1 (red) in rat aorta appears as red punctate 
staining in the cytosol of the cells (Figure 4-10). Moreover, it was also demonstrated that 
exposure of rat aortic rings to hypoxia for 30 min resulted in a significant increase (61%) 
in integrated density (2.6 x 10
6
 ± 2.6 x 10
5
AU, n=4) corresponding to SK1 expression in 
comparison with arteries maintained under normoxic conditions (1.0 x 10
6
 ± 1.7 x 10
5
AU, 
n=4; Figure 4-11). In contrast, hypoxia had no effect on phosphorylated-SK1 (pSK1) 
integrated density (1.1 x 10
6
 ± 1.7 x 10
5
AU, n=3) compared with the corresponding levels 
in control vessels (1.0 x 10
6
 ± 1.2 x 10
5
AU, n=4; Figure 4-12). 
4.3.5 Effect of cycloheximide on hypoxia-induced increase in SK1 
expression. 
Pre-treatment of aortic rings with cycloheximide for 30 min under normoxic conditions 
resulted in a small reduction in SK1 integrated density (0.83 x 10
6
 ± 1.0 x 10
5
AU, n=4) 
compared with controls (1.0 x 10
6
 ± 1.7 x 10
5
AU, n=4; Figure 4-13). However, in arteries 
preincubated with cycloheximide prior to exposure to hypoxia, there was a significant 
reduction (50%) in hypoxia-induced increase in integrated density of SK1 (1.3 x 10
6
 ± 2.5 
x 10
5
AU, n=3) compared with controls (2.6 x 10
6
 ± 2.6 x10
5
AU, n=5; Figure 4-13). 
4.3.6 Effect of hypoxia on S1P-stimulated vascular relaxation 
Addition of 5 x 10
-9
M U46619 was used to constrict the aortic rings after exposure to 
hypoxia. This concentration was used as it generated contraction of a similar magnitude to 
3 x 10
-8
M U46619 under control conditions. Inhibitors used in these experiments did not 
affect the U46619-induced tone (Table 4-1 and 4-2). In experiments involving SKi, 
U46619 at 3 x 10
-8
M was used under both control and hypoxic conditions since SKi had 
previously been found to attenuate contraction in hypoxic rings (Figure 4-4). The S1P-
induced relaxation in rat aorta was markedly increased in those arteries subjected to 30 min 
hypoxia. The maximal relaxation in response to S1P under hypoxic conditions was 31.8 ± 
6.3%, n=10 compared to control vessels (maximal relaxation 19.3 ± 3.1%, n=9; Figure 4-
15A). This was also significantly greater than loss of tone in time control vessels after 
exposure to hypoxia (maximal relaxation 19.7 ± 5.9%, n=10; Figure 4-15B). In aortic rings 
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where the endothelial layer was removed, the enhanced relaxation in response to S1P under 
hypoxic conditions was abolished (maximal relaxation 11.4 ± 1.3%, n=8; Figure 4-15C). 
 
 
Figure  4-10 Expression of SK1 in endothelial cells of rat aorta.  
Rat aortic sections were immunostained for SK1 (red) with anti-SK1 antibody. Syto 61 nuclear stain 
was used to stain the endothelial and smooth muscle cell nuclei (blue). The green colour in the 
merged image represents the autofluorescence of the internal elastic lamina. Scale bar is 30 µm in 
all images. Images are representative of at least 3 separate experiments. 
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Figure  4-11 Effect of hypoxia on SK1 expression levels. 
Representative immunofluorescent images showing expression of SK1 (red) in rat aortic 
endothelium under normoxic conditions (A) and hypoxic conditions (B). (C) Quantitative 
fluorescence measurement of SK1 under normoxia and hypoxia. Scale bar is 30 µm for both 
images. **p<0.01 vs normoxia as determined by unpaired two tailed t-test. Results are 
representative of 4 separate experiments.  
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Figure  4-12 Effect of hypoxia on pSK1 levels. 
Representative immunofluorescent images showing effect of hypoxia on pSK1 (red) level in rat 
aortic endothelium (B) compared with normoxia (A). (C) Quantitative fluorescence measurement of 
pSK1 under normoxia and hypoxia. Results are representative of 3-4 separate experiments. Scale 
bar is 30 µm for both images. 
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Figure  4-13 Effect of cycloheximide on hypoxia-induced increase in SK1 expression. 
Representative immunofluorescent images show expression of SK1 (red) in rat aortic endothelium 
(A) and following pre-treatment with cycloheximide (10 µM, 30 min) under normoxic conditions (B). 
Expression of SK1 in rat aorta subjected to 30 min hypoxia (C). Preincubation of rat aorta with 
cycloheximide reduced the hypoxia-induced increase in SK1 expression (D). (E) Quantitative 
fluorescence measurement of SK1 in the presence and absence of cycloheximide. **p<0.01, 
***p<0.001 vs hypoxia alone as determined by one way ANOVA with Bonferroni’s‎ post-test. 
Results are representative of 3-4 separate experiments. Scale bar is 30 µm for all images.   
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Table  4-1 Effect of enzyme inhibitors and antagonists (all used at 10 µM concentration 
except PF543 which was used at 100 nM) on U46619-induced contraction (3 x 10
-8 
M) in rat 
aortae under control conditions. 
 
 Mean U46619-induced 
contraction (g) 
Number of arteries from 
different animals (n) 
Control 1.7 ± 0.2 7 
SKi 1.4 ± 0.1 8 
PF543 1.9 ± 0.1 9 
ROMe 1.6 ± 0.2 6 
L-NNA 1.9 ± 0.2 7 
CAY10444 1.5 ± 0.2 12 
Data are expressed as mean ± SEM for (n) number of arteries from different animals. Statistical 
analysis‎using‎one‎way‎ANOVA‎with‎Dunnett’s‎post‎test‎revealed‎no‎significant‎differences. 
Table  4-2 Effect of enzyme inhibitors and antagonists (all used at 10 µM concentration 
except PF543 which was used at 100 nM) on U46619-induced contraction (5 X 10
-9 
M) in rat 
aortae under hypoxic conditions. 
 
 Mean U46619-induced 
contraction (g) 
Number of arteries from 
different animals (n) 
Control 1.7 ± 0.1 6 
SKi 1.6 ± 0.1 8 
PF543 1.5 ± 0.2 7 
ROMe 1.5 ± 0.1 6 
L-NNA 1.5 ± 0.2 6 
CAY10444 1.4 ± 0.3 10 
Data are expressed as mean ± SEM for (n) number of arteries from different animals. Statistical 
analysis‎using‎one‎way‎ANOVA‎with‎Dunnett’s‎post‎test‎revealed‎no‎significant‎differences. 
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Figure  4-14 Representative trace showing the vasorelaxation response to S1P following 
exposure to hypoxia.  
The vessels are exposed to hypoxia for 30 min, and then reoxygenated, pre-contracted by U46619 
and S1P (1 nM–30 µM) dose response curve is created.  
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Figure  4-15 Effect of hypoxia on S1P-induced relaxation in rat aorta.  
(A) Concentration–response curves showing the vasorelaxant effect of S1P (1 nM–30 µM) on 
U46619-pre-contracted endothelium-intact rat aorta in the presence (n=10) and absence (n=9) of 
hypoxia. (B) Concentration–response curves showing the vasorelaxant effect of S1P (1 nM–30 µM) 
on U46619-pre-contracted endothelium-intact rat aorta (n=10) compared with time control (n=10) 
and under hypoxic conditions. (C) Concentration–response curves showing the vasorelaxant effect 
of S1P (1 nM–30 µM) on U46619-pre-contracted endothelium-intact (n=10) and endothelium 
denuded (n=8) rat aorta under hypoxic conditions.  ***p<0.001 vs S1P control (A), **p<0.01 vs time 
control (B), ***p<0.001 vs S1P (hypoxia, C) as determined by two-way ANOVA.   
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4.3.7 Effect of sphingosine kinase inhibitors on hypoxia-induced 
increase in SK1 expression. 
Under normoxic conditions, pre-treatment of aortic rings with the non-selective SK 
inhibitor, SKi (10 µM) or the selective SK1 inhibitor, PF543 (100 nM) led to an obvious 
reduction in SK1 immunostaining (red punctate staining in the images). However image J 
software yielded no significant differences in the integrated density of SK1 and this is 
likely because image J is also quantifying the background noise (1.1 x 10
6
 ± 2.9 x 10
5
AU, 
n=3; Figure 4-16 and 1.1 x 10
6
 ± 1.8 x 10
5
AU, n=3; Figure 4-18 respectively). In contrast, 
addition of either SKi (Figure 4-16) or PF543 (Figure 4-18) markedly reduced (54%) the 
increase in SK1 expression caused by hypoxia when added 30 min prior to exposure to 
hypoxia (1.2 x 10
6
 ± 1.0 x 10
5
AU, n=3; Figure 4-16 and 1.2 x 10
6 
± 1.0 x 10
5
AU, n=3; 
Figure 4-18 respectively) compared with controls (2.6 x 10
6
 ± 2.6 x 10
5
 AU, n=4). 
4.3.8 Effect of inhibitors and antagonists on S1P-stimulated 
relaxation. 
4.3.8.1 Effect of SK inhibitors on S1P-induced relaxation in endothelium-
intact rat aorta 
Under control conditions, preincubation of endothelium-intact rat aortic rings with the non 
-selective SK inhibitor, SKi (10 µM) caused a significant attenuation of S1P-induced 
relaxation (maximal relaxation 9.6 ± 1.3%, n=6) compared with control vessels (maximal 
relaxation 20.8 ± 3.2%, n=10; Figure 4-17A). SKi also markedly reduced the enhanced 
S1P-induced relaxation caused by hypoxia (maximal relaxation 9.5 ± 3.4%, n=7) compared 
with control vessels (31.8 ± 6.3%, n=10; Figure 4-17B). Moreover, the selective SK1 
inhibitor, PF543 (100 nM) also significantly inhibited the S1P-stimulated relaxation in 
endothelium-intact vessels under control conditions (maximal relaxation 8.9 ± 2.1%, n=9) 
compared to control vessels (maximal relaxation 13.6 ± 1.8%, n=8; Figure 4-19A). The 
hypoxia-enhanced S1P-induced relaxation was also markedly decreased by pre-treatment 
with PF543 before exposure to hypoxia (maximal relaxation 13.6 ± 4.1%, n=7) compared 
with control vessels (maximal relaxation 26.8 ± 5.8%, n=7; 4-19B). However, responses to 
S1P were not significantly inhibited by pre-treatment with the selective SK2 inhibitor, 
ROMe (10 µM) under either control conditions (maximal relaxation 11.4 ± 1.6%, n=5; 
Figure 4-20A) or hypoxic conditions (maximal relaxation 22.5 ± 5.1, n=6; Figure 4-20B). 
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4.3.8.2 Effect of L-NNA and CAY10444 on S1P-induced relaxation in 
endothelium-intact rat aorta. 
30 min preincubation of endothelium-intact aortic rings with the nitric oxide synthase 
inhibitor L-NNA (10
-4
 M) led to inhibition of S1P-stimulated relaxation under control 
conditions (maximal relaxation 9.7 ± 2.2%, n=7) compared with control vessels (maximal 
relaxation 23.1 ± 6.5, n=7; Figure 4-21A). L-NNA also caused a marked attenuation in 
enhanced S1P-induced relaxation caused by hypoxia (maximal relaxation 13.8 ± 8.2%, 
n=6) compared with control vessels (maximal relaxation 42.9 ± 18.0%, n=5; Figure 4-
21B). The selective S1P3 receptor antagonist, CAY10444 (10 µM, 30 min pre-treatment) 
did not significantly attenuate the responses to S1P under either control conditions 
(maximal relaxation 21.7 ± 4.2%, n=8) compared with control vessels (maximal relaxation 
18.1 ± 3.3%, n=6; Figure 4-22A) or hypoxic conditions (maximal relaxation 38.1 ± 7.8%, 
n=6) compared with control vessels (29.1 ± 5.9%, n=5; Figure 4-22B). 
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Figure  4-16 Effect of SKi on hypoxia-induced increase in SK1 expression. 
Representative immunofluorescent images show expression of SK1 (red) in rat aortic endothelium 
(A) and following pre-treatment with SKi, a non-selective SK inhibitor, (10 µM, 30 min) under 
normoxic conditions (B). Expression of SK1 in rat aorta subjected to 30 min hypoxia (C). 
Preincubation of rat aorta with SKi reduced the hypoxia-induced increase in SK1 expression (D). 
(E) Quantitative fluorescence measurement of SK1 in the presence and absence of SKi. **p<0.01, 
***p<0.001‎ vs‎ hypoxia‎ alone‎ as‎ determined‎ by‎ one‎ way‎ ANOVA‎ with‎ Bonferroni’s‎ post-test. 
Results are representative of 3-4 separate experiments. Scale bar is 30 µm for all images. 
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Figure  4-17 Effect of SKi on S1P-induced relaxation in rat aorta.  
(A) Concentration–response curves showing the vasorelaxant effect of S1P (1 nM–30 µM) on 
U46619-pre-contracted endothelium-intact rat aorta in presence (n=6) and absence (n=10) of SKi, 
a non-selective SK inhibitor, (10 µM) under control conditions. (B) Concentration–response curves 
showing the vasorelaxant effect of S1P (1 nM–30 µM) on U46619-pre-contracted endothelium-
intact rat aorta in presence (n=7) and absence (n=10) of SKi (10 µM) under hypoxic conditions. 
***p<0.001 vs S1P alone as determined by two-way ANOVA.  
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Figure  4-18  Effect of PF543 on hypoxia-induced increase in SK1 expression. 
Representative immunofluorescent images show expression of SK1 (red) in rat aortic endothelium 
(A) and following pre-treatment with PF543, a selective SK1 inhibitor, (100 nM, 30 min) under 
normoxic conditions (B). Expression of SK1 in rat aorta subjected to 30 min hypoxia (C). 
Preincubation of rat aorta with PF543 reduced the hypoxia-induced increase in SK1 expression 
(D). (E) Quantitative fluorescence measurement of SK1 in the presence and absence of PF543. 
**p<0.01, ***p<0.001 vs hypoxia alone as determined by one way ANOVA with Bonferroni’s‎post-
test. Results are representative of 3-4 separate experiments. Scale bar is 30 µm for all images.  
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Figure  4-19 S1P-induced relaxation in rat aorta in presence and absence of PF543.  
(A) Concentration–response curves showing the vasorelaxant effect of S1P (1 nM–30 µM) on 
U46619-pre-contracted endothelium-intact rat aorta in presence (n=9) and absence (n=8) of 
PF543, a selective SK1 inhibitor, (100 nM) under control conditions. (B) Concentration–response 
curves showing the vasorelaxant effect of S1P (1 nM–30 µM) on U46619-pre-contracted 
endothelium-intact rat aorta in the presence (n=7) and absence (n=7) of PF543 (100 nM) under 
hypoxic conditions. **p<0.01, ***p<0.001 vs S1P alone as determined by two-way ANOVA.  
 
 
125 
 
A
-10 -9 -8 -7 -6 -5
0
5
10
15
20
S1P
S1P+ROMe
log [S1P](M)
R
e
la
x
a
ti
o
n
 (
%
 l
o
s
s
 o
f
U
4
6
6
1
9
-i
n
d
u
c
e
d
 t
o
n
e
)
B
-10 -9 -8 -7 -6 -5
0
10
20
30
40
S1P (Hypoxia)
S1P+ROMe (Hypoxia)
log [S1P](M)
R
e
la
x
a
ti
o
n
 (
%
 l
o
s
s
 o
f
U
4
6
6
1
9
-i
n
d
u
c
e
d
 t
o
n
e
)
 
Figure  4-20 S1P-induced relaxation in rat aorta in presence and absence of ROMe.  
(A) Concentration–response curves showing the vasorelaxant effect of S1P (1 nM–30 µM) on 
U46619-pre-contracted endothelium-intact rat aorta in presence (n=5) and absence (n=8) of 
ROMe, a selective SK2 inhibitor, (10 µM) under control conditions. (B) Concentration–response 
curves showing the vasorelaxant effect of S1P (1 nM–30 µM) on U46619-pre-contracted 
endothelium-intact rat aorta in the presence (n=6) and absence (n=7) of ROMe (10 µM) under 
hypoxic conditions. 
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Figure  4-21 S1P-induced relaxation in rat aorta in presence and absence of L-NNA. 
(A) Concentration–response curves showing the vasorelaxant effect of S1P (1 nM–30 µM) on 
U46619-pre-contracted endothelium-intact rat aorta in the presence (n=7) and absence (n=7) of L-
NNA, a nitric oxide synthase inhibitor, (10
-4
 M) under control conditions. (B) Concentration–
response curves showing the vasorelaxant effect of S1P (1 nM–30 µM) on U46619-pre-contracted 
endothelium-intact rat aorta in the presence (n=6) and absence (n=5) of L-NNA (10
-4
 M) under 
hypoxic conditions. ***p<0.001 vs S1P alone as determined by two-way ANOVA.  
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Figure  4-22  S1P-induced relaxation in rat aorta in presence and absence of CAY10444.  
(A) Concentration–response curves showing the vasorelaxant effect of S1P (1 nM–30 µM) on 
U46619-pre-contracted endothelium-intact rat aorta in the presence (n=8) and absence (n=6) of 
CAY10444, a selective S1P3 antagonist, (10 µM) under control conditions. (B) Concentration–
response curves showing the vasorelaxant effect of S1P (1 nM–30 µM) on U46619-pre-contracted 
endothelium-intact rat aorta in the presence (n=6) and absence (n=5) of CAY10444 (10 µM) under 
hypoxic conditions.  
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4.3.9 S1P-stimulated vascular relaxation in rat aorta from 
spontaneously hypertensive rats 
A series of experiments was carried out to directly assess the vasorelaxant effect of S1P on 
endothelium-intact rat aortic rings obtained from spontaneously hypertensive Wistar Kyoto 
rats under control and hypoxic conditions. It was found that S1P-induced relaxation was 
significantly reduced in vessels obtained from hypertensive rats (maximal relaxation 6.1 ± 
5.1%, n=6) compared with control vessels obtained from normal Sprague-Dawley rats 
(maximal relaxation 13.6 ± 1.7%, n=6; Figure 4-23A) under control conditions. In contrast, 
there was no significant difference between hypoxia-enhanced S1P-induced relaxation in 
vessels obtained from hypertensive rats (maximal relaxation 20.7 ± 6.8%, n=6) and normal 
Sprague-Dawley rats (maximal relaxation 26.8 ± 5.8%, n=7; Figure 4-23B). Thus, S1P was 
still able to stimulate relaxation in hypertensive vessels after exposure to hypoxia (maximal 
relaxation 20.7 ± 6.8%, n=6, 6.1 ± 5.1%, n=6 respectively; Figure 4-24A). Moreover, pre-
treatment of rat aortic rings obtained from hypertensive rats with the selective SK1 
inhibitor, PF543 (100 nM) before exposure to hypoxia significantly reduced the enhanced 
S1P-induced relaxation caused by hypoxia (maximal relaxation 9.7 ± 6.7%, n=6; Figure 4-
24B).       
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Figure  4-23 S1P-stimulated relaxation in rat aorta from normal and hypertensive rats.  
(A) Concentration–response curves showing the vasorelaxant effect of S1P (1 nM–30 µM) on 
U46619-pre-contracted endothelium-intact rat aortic rings from hypertensive rats (n=6) and normal 
rats (n=6) under control conditions. (B) Concentration–response curves showing the vasorelaxant 
effect of S1P (1 nM–30 µM) on U46619-pre-contracted endothelium-intact rat aortic rings from 
hypertensive rats (n=6) and normal rats (n=7) under hypoxic conditions. **p<0.01 vs S1P (control) 
as determined by two-way ANOVA.    
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Figure  4-24 S1P-induced relaxation in rat aorta from hypertensive rats.   
(A) Concentration–response curves showing the vasorelaxant effect of S1P (1 nM–30 µM) on 
U46619-pre-contracted endothelium-intact rat aortic rings from hypertensive rats in the presence 
(n=6) and absence (n=6) of hypoxia. (B) Concentration–response curves showing the vasorelaxant 
effect of S1P (1 nM–30 µM) on U46619-pre-contracted endothelium-intact rat aortic rings from 
hypertensive rats in the presence (n=6) and absence (n=6) of PF543, a selective SK1 inhibitor (100 
nM) under hypoxic conditions. **p<0.01 vs S1P (hypoxia), ***p<0.001 vs S1P alone as determined 
by two-way ANOVA. 
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4.4 Discussion 
In chapter 3, it was found that short periods of hypoxia increased SK1 expression in 
isolated rat coronary artery endothelium. To determine whether the hypoxia-induced 
increase in SK1 may regulate vascular function through the generation of S1P, it was 
important to carry out functional experiments. However, isolation of rat coronary artery is 
a slow and difficult process due to its small size (200 µm) and position within the 
myocardial tissue. In addition, the amount of tissue that can be dissected would not be 
enough to conduct immunofluorescence and functional studies at the same time. Thus, rat 
aortic rings were used to separately examine whether hypoxia can similarly increase SK1 
expression and whether this has an impact on vascular reactivity. 
First, a series of experiments was carried out to investigate the effect of hypoxia on 
U46619-induced contraction in endothelium-intact and denuded rat aortic rings. A number 
of studies have reported that hypoxia augmented contractile sensitivity to U46619 in 
isolated cerebral artery (Sillau et al., 2002) and phenylephrine in isolated rat abdominal 
aorta (Gräser and Rubanyi, 1993). In the current study, it was found that exposure of 
endothelium-intact rat aortic rings to hypoxia increased the contractile sensitivity to 
U46619 compared with controls (Figure 4-2A). Removal of the endothelium had no effect 
on the enhanced contractile response to U46619 (Figure 4-2B). Moreover, pre-treatment 
with SKi significantly decreased the hypoxia-augmented contractile response to U46619 in 
endothelium-intact aortic rings. In contrast SKi did not reduce the hypoxia-enhanced 
contractile sensitivity to U46619 in endothelium-denuded aortic rings. These findings 
suggest that hypoxia increases sensitivity of smooth muscle cells to contractile agents. The 
effect of SKi in endothelium-intact but not denuded rings is more difficult to explain. It 
must be assumed that the effect of SKi is at the level of the endothelium and that the 
reduction in generation of S1P from the endothelium is what reduces contractility in 
response to U46619. Although, S1P has been demonstrated to stimulate relaxation of pre-
contracted arterial preparations, S1P also exhibited a vasoconstrictor effect on basal arterial 
tone in isolated arteries (Coussin et al., 2002, Salomone et al., 2003). Therefore, it might be 
possible that the S1P generated in endothelial cells during hypoxia is transported out to 
activate S1P2 in smooth muscle cells in a paracrine manner and this may explain why SKi 
attenuated the hypoxia-augmented contractile response to U46619 in endothelium-intact 
vessels. However, a direct effect of SKi on the smooth muscle under hypoxic conditions is 
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also a possibility which cannot be ruled out. Using a selective S1P2 receptor antagonist and 
S1P transporter inhibitors may further elucidate this mechanism.      
Several studies have previously shown that S1P induces endothelium-dependent 
vasorelaxation in rat aorta (Nofer et al., 2003, Roviezzo et al., 2006). Here, it was also 
shown that S1P stimulates relaxation in isolated rat aortic rings and this effect was almost 
entirely dependent on the presence of an intact endothelium, suggesting that S1P-induced 
relaxation is endothelium-dependent (Figure 4-5B). Moreover, various studies have 
reported that S1P-induced relaxation is mediated through its S1P1 (Igarashi and Michel, 
2000, Igarashi et al., 2001) and/or S1P3 receptor (Nofer et al., 2003, Mair et al., 2010). 
Therefore, S1P receptor agonists were used to explore whether S1P-induced relaxation in 
rat aortae is mediated through S1P1 and/or S1P3 receptors. It was found that addition of 
CYM5541, an S1P3 agonist, stimulated relaxation in endothelium-intact but not 
endothelium-denuded isolated rat aortic rings whereas SEW2871, an S1P1 agonist had no 
effect, suggesting that S1P may elicit its effect via S1P3 receptors (Figure 4-8 A & B). 
Similar to experiments performed in the rat coronary artery (chapter 3), polyclonal 
antibodies to SK1 enzyme, S1P1 and S1P3 receptors were used to examine the expression 
of SK1 enzyme, S1P1 and S1P3 receptor subtypes in rat aortic endothelium. It was found 
that the rat aortic endothelium exhibits an intense immunostaining for SK1 enzyme and 
S1P1 and S1P3 receptors (Figure 4-6, 4-7, 4-10). Unlike S1P and CYM5541, which 
induced relaxation in rat aortic rings, SEW2871 was without effect. This may suggest that 
S1P-stimulated relaxation is mediated through S1P3 receptor. In line with this, it has also 
been reported that FTY720, an S1P analogue, stimulated endothelium-dependent 
relaxation in phenylephrine-pre-contracted aortic rings  and deletion of either eNOS or 
S1P3 inhibited the vasorelaxation response, suggesting that FTY720-induced relaxation is 
mediated by eNOS/NO pathway and S1P3 receptors (Tolle et al., 2005). In the same study, 
it was also shown that eNOS activation was attenuated by pre-treatment with the PI3K 
inhibitor LY294002, confirming involvement of Akt in eNOS activation and also by the 
SK inhibitor DMS, demonstrating a critical role for SK in mediating FTY720-stimulated 
relaxation.     
Recent studies have shown that TRPV1 is widely expressed in blood vessels such as rat 
skeletal muscle arteries, mesenteric, femoral, carotid and aorta (Lizanecz et al., 2006, Toth 
et al., 2014). Kark et al demonstrated that stimulation of TRPV1 in blood vessels may 
induce constriction or dilation depending on the vascular bed used (Kark et al., 2008). It 
was suggested that TRPV1-stimulted relaxation may be related to the perivascular sensory 
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neuronal terminals, which were thought to stimulate vasodilation via release of 
neurotransmitters such as CGRP and substance P (Zygmunt et al., 1999). Another study 
showed that TRPV1 stimulation induces porcine coronary vasodilation and this effect was 
inhibited by removal of endothelium, the TRPV1 antagonist capsazepine, the NOS 
inhibitor L-NAME as well as K
+
 channel antagonists (Bratz et al., 2008). In contrast, 
stimulation of TRPV1 in arteriolar smooth muscle cells induced vasoconstriction through 
an increase in intracellular Ca
2+
 concentration (Cavanaugh et al., 2011, Czikora et al., 
2012). The present study found that the TRPV1 antagonist, AMG 9810 significantly 
decreased the S1P-stimulated vasorelaxation in endothelium-intact rat aorta, suggesting 
that part of the S1P-induced relaxation may be mediated through activation of TRPV1 
channels (Figure 4-9). Therefore, vascular TRPV1 may play an important role in regulation 
of vascular tone via a NO-dependant pathway. Stimulation of endothelial TRPV1 by S1P 
may represent a novel pharmacological target for treatment of vascular diseases.  
In chapter 3, short-term hypoxia was shown to increase SK1 expression in rat coronary 
artery endothelium and this effect was significantly reduced by pre-treatment with 
cycloheximide, a protein synthesis inhibitor, SKi, a non-selective SK inhibitor or PF543, a 
selective SK1 inhibitor. Indeed, short term hypoxic stress has been shown to increase SK1 
protein levels in glioma cell lines starting from 1 hr after commencing hypoxic stress and 
this was accompanied by an increase in expression of HIF-1α and HIF-2α (Anelli et al., 
2008). SK1 but not SK2 mRNA was also increased with a maximal 2-fold enhancement 
occurring after 4 h of treatment with a hypoxia-mimicking agent. Another study 
demonstrated that short periods of hypoxia significantly increased SK1 
immunofluorescence in rat amoeboid microglial cells and this increase in SK1 
immunofluorescence started 15 min after exposure to hypoxia and reached a maximum 
level after 1 hr hypoxia (Lin et al., 2011). Therefore, one of the aims of this chapter was to 
determine whether hypoxia increases SK1 expression in rat aortic rings and how this may 
regulate vascular function through the generation of S1P. In agreement with data obtained 
from the rat coronary artery, exposure of rat aortic rings to short-term (30 min) hypoxia 
resulted in a marked increase in SK1 expression in rat aortic endothelium compared with 
controls (Figure 4-10). Using human anti-phospho-specific SK1 (Ser-225) antibody 
revealed no differences in pSK1 immunostaining under normoxic and hypoxic conditions 
(Figure 4-11). However, SK1 can also be activated via phosphorylation-independent 
mechanisms (ter Braak et al., 2009, Gault et al., 2012). It was also observed that pre-
treatment with cycloheximide 30 min before exposure to hypoxia resulted in a significant 
reduction in the hypoxia-induced increase in SK1 expression (Figure 4-13). A small 
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decrease in SK1 expression under normoxic conditions with cycloheximide was also seen. 
This data suggests that hypoxia may increase SK1 synthesis in rat aortic rings. 
Furthermore, pre-treatment of rat aortae with SKi (Figure 4-16) or PF543 (Figure 4-18) 
visually appeared to reduce SK1 immunostaining (red punctate staining in the images) 
under normoxic conditions but image J software yielded no significant differences in the 
integrated density of SK1 and this is likely because image J is also quantifying the 
background noise in these images. Pre-treatment with SKi (Figure 4-16) or PF543 (Figure 
4-18) prior to exposure to hypoxia resulted in a reversal of the hypoxia-induced increase in 
SK1 expression. 
Various previous studies have demonstrated arterial relaxation in response to hypoxia in 
several arteries from different animal species including rat, and human coronary arteries 
precontracted with KCL or U46619 (Kerkhof et al., 2002, Lynch et al., 2006). Lynch et al 
showed that hypoxic dilation was reversed by retuning to normoxic conditions but addition 
of glibenclamide, a KATP channel blocker, had no effect (Lynch et al., 2006). 
Vasorelaxation in response to hypoxia was also reported in rabbit basilar and carotid 
arteries (Pearce et al., 1992) and porcine and rat aortae pre-contracted with phenylephrine 
(Gasser et al., 1993, Herrera and Walker, 1998). In endothelium-denuded rat aortae pre-
contracted with phenylephrine, the L-type Ca
2+
 channel antagonist nifedipine abolished the 
vasorelaxation response to mild hypoxia and reduced the vasodilation response to 
moderate hypoxia whereas glibenclamide only diminished the response to moderate 
hypoxia (Herrera and Walker, 1998). Therefore the mechanism of hypoxic-induced 
vascular relaxation is still an area of controversy and further experiments are required to 
elucidate the underlying mechanism of vasodilation in response to hypoxia. In the present 
study, it was important to investigate whether the hypoxic-induced increase in SK1 may be 
involved in regulation of vascular activity. This study found that the S1P-induced 
relaxation in endothelium-intact aortic rings was significantly enhanced in those rings 
subjected to a short period of hypoxia compared with control vessels and time controls 
(Figure 4-15A & B). Moreover, the hypoxia-enhanced S1P-induced relaxation was 
abolished by removal of endothelium, specifically implicating the vascular endothelium in 
this response (Figure 4-15C). Mair et al (2010) showed that the relaxation response to 
anandamide, an endogenous cannabinoid, and S1P in the rat coronary artery was 
significantly attenuated by SKi. Therefore, SK inhibitors were used here to examine 
whether the increase in SK1 caused by hypoxia may mediate the augmented relaxation 
response to exogenous S1P. In the current study, it was found that pre-treatment of 
endothelium-intact rat aortic rings with either SKi (Figure 4-17A & B) or PF543 (Figure 4-
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19A & B) prior to exposure to hypoxia inhibited the relaxation response to S1P in both 
control and hypoxic vessels. In contrast, addition of the selective SK2 inhibitor ROMe 30 
min before commencing hypoxia failed to inhibit either S1P-induced relaxation under 
control conditions or the hypoxic augmented relaxation response to S1P (Figure 4-20A & 
B). These findings suggest that the relaxation response of rat aortae to S1P under control 
and hypoxic conditions is partly-dependent on SK1 but not SK2. SK1 is likely to be 
activated by addition of S1P and translocated to the plasma membrane to generate more 
S1P from sphingosine and the generated S1P contributes to endothelium-dependent 
vasorelaxation through downstream activation of eNOS/NO signalling pathway (Figure 4-
25). In agreement with this, a previous study has shown that intracellular generation of S1P 
mediates ACh-induced vasorelaxation in thoracic aortae via activation of NO pathway 
without transport of S1P extracellularly to activate cell surface S1P receptors, 
demonstrating a critical role of intracellular S1P in ACh-induced vasorelaxation (Roviezzo 
et al., 2006).  
Various studies have shown that S1P is likely to elicit its relaxation response via S1P3 
receptor in rat thoracic aortae (Nofer et al., 2004) and coronary arteries (Mair et al., 2010). 
In line with this, it was found that the S1P3 agonist, CYM5541, but not the S1P1 agonist, 
SEW2871 induced a similar magnitude relaxation response in isolated rat aortae compared 
to S1P, suggesting that S1P3 agonist-induced vasorelaxation is a Gq mediated effect which 
is regulated by S1P3 but not S1P1 receptors (Figure 4-25). Evidence for Gq mediated 
translocation of SK1 was reported in HEK-293 cells (ter Braak et al., 2009). Activation of 
Gq-coupled receptors stimulated a rapid and long lasting relocalisation of SK1 to the 
plasma membrane and this effect was independent of the two downstream effectors of Gq: 
protein kinase C (PKC) and elevated calcium (ter Braak et al., 2009). However, addition of 
CAY10444, a selective S1P3 antagonist, prior to commencing hypoxia failed to inhibit the 
relaxation response to S1P (Figure 4-22B). CAY10444 is a low potency antagonist and 
therefore a proportion of S1P3 receptors might be left unoccupied by CAY10444 (receptor 
reserve) in the aortic rings which could then be activated by exogenous S1P (Jongsma et 
al., 2006). Further studies utilising another S1P3 antagonist are required to investigate the 
role of S1P3 receptors fully. Moreover, stimulation of TRPV1 channels in response to S1P 
may provide an alternative mechanism by which S1P induces vasorelaxation in isolated 
arteries (Figure 4-8). However, the role of TRPV1 under hypoxic conditions in mediating 
the relaxation to S1P has still to be investigated.           
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Several studies have reported that the eNOS pathway may function as a downstream target 
for the biological responses to S1P including vasorelaxation (di Villa Bianca et al., 2006, 
Roviezzo et al., 2006). It has also been shown that stimulation of cultured vascular 
endothelial cells by S1P increases eNOS activity and subsequently enhances nitric oxide 
generation (Igarashi et al., 2001). Thus, increased NO production in vascular endothelium 
may play a key role in modulations of vascular tone. Strong evidence exists that S1P1 
and/or S1P3 receptor subtypes play an important role in mediating S1P activation of eNOS 
(Nofer et al., 2004, Theilmeier et al., 2006, Tatematsu et al., 2013). Roviezzo et al showed 
that S1P induced endothelium-dependent vasorelaxation in rat aorta was inhibited by L-
NAME. Therefore, a nitric oxide synthase inhibitor (L-NNA) was used to determine 
whether the hypoxia-enhanced relaxation response is mediated by NO. It was observed that 
pre-treatment of rat aortic rings with L-NNA, before exposure to hypoxia inhibited the 
vasorelaxation response to S1P (Figure 4-21B). The S1P-induced relaxation was also 
inhibited by L-NNA in control vessels (Figure 4-21A). This suggests that generation of NO 
is a critical downstream event in S1P-mediated vascular relaxation. 
Another aim of this study was to determine the effect of hypertension on the S1P-mediated 
relaxation in rat aortic rings obtained from spontaneously hypertensive Wistar Kyoto rats 
under control and hypoxic conditions. It was found that the vasorelaxation response to S1P 
was significantly attenuated in aortic rings obtained from hypertensive rats under control 
conditions (Figure 4-23A). In contrast, there was no significant difference in hypoxia-
enhanced vasorelaxation responses to S1P between aortic rings from hypertensive and 
control rats (control vessels obtained from male Sprague-Dawley rats) (Figure 4-23B). 
Moreover, pre-treatment of aortic rings that were obtained from hypertensive rats with 
PF543, a selective SK1 inhibitor, prior to exposure to hypoxia markedly attenuated the 
hypoxia-enhanced response to S1P, suggesting that hypoxia may increase SK1 levels and 
in turn generate more S1P (Figure 4-24B). In summary, although the vasorelaxation 
response to S1P was markedly attenuated under control conditions in aortic rings from 
hypertensive rats, the hypoxia-enhanced vasorelaxation response to S1P was maintained.  
More experiments are required to elucidate the role of SK1/S1P/S1P receptors signalling 
pathway in regulation of blood pressure and the pathogenesis of hypertension.  
4.5 Conclusion 
This study shows that hypoxia induced an increase in SK1 expression in rat aortic 
endothelium and enhanced vasorelaxation responses to S1P. S1P stimulated NO-dependent 
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vascular relaxation via the S1P3 receptor. SK1 but not SK2 enzyme was involved in the 
S1P-induced relaxation under control and hypoxic conditions. The underlying mechanism 
of hypoxia-enhanced S1P-induced relaxation is likely related to the increase in 
SK1expression induced by hypoxia. Furthermore, the SK1 mediated hypoxia-enhanced 
vasorelaxation response to S1P is maintained in hypertension. This is a novel area of 
investigation, which requires further development and may potentially provide further 
targets in the modulation of S1P cardiovascular effects. 
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Figure  4-25 A schematic diagram showing the mechanism of S1P-induced relaxation. 
Exogenous S1P acts as agonist for S1P3 receptor which leads to activation of SK1 via Gq-mediated 
effect. The activated SK1 generates more S1P which functions as intracellular messenger and 
activates eNOS to produce NO. Hypoxia increases SK1 expression in endothelial cells and when 
activated through S1P/S1P3/Gq signalling pathway, it generates more intracellular S1P that 
stimulates eNOS to generate more NO.  
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Chapter five 
5 Influence of hypoxia on SK1 expression in 
cultured endothelial cells and cardiac tissue 
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5.1 Introduction 
Three variants of SK1 exist that differ only at their N-terminus. SK1a has a molecular mass 
of 42.5 kDa, while SK1b has an 86 amino acid N-terminal extension and is a 51 kDa 
protein compared to SK1a (Pitson et al., 2000, Ota et al., 2004). SK1c possesses an 
additional 14 amino acids compared to SK1a and so has a molecular mass of 43.9 kDa. 
Several stimuli have been shown to regulate SK1 activity including agonists of GPCRs, 
tyrosine kinase receptors and immunoglobulin receptors, proinflammatory cytokines, 
calcium and protein kinase activators (Taha et al., 2006b, Alemany et al., 2007, Pyne et al., 
2009). Decreased oxygen availability (hypoxia) has also been shown to increase SK1 
expression in human pulmonary smooth muscle cells and the human endothelial cell line 
EA.hy926 (Ahmad et al., 2006, Schwalm et al., 2008). Moreover, it has become 
increasingly recognized that the SK/S1P signalling pathway plays a critical role in 
cardioprotection against conditions associated with oxidative stress, such as acute or 
chronic ischaemia or ischaemia/reperfusion injury. For instance, addition of S1P to adult 
mouse cardiomyocytes enhances survival during exposure to in vitro hypoxia (Zhang et al., 
2007). The protective effect of exogenously applied S1P was also reported in isolated 
mouse hearts subjected to ischaemia/reperfusion injury (Jin et al., 2002, Lecour et al., 
2002). Moreover, it is well established that ischaemic preconditioning followed by 
extended ischaemia and then reperfusion protects the heart against ischaemia/reperfusion 
injury although the precise mechanism remains elusive. Ischaemic preconditioning is 
associated with increased SK activity compared with non-preconditioned hearts, 
suggesting that SK may mediate the cardioprotection afforded by ischaemic 
preconditioning (Jin et al., 2004). Vessey et al demonstrated that exposure of non-
preconditioned mouse hearts to 45 min ischaemia decreased SK activity more than 60% 
which did not recover during 45 min reperfusion (Vessey et al., 2006). 30 min ischaemia 
also led to a decline in SK activity but this partially recovered during reperfusion in the 
same study. In preconditioned hearts, SK activity decreased by only half of that seen in 
non-preconditioned hearts during ischaemia and upon reperfusion, activity then recovered 
to more than 90% of normal (Vessey et al., 2006). Therefore, SK1 is cardioprotective but 
more in depth insight into the regulation of this enzyme by hypoxia/ischaemia in vascular 
and cardiac cells is required in order to understand the mechanism by which SK1 elicits 
this effect. 
In chapter 3 and 4, it has been demonstrated that hypoxia increases SK1 expression in rat 
coronary and aortic endothelium. Furthermore, the hypoxia-induced increase in SK1 
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expression was inhibited by pre-treatment with SK1 inhibitors. Therefore, a series of 
experiments was carried out to determine whether the hypoxia-induced increase in SK1 
expression is limited to whole vessel preparations or can also be induced in a cultured 
human endothelial cell line and rat cardiac tissue. 
5.1.1 Aims 
The aims investigated in this chapter were: 
 Study the effect of hypoxia on SK1 expression in HUVECs in the presence 
and absence of SK1inhibitors. 
 Study the effect of hypoxia on SK1 expression in cardiac tissue in the 
presence and absence of SKi, a non-selective SK inhibitor, PF543, a selective 
SK1 inhibitor, and cycloheximide, a protein synthesis inhibitor. 
 To determine whether hypoxia induces phosphorylation of SK1 in cardiac 
tissue.  
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5.2 Methods 
5.2.1 Cell culture 
The HUVEC cell culture protocol was detailed in Section 2.5.1. Briefly, HUVECs were 
grown in 75 cm
3
 culture flasks and maintained in Endothelial Cell Growth Media MV / 
MV2 (PromoCell, Germany). The cells were kept incubated at 37 °C in a humidified 
atmosphere of 5% CO2 and 95% air. The media was replaced every 48 hr. Cells were 
routinely sub-cultured when approximately 80-90% confluence was reached and used for 
experiments at passage 4 to 6. 
5.2.2 Experimental protocols 
HUVECs were seeded in 6 well plates and grown to approximately 90% confluence. The 
cells were then incubated for 24 hr with serum-free medium. Then the cells were treated 
with specific inhibitory agents as outlined below and subjected to 30 min 
normoxia/hypoxia. Hypoxia was induced by constant supply of the media with gas 
composed of 95% N2, 5% CO2 for approximately 30 mins to reduce oxygen tension to 5-
7% O2 saturation. 
5.2.2.1  Inhibitory agents 
A series of experiments was performed where the cells were pre-treated with 
cycloheximide, a protein synthesis inhibitor, SKi, a non-selective SK inhibitor, MG132, 
proteasomal inhibitor, CA-074ME, lysosomal inhibitor, or a combination of MG132 and 
CA-074ME (all at 10 µM concentration) for 30 min prior to exposure to normoxia/hypoxia 
for 30 min. 
5.2.2.2 Western blotting 
Following pre-treatment with the inhibitory agents, HUVEC lysates were prepared and 
samples were then loaded on NuPAGE® Novex® 4-12 % Bis-Tris mini gels at 10 µg of 
protein per well. Immunoblotting was then carried out with antibodies against SK1 and the 
loading control GAPDH (the dilutions used are found in Table 2-4). 
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5.2.3 Preparation of heart tissue 
Heart tissue was removed and dissected immediately after death from Male Sprague-
Dawley rats as described in Section 2.5.3. The right ventricular wall was cut into 8 pieces 
and each piece of tissue was pre-incubated with a specific inhibitory compound before 
exposure to hypoxia or normoxia for a particular length of time as outlined below. 
5.2.3.1 The used inhibitory agents 
A series of experiments was carried out where the tissue pieces were pre-incubated with 
SKi, a non-selective SK inhibitor (10 µM), PF543, a selective SK1 inhibitor (100 nM) or 
cycloheximide, a protein synthesis inhibitor (10 µM) for 30 min before exposure to 
normoxia/hypoxia for 30 min. 
5.2.3.2 Western blotting 
Following pre-treatment with the inhibitory agents and exposure to hypoxia, heart tissue 
was pulverised in liquid nitrogen into a fine powder by using a mortar and pestle and 
resuspended in ice-cold lysis buffer. The extract was transferred into ice-cold centrifuge 
tubes and centrifuged (8000 x g, 10 min) on a bench top centrifuge. The supernatants were 
then collected, prepared and protein estimation was carried out with addition of 30 µg of 
protein per well. Immunoblotting was then carried out with antibodies against SK1, pSK1 
and the loading control GAPDH (the dilutions used are found in Table 2-4). 
5.2.4 Statistical analysis 
Graph Pad Prism (version 5) software was used to analyse all the data. All results were 
expressed as mean ± standard error of the mean (S.E.M) and n represents the number of 
independent experiments conducted. ANOVA with Dunnett’s post-test was used. P-values 
were considered statistically significant when p<0.05. 
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5.3 Results 
5.3.1 Expression of SK1 in HUVECs in presence and absence of 
different inhibitory agents under normoxia and hypoxia 
We first investigated the effect of different inhibitors on SK1 expression under normoxic 
and hypoxic conditions in HUVECs. The cells were pre-incubated with SKi, a non-
selective SK inhibitor or cycloheximide, a protein synthesis inhibitor or MG132, a 
proteasomal inhibitor or CA-074ME, a lysosomal inhibitor or a combination of MG132 
and CA-074ME for 30 min prior to exposure to normoxia/hypoxia. Cell samples were then 
Western blotted with anti-SK1 antibody. Band densities were quantified as the ratio of SK1 
to GAPDH. The specificity of the anti-SK1 antibody was tested by comparison with a 
previously validated antibody. 
The anti-SK1 antibody used in this study detected SK1b (Mr = 51 kDa) in HUVECs. No 
change in expression of SK1b was seen following exposure to 30 min hypoxia compared 
with normoxia in HUVECs (Figure 5-1). Under normoxia, there was no effect on the 
expression of SK1b with any of the inhibitory agents (Figure 5-2). Moreover, pre-treatment 
with CA-074ME or a combination of MG132 and CA-074ME before exposure to hypoxia 
led to a trend of increase in relative expression of SK1b compared to untreated hypoxic 
control. A small increase in SK1b expression was also observed when the cells were pre-
treated with MG132 alone prior to exposure to hypoxia. The representative blot (Figure 5-
3) demonstrates the trend of increase in SK1b expression following pre-incubation with 
MG132, CA-074ME or a combination of MG132 and CA-074ME relative to control. Pre-
treatment with SKi or cycloheximide had no effect on SK1b expression (Figure 5-3).  
5.3.2 Expression of SK1 in cardiac tissue following treatment with 
specific inhibitory agents under normoxia and hypoxia 
To examine the influence of specific inhibitory drugs on the expression of SK1 in cardiac 
tissue under normoxic and hypoxic conditions, pieces of cardiac tissue were pre-treated 
with SKi, a non-selective SK inhibitor, PF543, a selective SK1 inhibitor or cycloheximide, 
protein synthesis inhibitor for 30 min before exposure to normoxia/hypoxia. 
The anti-SK1 antibody used in these experiments detected SK1a in the heart tissue as the 
immunostaining corresponded to a band of ~ 42 kDa. Compared with normoxia, hypoxia 
had no significant effect on expression of SK1a in rat heart tissue (Figure 5-4). Under 
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normoxia, a significant reduction in SK1 expression was observed following pre-treatment 
with PF543 or cycloheximide relative to untreated control (Figure 5-5). Pre-treatment with 
SKi led to a small reduction in relative SK1 expression under normoxia as well. Unlike 
normoxia, pre-treatment with SKi or PF543 or cycloheximide was without effect on 
expression of SK1 following exposure to hypoxia compared with hypoxia alone (Figure 5-
6). There was also no effect on relative expression of phosphorylated SK1 following 
exposure to hypoxia compared to normoxia in heart tissue (Figure 5-7). 
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Figure  5-1 Expression of SK1b in HUVECs under normoxia and hypoxia.   
(A) Representative immunoblot showing the SK1b expression under normoxic conditions and 
following the exposure to 30 min hypoxia. (B) Quantification of SK1 relative to GAPDH was 
determined by densitometric analysis. (C) A representative full-length blot shows which bands were 
used for analysis. The data are expressed as mean ± SD for two separate experiments.  
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Figure  5-2 Effect of SKi, cycloheximide, MG132 and CA-074ME on SK1 in HUVECs under 
normoxia.   
(A) Representative immunoblot showing the effect of SKi, a non-selective SK inhibitor (10 µM, 30 
min pre-treatment), cycloheximide, a protein synthesis inhibitor (10 µM, 30 min pre-treatment), 
MG132, a proteasomal inhibitor (10 µM, 30 min pre-treatment), CA-074ME, a lysosomal inhibitor 
(10 µM, 30 min pre-treatment) and the effect of combined pre-treatment with MG132 and CA-
074ME on expression of SK1 in HUVECs under normoxic conditions. (B) Quantification of SK1 
relative to GAPDH was determined by densitometric analysis. The data are expressed as mean ± 
SD for two separate experiments.   
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Figure  5-3 Effect of SKi, cycloheximide, MG132 and CA-074ME on SK1 in HUVECs under 
hypoxia.   
(A) Representative immunoblot showing the effect of SKi, non-selective SK inhibitor (10 µM, 30 min 
pre-treatment), cycloheximide, protein synthesis inhibitor (10 µM, 30 min pre-treatment), MG132, 
proteasomal inhibitor (10 µM, 30 min pre-treatment), CA-074ME, lysosomal inhibitor (10 µM, 30 
min pre-treatment) and the effect of combined pre-treatment with MG132 and CA-074ME on 
expression of SK1 in HUVECs under hypoxic conditions. (B) Quantification of SK1 relative to 
GAPDH was determined by densitometric analysis. The data are expressed as mean ± SD for two 
separate experiments. *p<0.05 vs control as determined by ANOVA‎with‎Dunnett’s‎post-test.    
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Figure  5-4 Expression of SK1a in rat heart tissue under normoxia and hypoxia.  
(A) Representative immunoblot showing the SK1a expression under normoxic conditions and 
following the exposure to 30 min hypoxia. (B) Quantification of SK1 relative to GAPDH was 
determined by densitometric analysis. (C) A representative full-length blot shows which bands were 
used for analysis.  The data are expressed as mean ± SEM for three separate experiments.   
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Figure  5-5 Effect of SKi, PF543 and cycloheximide on SK1 in rat cardiac tissue under 
normoxia. 
(A) Representative immunoblot showing the effect of SKi, non-selective SK inhibitor (10 µM, 30 min 
pre-treatment), PF543, a selective SK1 inhibitor (100 nM, 30 min pre-treatment) and 
cycloheximide, protein synthesis inhibitor (10 µM, 30 min pre-treatment) on expression of SK1 in 
rat cardiac tissue under normoxic conditions. (B) Quantification of SK1 relative to GAPDH was 
determined by densitometric analysis. The data are expressed as mean ± SEM for three separate 
experiments.      
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Figure  5-6 Effect of SKi, PF543 and cycloheximide on SK1 in rat cardiac tissue under 
hypoxia. 
(A) Representative immunoblot showing the effect of SKi, non-selective SK inhibitor (10 µM, 30 min 
pre-treatment), PF543, a selective SK1 inhibitor (100 nM, 30 min pre-treatment) and 
cycloheximide, protein synthesis inhibitor (10 µM, 30 min pre-treatment) on expression of SK1 in 
rat cardiac tissue under hypoxic conditions. (B) Quantification of SK1 relative to GAPDH was 
determined by densitometric analysis. The data are expressed as mean ± SEM for three separate 
experiments.      
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Figure  5-7 Effect of hypoxia on pSK1 in rat cardiac tissue.   
(A) Representative western blot showing expression of pSK1 rat cardiac tissue following exposure 
to 30 min hypoxia. (B) Quantification of pSK1 relative to GAPDH was determined by densitometric 
analysis. (C) A representative full-length blot shows which bands were used for analysis. The data 
are expressed as mean ± SEM for three separate experiments.      
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5.4 Discussion 
In chapter 3 and 4, it was shown that short periods of hypoxia induced an increased SK1 
expression in coronary and aortic endothelium. The hypoxia-induced increase in SK1 was 
inhibited by pre-treatment with SKi, PF543 and cycloheximide. Thus, one of this chapter’s 
aims was to determine the effect of hypoxia on SK1 expression in human cultured 
endothelial cells, HUVECs. A number of studies have demonstrated that exposure of 
human endothelial cell line EA.hy926 and human pulmonary smooth muscle cells to 
hypoxia led to an increase in SK1 expression (Ahmad et al., 2006, Schwalm et al., 2008). 
Furthermore, Lin et al showed that exposure of rat amoeboid microglial cells to a short 
period of hypoxia resulted in a rapid increase in SK1 expression starting 15 min after 
exposure to hypoxia (Lin et al., 2011). In the present study, hypoxia did not change the 
expression of SK1 in HUVECs (Figure 5-1). Moreover, pre-treatment of HUVECs with 
SKi, cycloheximide, MG132, CA-074ME or a combination of MG132 and CA-074ME had 
no effect on the SK1 expression compared with untreated control under normoxic 
conditions (Figure 5-2). However, pre-treatment with CA-074ME or a combination of 
MG132 and CA-074ME led to a trend of increase in the SK1 expression compared with 
untreated control cells under hypoxic conditions (Figure 5-3). A small increase in SK1 
expression was also observed in cells pre-treated with MG132. These data suggest that 
there is a more rapid turnover of SK1 under hypoxic conditions in HUVECs. Only two 
independent experiments were carried out and further experiments are required to draw 
firm conclusions.  Although, SKi has been shown to induce lysosomal degradation in a 
number of cell lines including human endothelial cells EA.hy 926, human podocytes and 
mesangial cells (Ren et al., 2010) and proteasomal degradation in human pulmonary 
smooth muscle cells, breast cancer cells and androgen sensitive prostate cancer cells 
(Loveridge et al., 2010), in HUVECs, SKi failed to reduce SK1 expression under normoxia 
and hypoxia. In this study, the anti-SK1 antibody used identified SK1b (band at 51 kDa) in 
HUVECs and it is likely that hypoxia induces SK1 expression and therefore this 
compensates for the degradation of SK1 in response to SKi. Resistance of SK1b to SKi-
induced degradation has been previously shown in androgen-independent prostate cancer 
(LNCaP-AI) cells (Loveridge et al., 2010). In LNCaP-AI, SK1 siRNA or cycloheximide 
was not effective in reducing SK1b expression and it is likely due to a slow turnover rate 
of SK1b. Thus, a combined treatment of LNCaP-AI with SK1 siRNA and SKi succeeded 
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in reducing the SK1b expression as the SKi-induced degradation was not opposed by de 
novo synthesis of the enzyme (Loveridge et al., 2010). 
Another aim of this study was to investigate the effect of hypoxia on expression of SK1 in 
rat cardiac tissue with and without pre-treatment with specific inhibitory agents including 
SKi, PF543 and cycloheximide. It has been previously shown that deletion of SK1 or SK2 
increased the extent of ischaemia/reperfusion-induced damage in mouse hearts and the 
protective effect of IPC was impaired in SK1 or SK2 null hearts compared with wild type 
(Jin et al., 2007, Vessey et al., 2011). Therefore, it has been proposed that the SK/S1P 
pathway may play an important role in cardiac protection against an ischaemic insult. 
Here, short-term hypoxia had no effect on expression of SK1 in rat heart tissue (Figure 5-
4). Pre-treatment with PF543 or cycloheximide led to a significant reduction in the SK1 
expression under normoxic conditions (Figure 5-5). A small decrease in SK1 expression 
was also seen with SKi pre-treatment. In contrast, no significant change in expression of 
SK1 was observed with SKi or PF543 or cycloheximide pre-treatment prior to exposure to 
hypoxia (Figure 5-6). These data support similar observations reported recently in 
pulmonary vessels and right ventricles where treatment with PF543 had no effect on 
expression of SK1 in mice subjected to chronic hypoxia for 21 days  (MacRitchie et al., 
2016). In the current study, it was also observed that hypoxia had no effect on ser225 
phosphorylation of SK1 compared with normoxia (Figure 5-7). It is important to note that 
the anti-SK1 antibody used in these experiments identified SK1a (band at ~ 42 kDa) in rat 
heart tissue. Hypoxia obviously induces resistance to SK inhibitors in terms of degradation 
in rat heart tissue. The resistance of SK1a to SK inhibitors is likely due to the 
compensatory increase in SK1a expression and not a result of SK1 phosphorylation as 
hypoxia did not increase it. Collectively, reduction of SK1 expression and/or activity due 
to hypoxic/ischaemic insult may enhance cardiomyocyte apoptosis by shifting the 
‘rheostat’ in favour of ceramide (a pro-apoptotic signal). Thus, maintenance of SK1 
activity following hypoxia/ischaemia insult might be a promising therapeutic strategy in 
prevention of cardiomyocyte apoptosis and recovery of cardiac function.              
5.5 Conclusion 
In summary, I have shown that pre-incubation of endothelial cells, HUVECs, with 
lysosomal and/or proteasomal inhibitor prior to exposure to a short period of hypoxia 
apparently increases the SK1 expression in comparison with untreated control, suggesting 
that hypoxia increased turnover rate of SK1 in particular cell lines. However, hypoxia also 
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makes SK1 resistant to SKi-induced degradation which is likely due to a compensatory 
increase in SK1 expression. This is also the case in heart tissue where hypoxia-induced 
resistance to the effect of the SK inhibitor in causing degradation was likely through a 
compensatory upregulation of SK1 expression.    
156 
 
Chapter six 
6 General discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
157 
 
6.1 General Discussion 
A growing body of evidence exists for the significant contribution of the SK1/S1P pathway 
in cardioprotection against ischaemic insult. For instance, deletion of SK1 gene in 
ventricular cardiomyocytes led to increased cell death following exposure to hypoxia (Tao 
et al., 2007). Moreover, exogenous S1P was found to prevent hypoxic cell death in SK1 
null cardiomyocytes. It has also been shown that monoganglioside GM-1, which increases 
intracellular S1P by activating SK1 was cytoprotective in wild type cardiomyocytes but not 
in SK1 null myocytes (Tao et al., 2007). Exogenous S1P also exhibited protective effects 
against IR injury in isolated adult mouse hearts (Jin et al., 2002, Lecour et al., 2002). 
However, little is known about the role of the SK/S1P signalling pathway at the level of 
coronary arteries during hypoxic/ischaemic event. This thesis has examined the effect of 
hypoxia on SK1 expression in several cell types, but with a focus on vascular endothelium 
and how this may regulate vascular tone through generation of S1P. The present study 
shows for first time that a short period of hypoxia causes an increase in SK1 expression in 
coronary and aortic endothelium. Although this has been demonstrated previously in 
human glioma cells and rat amoeboid microglial cells (Anelli et al., 2008, Lin et al., 2011), 
this observation in endothelial cells is novel. Examination of the mechanism responsible 
for the hypoxia-induced increase in SK1 revealed that hypoxia increases synthesis of SK1, 
as it was inhibited by cycloheximide, a protein synthesis inhibitor. Moreover, pre-treatment 
with a number of proteasomal or lysosomal degradation inhibitors did not increase SK1 
expression under normoxic conditions or induce any further increase in SK1 level under 
hypoxia. 
It was also demonstrated that SKi, a non-selective SK inhibitor, and PF543, a selective 
SK1 inhibitor not only inhibit the catalytic activity of SK1 but they also reduce SK1 
expression in coronary and aortic endothelium under normoxic and hypoxic conditions. 
Previous work showed that SKi enhances proteasomal degradation in human pulmonary 
artery smooth muscle cells, prostate and breast cancer cells (Loveridge et al., 2010) and 
lysosomal degradation in human endothelial cells EA.hy 926, human podocytes and 
mesangial cells (Ren et al., 2010). In the present study SKi induced both proteasomal and 
lysosomal degradation of SK1 in coronary artery endothelium as pre-treatment with 
MG132, a proteasomal inhibitor, and/or CA-074ME reversed the SKi triggered 
degradation of SK1.  
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The increase in SK1 due to hypoxia/ischaemia in coronary and aortic endothelium may 
contribute significantly to generation of more S1P which acts as a cardioprotective lipid 
(Kennedy et al., 2009). To explore the importance of this hypoxia-induced increase in SK1 
in regulation of vascular function, S1P-stimulated vasorelaxation was assessed in rat aorta 
under normoxic and hypoxic conditions. In the current study, S1P was found to induce 
vasodilatation in endothelium-intact but not endothelium-denuded rat aortae, indicating 
that it is an endothelium-dependent effect. Moreover, the vasorelaxation response to S1P 
was likely mediated through S1P3 receptors as CYM5541, a selective S1P3 agonist but not 
SEW2871, a selective S1P1 receptor agonist induced relaxation of a similar magnitude to 
that induced by S1P itself. These data support similar observations reported in rat coronary 
artery and aorta where endothelial S1P3 receptor mediated the vasorelaxation response to 
exogenous S1P (Nofer et al., 2004, Mair et al., 2010). In the present study, it was also 
shown that exposure of aortic rings to hypoxia led to enhancement of the vasorelaxation 
response to exogenous S1P. Removal of endothelium also inhibited the enhanced 
vasorelaxation response to S1P seen under hypoxic conditions. SK1, likely via generation 
of S1P, has previously been found to mediate vasorelaxation responses to anandamide and 
S1P in rat coronary artery under normoxic conditions (Mair et al., 2010). In the current 
study, it was also demonstrated that the vasorelaxation response to exogenous S1P was 
SK1-dependent under normoxia and hypoxia in endothelium-intact aortic rings. 
Collectively, these data indicate that S1P exerts its vasodilator effect via activation of 
S1P3/SK1/S1P signalling pathway. Moreover, it is likely that S1P3 agonist-induced 
vasorelaxation is a Gq-mediated effect which is regulated by S1P3 but not S1P1 receptors. 
This argument is supported by a previous work where it has been shown that activation of 
Gq-coupled receptors stimulated a rapid and long lasting relocalisation of SK1 to the 
plasma membrane in HEK-293 cells (ter Braak et al., 2009).    
The eNOS/NO pathway has previously been demonstrated to function as a downstream 
target for the biological responses to S1P including vasorelaxation (di Villa Bianca et al., 
2006, Roviezzo et al., 2006). Increased eNOS activity was also reported in cultured 
vascular endothelial cells stimulated by S1P (Igarashi et al., 2001). Moreover, Roviezzo et 
al (2006) has demonstrated that ACh-induced vasorelaxation in thoracic aortae was 
mediated by SK, S1P and NO, suggesting that the SK/S1P pathway is critical for ACh-
induced vasorelaxation. In the present study, S1P was found to exert vasorelaxation in rat 
aorta via a NO-dependant mechanism. Therefore, NO is the downstream effector which 
induces relaxation of the aortic smooth muscle cells. Moreover, the present study has 
demonstrated a novel mechanism of S1P-stimulated vasorelaxation by activation of 
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TRPV1 channels in endothelium-intact aortae. It is therefore possible that S1P can exert its 
vasorelaxant effect through an alternative S1P receptor-independent mechanism. However, 
involvement of TRPV1 channels in S1P-induced relaxation was only tested under 
normoxia. Thus, further experiments are required to examine whether S1P stimulated 
relaxation is mediated by TRPV1 channels under hypoxic conditions.   
The significant role of S1P in control of vascular tone is well recognised and S1P, 
therefore, may play an important role in regulation of blood pressure and in the 
pathogenesis of hypertension. It has recently been shown that increasing S1P levels via 
deletion/loss of Nogo B, a membrane protein of the endoplasmic reticulum that negatively 
controls endothelial S1P levels, exerted a protective role against angiotensin II-induced 
hypertension (Cantalupo et al., 2015). Moreover, it was also observed that eNOS activity is 
increased in Nogo-B-null mice and addition of an S1P1 antagonist reversed the enhanced 
vasorelaxation seen in Nogo-B-null mice. However, another study reported that S1P may 
play a pro-hypertensive role as loss of SK1 led to inhibition of both the acute hypertensive 
response to angiotensin II in anaesthetised mice and the sustained hypertensive response to 
continuous infusion of angiotensin II in conscious mice (Wilson et al., 2015). Thus, the 
role of S1P in regulation of blood pressure is still requires more investigation to delineate 
its complex role. In the present study, it was observed that the vasorelaxation response to 
S1P is abolished in aortic rings obtained from spontaneously hypertensive rats compared 
with control rats. In contrast, S1P-induced vasorelaxation was not impaired in aortic rings 
obtained from spontaneously hypertensive rats following exposure to hypoxia compared 
with control. Furthermore, the hypoxia-enhanced vasorelaxation response to S1P was also 
mediated through SK1 in vessels dissected from hypertensive rats and this is consistent 
with increased SK1 expression. Obviously, more experiments are required to clarify the 
importance of SK/S1P pathway in regulation of blood pressure and the pathogenesis of 
hypertension. 
The influence of hypoxia on SK1 expression was also investigated at the level of cultured 
endothelial cells (HUVECs). No change in SK1 expression was seen following exposure of 
HUVECs to hypoxia compared with normoxia. Presence of SKi or cycloheximide was also 
without effect on SK1 expression under normoxic and hypoxic conditions. In contrast, pre-
treatment with MG132, CA-074ME or a combination of MG132 and CA-074ME 
apparently increases SK1 expression under hypoxic but not normoxic conditions, 
indicating that there is a more rapid turnover of SK1 under hypoxic conditions in 
HUVECs. The anti-SK1 antibody used in this study identified SK1b (band at 51 kDa) in 
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HUVECs and hypoxia appears to increase SK1 expression and this perhaps compensates 
for the SKi-induced degradation. Therefore, a compensatory increase in SK1b expression 
counteracts the SK1b downregulation induced by SKi and maintains no change in SK1b 
expression overall. This is in accordance with a previous study where it has been 
demonstrated that treatment with SK1 siRNA or SKi or cycloheximide was not effective in 
decreasing SK1b expression in androgen-independent prostate cancer (LNCaP-AI) cells 
(Loveridge et al., 2010). However, SK1 expression was reduced when the LNCaP-AI were 
treated with a combination of SKi and SK1 siRNA and this is because the SKi-induced 
degradation was not opposed by de novo synthesis of the enzyme (Loveridge et al., 2010). 
Thus, there is resistance to SKi in HUVECs because of a compensatory increase in SK1b 
expression. Similarly, in heart tissue, no significant difference in expression of SK1 was 
observed between normoxia and hypoxia. However, in the case of heart tissue, the anti-
SK1 antibody detected SK1a (band at ~ 42 kDa). Under normoxic conditions, SK 
inhibitors or cycloheximide was effective in reducing expression of SK1a. Loveridge et al 
(2010) has also demonstrated that SK1a is more sensitive to SKi-induced degradation than 
SK1b in the LNCaP-AI. In contrast, SK inhibitors or cycloheximide failed to reduce SK1a 
expression under hypoxic conditions in the current study, suggesting that hypoxia induces 
resistance to SK inhibitors and cycloheximide. It is possible that hypoxia induces 
resistance to SK inhibitors in terms of degradation through an increase in SK1a expression 
and therefore, the SK1a-induced degradation by SK inhibitors is balanced by a 
compensatory upregulation of SK1 expression.                 
6.2 Limitations and future work 
In this thesis, the use of confocal imaging provided very important information in 
investigating the effect of hypoxia on SK1 in the endothelium of isolated vascular 
preparations under conditions which are more physiological compared with cultured cell 
lines. However, the physiological relevance could be improved further in future with 
additional experiments using in vivo models. The influence of hypoxia/ischaemia on SK1 
in isolated vascular preparations could be assessed in vivo by inducing ischaemia via 
ligation of the coronary artery or exposure of animals to hypoxia and then dissecting the 
artery in the ischaemic area to assess SK1 expression. It would also be important to 
investigate the effect of ischaemia/reperfusion on SK1 in isolated arteries and in vivo to 
establish the effect of reoxygenation/reperfusion itself on SK1 expression. Moreover, in 
the present study it was shown that pre-treatment with PF543, a potent selective SK1 
inhibitor reduced SK1 expression in coronary and aortic endothelium. Further experiments 
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are required to interrogate the mechanism of PF543-induced reduction in SK1. Previous 
work has demonstrated that PF543 enhances proteasomal degradation of SK1 in human 
pulmonary artery smooth muscle cells and prostate cancer cells (Byun et al., 2013, 
McNaughton et al., 2016). Thus, the vascular rings could be pre-treated with proteasomal, 
lysosomal, or a combination of both proteasomal and lysosomal inhibitor prior to addition 
of PF543 to assess SK1 expression in presence of the degradation inhibitors. 
The specificity of the antibody used to detect SK1 was tested by using a blocking peptide 
and by comparison with a previously validated antibody. Further experiments can be 
carried out to test antibody specificity by using negative controls. For instance, a cell line 
or tissue that is known not to express the SK1 enzyme can provide a better negative 
control. SK1 siRNA can also be used to knockdown SK1 and thus provide reliable 
negative controls. It is also important to carry out a number of experiments in order to 
examine whether the diluents for the used inhibitors affect the SK1 expression or not. 
Different diluents were used to dilute the used inhibitors including distilled water, 
BSA/PBS, DMSO and ethanol. Therefore, effect of the diluents on results obtained from 
immunofluorescent and functional studies should be tested. Normoxia is another issue that 
should be further evaluated. Currently exposure of cultured cells or isolated tissue to 
atmospheric normoxic (21 %) oxygen concentrations is widely used technique. It is, 
however, not considering the fact that oxygen levels within the human body are much 
lower than that of the atmosphere (McKeown, 2014). For instance, the oxygen 
concentration in arteries, lungs, and liver is about 10-13% and 7 % in the bone marrow. 
Further evaluation, therefore, should be considered for using normoxic (20 % oxygen) 
solutions for in vitro experiments.           
Hypoxia-induced increase in expression of SK1 has previously been shown in vascular 
smooth muscle cells (Ahmad et al., 2006). However, it was not possible to examine the 
influence of hypoxia on SK1 expression in vascular smooth muscle cells in the current 
study due to poor penetration of the antibodies deep to smooth muscle layers. It was 
expected that antibodies may pass through the opening of internal and external lamina but 
it seems they act as a barrier. Theoretically, it might be possible to use a digestive enzyme 
(very low concentration) to induce larger openings in the internal and external lamina 
without losing the whole vessel structure. This may help the antibodies to penetrate deep 
towards smooth muscle cells. 
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Dissection of rat coronary artery is another issue in the present study as it is very slow and 
tricky. I have often been able to dissect two small rings one from right and the other from 
left coronary artery. This amount of tissue was not enough to carry out functional and 
immunofluorescent studies at the same time. Thus, I used rat aorta to conduct functional 
experiments. However, using large vessels such as aorta may not always reflect vascular 
reactivity of smaller arteries such as coronary, cerebral and renal arteries. However, 
although use of the aorta as a model to study vascular responses to S1P under normoxic 
and hypoxic conditions might be a limitation of this study, immunofluorescent studies 
showed that the response of SK1 to hypoxia in the aorta was similar to the coronary artery. 
Furthermore, previous work showed that S1P induces vasorelaxation in rat aorta (Nofer et 
al., 2004, Roviezzo et al., 2006) and exposure of aortic rings to hypoxia was also reported 
to induce vasodilation (Herrera and Walker, 1998). Therefore, understanding how hypoxia 
affects the SK/S1P pathway in vascular tissue such as aorta may help to clarify how 
hypoxia/ischaemia alters cardiovascular function in the whole animal. 
Moreover, it has been shown in chapter five that hypoxia induces resistance to SK 
inhibitors or cycloheximide-triggered reduction in SK1 expression in HUVECs and rat 
heart tissue. It is likely that hypoxia increases SK1 expression and this is outweighing the 
degradation induced by SK inhibitors. Using a combined treatment with SK1 siRNA or 
cycloheximide and SK inhibitors may clarify the mechanism of hypoxia-induced SK1 
resistance to SK inhibitors. Measurement of SK1 mRNA could also provide additional 
evidence for the compensatory hypoxia-induced increase in SK1 expression in HUVECs 
and heart tissue.  
6.3 Clinical Relevance 
Several studies have demonstrated that the S1P/SK pathway exhibited protective effects 
against hypoxic injuries in cardiomyocytes (Karliner et al., 2001, Tao et al., 2007). 
However, little is known about whether S1P/SK pathway play a role in protection of 
coronary arteries against hypoxic/ischaemic and reperfusion insult. Restoration of blood 
supply is critical to provide oxygen and nutrients to the starved myocardium and to 
minimise the size of the infarcted zone. However, reperfusion itself is also associated with 
microvascular dysfunction, inflammation, and oxidative damage. This vascular injury, in 
turn, leads to inadequate myocardial perfusion (the “no-reflow” phenomenon). It was 
shown that 30% of patients had this phenomenon which is associated with higher incidence 
of death (Ahmad et al., 2006, Niccoli et al., 2009). Prevention of microvascular damage 
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during ischaemia and reperfusion may enhance myocardial flow and therefore represents a 
promising therapeutic strategy to improve outcome. Recent studies demonstrated that pre-
treatment with FTY720, a S1P receptor agonist, and SEW2871, a S1P1 receptor agonist 
relieved coronary and mesenteric vascular dysfunction induced by cardiopulmonary bypass 
(Samarska et al., 2014). Galvani et al reported that HDL-bound S1P exhibited anti-
inflammatory properties in mouse aorta through its function as a biased S1P1 agonist 
(Galvani et al., 2015). Moreover, it has been shown that anandamide, an endogenous 
cannabinoid, induces coronary vasodilation through activation of SK1/S1P/S1P3 signalling 
pathway (Mair et al., 2010). Therefore, targeting SK/S1P/S1P receptor pathway in vascular 
endothelium perhaps offers the potential for a more clinically useful treatment to limit 
vascular damage during an ischaemic event. This may include administration of S1P, its 
analogues or SK1 activators during the ischaemic attack which could limit microvascular 
dysfunction and allow for adequate cardiac perfusion and recovery.      
6.4 Conclusion 
In summary, this thesis has demonstrated for the first time that short periods of hypoxia 
induces an increase in SK1 expression in coronary and aortic vascular endothelium. 
Moreover, the current study has found that the enhanced vasorelaxation response to S1P 
under hypoxic conditions is mediated by SK1/S1P3 signalling pathway. The thesis has also 
generated novel data on an alternative mechanism for the S1P stimulated vasorelaxation 
through activation of TRPV1 channels in aorta. Another important novel observation is 
that the SK1-mediated hypoxia-enhanced vasorelaxation response to S1P is maintained in 
hypertension. Furthermore, the present study has highlighted that hypoxia induces 
resistance of SK1 to SK inhibitors in terms of degradation in HUVECs and rat heart tissue. 
Additional experiments are required to clarify the mechanism of hypoxia-induced 
resistance to SK inhibitors which is likely through a compensatory SK1 upregulation. 
Considering the findings of the current study, targeting the SK1/S1P pathway could 
provide a novel therapeutic strategy to ameliorate the clinical signs associated with 
vascular complications caused by myocardial infarction. 
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